<html lang="en"><head>
	<!-- Required meta tags -->
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

	<!-- Favicon -->
	<!-- cpcommit -->
	<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

	<script>
		(function () {
			var hostName = window.location.hostname;

			var browserAccepted = function () {

				var ua = window.navigator.userAgent;
				var trident = ua.indexOf('Trident/'); //IE 11;
				var msie = ua.indexOf('MSIE '); // IE 10 or older
				if (msie > 0) {
					return false;
				}
				return true;
			}();

			var pathToLibs = './js';
			var pathToError = './';
			// uncomment following lines only when running ix symlink to ix.xhtml on *.sec.gov
			/* commented out for running ix redirector script
			if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
				pathToLibs = './ixviewer/js';
				pathToError = '/ixviewer/';
			}
			*/
			if (browserAccepted) {

				// css
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

				// js
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.7.1.slim.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

				var date = new Date();
				var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
				document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
			} else {
				// user us on a browser that we do not support
				var currentUrl = window.location.href.split('?')[0];
				var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
				browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
				window.location.href = browserError;
			}
		})();
	</script><link rel="stylesheet" href="./js/css/custom-bootstrap.css"><link rel="stylesheet" href="./js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="./js/css/app.css"><script type="text/javascript" src="./js/lib/jquery-3.7.1.slim.min.js"></script><script type="text/javascript" src="./js/lib/popper.min.js"></script><script type="text/javascript" src="./js/lib/bootstrap.min.js"></script><script type="text/javascript" src="./js/lib/moment.js"></script><script type="text/javascript" src="./js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="./js/lib/he.js"></script><script type="text/javascript" defer="true" src="./js/production.min.js?d=22-4-2024"></script>
	<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} #dynamic-xbrl-form .text-block-indicator-left{border-left:.75rem solid ##003768;} #dynamic-xbrl-form .text-block-indicator-right{border-right:.75rem solid ##003768;} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>

<body>
	<noscript>This application relies heavily on JavaScript, you
		will need to allow JavaScript to use this application.</noscript>
	<nav class="reboot navbar navbar-expand-md navbar-dark navbar-height bg-sec fixed-top w-100 pl-0">
		<button class="reboot navbar-toggler ml-1" type="button" data-test="" data-toggle="collapse" data-target="#main-navbar" aria-controls="main-navbar" aria-expanded="false" aria-label="Toggle navigation">Inline Viewer</button>
		<div class="reboot navbar-height collapse navbar-collapse bg-sec w-100" data-test="main-navbar" id="main-navbar">
			<ul class="reboot navbar-nav mr-auto bg-inherit">
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a id="menu-dropdown-link" data-test="menu-dropdown-link" class="reboot nav-link dropdown-toggle click disabled" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="1" accesskey="1">
						<i class="reboot nav-loading fas fa-bars" title="Menu"></i>
						<span class="reboot d-md-none d-lg-inline">Menu</span>
						<span class="reboot sr-only sr-only-focusable">Menu</span>
					</a>
					<div class="reboot dropdown-menu">
						<a id="menu-dropdown-information" data-test="menu-dropdown-information" class="reboot dropdown-item click text-body" tabindex="1">Information</a>
						<a id="form-information-instance" data-test="form-information-instance" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL
							Instance</a>
						<a id="form-information-zip" data-test="form-information-zip" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL Zip
							File</a>
						<a id="form-information-html" data-test="form-information-html" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Open as HTML</a>
						<a id="menu-dropdown-settings" data-test="menu-dropdown-settings" class="reboot dropdown-item click text-body" tabindex="1">Settings</a>
						<a id="form-information-help" data-test="form-information-help" class="reboot dropdown-item click text-body" tabindex="1">Help</a>
						<span id="form-information-version" class="reboot dropdown-item-text text-body" tabindex="1"></span>
					</div>
				</li>
				<li class="reboot nav-item my-auto ml-1">
					<a id="sections-dropdown-link" data-test="sections-dropdown-link" class="reboot nav-link click disabled meta-required" tabindex="2" accesskey="2">
						<i class="reboot fas fa-layer-group" title="Sections"></i>
						<span class="reboot d-md-none d-lg-inline">Sections</span>
						<span class="reboot sr-only sr-only-focusable">Sections</span>
					</a>
				</li>
				<li class="reboot nav-item my-auto ml-1 mr-1">
					<form id="global-search-form" data-test="global-search-form" class="reboot my-2 my-lg-0 input-group disabled" novalidate="">
						<div class="reboot input-group-prepend">
							<button data-name="global-search-options" class="reboot dropdown btn btn-outline-light disabled" type="button" data-toggle="dropdown" tabindex="3">
								<i class="reboot nav-loading fas fa-cog" title="Additional Search Options">
									<span class="reboot sr-only sr-only-focusable">Additional
										Search Options</span>
								</i>
							</button>
							<div class="reboot dropdown-menu px-2">
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="1" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Name</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="2" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Content</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="3" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Labels</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="4" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Definitions</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="5" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Dimensions</span>
									</label>
								</div>
								<div class="reboot bg-light border p-1">
									<span class="reboot dropdown-item-text">Reference
										Options</span>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="6" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="7" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Sub-Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="8" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Paragraph</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="9" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Publisher</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="10" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="disabled">Include Section</span>
										</label>
									</div>
								</div>
								<div class="reboot form-check">
									<input class="reboot form-check-input" type="checkbox" name="search-options" value="11" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Match Case</span>
									</label>
								</div>
							</div>
						</div>
						<input type="text" class="reboot form-control disabled" id="global-search" data-test="global-search" placeholder="Search Facts" disabled="" aria-label="Search all Facts and highlight them accordingly." tabindex="4">
						<div class="reboot input-group-append">
							<button id="search-btn-clear" data-name="global-search-clear" class="reboot btn btn-outline-light disabled" type="button" tabindex="5">
								<i class="reboot nav-loading fas fa-times-circle" title="Clear Search"></i>
								<span class="reboot sr-only sr-only-focusable">Clear
									Search</span>
							</button>
							<button class="reboot btn btn-outline-light disabled" type="submit" tabindex="6">
								<i class="reboot nav-loading fas fa-search" title="Submit Search"></i>
								<span class="reboot sr-only sr-only-focusable">Submit
									Search</span>
							</button>
						</div>
					</form>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-data" data-test="nav-filter-data" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="7" accesskey="3">
						<i class="reboot nav-loading fas fa-list-alt" title="Data"></i>
						<span class="reboot d-md-none d-lg-inline">Data</span>
						<span class="reboot sr-only sr-only-focusable">Data</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-dropdown" data-name="data-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="0" checked="" tabindex="7">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="1" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Amounts Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="2" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Text Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="data-radios" value="3" disabled="" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Calculations Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="4" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Negatives Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="5" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Additional Items Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-tags" data-test="nav-filter-tags" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="8" accesskey="4">
						<i class="reboot nav-loading fas fa-tags" title="Tags"></i>
						<span class="reboot d-md-none d-lg-inline">Tags</span>
						<span class="reboot sr-only sr-only-focusable">Tags</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-tags-dropdown" data-name="tags-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="0" aria-label="Radio Button for All Tag Types" checked="" tabindex="8">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="1" aria-label="Radio Button for Standard Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span>Standard Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="tags-radios" value="2" disabled="" aria-label="Radio Button for Custom Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="Facts whose tags are outside the realm of DEI, US-GAAP, etc." class="reboot far fa-question-circle"></i>
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Custom Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-more" data-test="nav-filter-more" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="9" accesskey="5">
						<i id="loading-more-filters" class="reboot nav-loading fas fa-filter" title="More Filters"></i>
						<span class="reboot d-md-none d-lg-inline">More Filters</span>
						<span class="reboot sr-only sr-only-focusable">More Filters</span>
						<span title="Total active filters." class="reboot badge badge-warning"></span>
					</a>
					<div class="reboot dropdown-menu dropdown-menu-width">
						<label class="reboot dropdown-item-text d-none performance-concern">
							Selecting any of the below will take a few moments.</label>
						<div class="reboot accordion" id="more-filters-accordion">
							<form class="reboot" data-test="more-filters-form">
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Period" data-target="#user-filters-periods" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Periods</span>
											<span data-test="Period-count" id="filters-periods-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-periods" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Measures" data-target="#user-filters-measures" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Measures</span>
											<span data-test="Measures-count" id="filters-measures-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-measures" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot  px-0 py-0">
										<a href="#" data-test="Axis" data-target="#user-filters-axis" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Axis</span>
											<span data-test="Axis-count" id="filters-axis-count" class="reboot badge badge-secondary">
												<i class="fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-axis" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Members" data-target="#user-filters-members" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Members</span>
											<span data-test="Members-count" id="filters-members-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-members" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Scale" data-target="#user-filters-scales" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Scale</span>
											<span data-test="Scale-count" id="filters-scales-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-scales" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Balance" data-target="#user-filters-balances" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Balance</span>
											<span data-test="Balance-count" id="filters-balances-count" class="reboot badge badge-secondary">2</span>
										</a>
									</div>
									<div id="user-filters-balances" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-debit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Debit</label>
											</div>
										</div>
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-credit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Credit</label>
											</div>
										</div>
									</div>
								</div>
							</form>
						</div>
					</div>
				</li>
				<li id="current-filters-reset" data-test="current-filters-reset" class="reboot nav-item d-none my-auto ml-1">
					<a href="#" id="current-filters-reset-all" data-name="current-filters-reset" class="reboot nav-link dropdown-toggle text-danger disabled click" tabindex="11" accesskey="7">
						<i class="reboot nav-loading fas fa-redo"></i>
						<span class="reboot d-md-none d-lg-inline">Reset All
							Filters</span>
					</a>
				</li>
				<li id="links-dropdown" data-test="links-dropdown" class="reboot nav-item dropdown d-none my-auto ml-1">
					<a href="#" id="additional-links-dropdown" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="12" accesskey="8">
						<i class="reboot nav-loading fas fa-link"></i>
						<span class="reboot d-md-none d-lg-inline">Links</span>
					</a>
					<div id="links-dropdown-content" class="reboot dropdown-menu dropdown-menu-width w-auto"></div>
				</li>
			</ul>
			<ul class="reboot navbar-nav pull-right bg-inherit">
				<li class="reboot nav-item my-auto ml-1">
					<a id="facts-menu" data-test="facts-menu" class="reboot nav-link click" tabindex="13" accesskey="9">
						Facts
						<span class="reboot taxonomy-total-count badge badge-light"><i class="fas fa-spinner fa-spin"></i></span>
					</a>
				</li>
			</ul>
		</div>
	</nav>
	<div class="reboot main-container">
		<div id="error-container" data-test="error-container" class="reboot px-0"></div>
		<div id="xbrl-form-loading" data-test="xbrl-form-loading" class="reboot jumbotron h-100 d-none">
			<h2 class="reboot display-4 text-center">
				<i class="reboot fas fa-spinner fa-spin"></i>
				Loading Inline Form.
			</h2>
		</div>
		<div id="sections-menu" data-test="sections-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">
			<div class="reboot mb-2">
				<span class="reboot lead">Tagged Sections</span>
				<a id="sections-menu-toggle" class="reboot float-right click color-inherit" tabindex="2">
					<i class="reboot fas fa-times-circle mt-2 text-dark"></i>
				</a>
			</div>
			<form id="sections-menu-search-submit" data-name="sections-menu-search" class="reboot my-2 my-lg-0 input-group" novalidate="">
				<div id="sections-search-additional" class="reboot input-group-prepend d-none">
					<button class="reboot dropdown btn btn-sec" type="button" data-toggle="dropdown" tabindex="2">
						<i class="reboot nav-loading fas fa-cog"></i>
					</button>
					<div class="reboot dropdown-menu px-2">
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="1" checked="" tabindex="2">
							<label class="reboot form-check-label">Search in All.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="2" tabindex="2">
							<label class="reboot form-check-label">Search in Internal
								Sections Only.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="3" tabindex="2">
							<label class="reboot form-check-label">Search in External
								Sections Only.</label>
						</div>
					</div>
				</div>
				<input type="text" class="reboot form-control" id="sections-search" data-test="sections-search" placeholder="Search Sections" aria-label="Search all Sections by their associated label." name="search-sections" tabindex="2" required="">
				<div class="reboot input-group-append">
					<button id="section-menu-search-btn-clear" data-name="sections-menu-search-clear" class="reboot btn btn-sec" type="button" tabindex="2">
						<i class="nav-loading fas fa-times-circle" title="Clear Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Clear
							Sections Search</span>
					</button>
					<button class="reboot btn btn-sec" type="submit" tabindex="2">
						<i class="reboot nav-loading fas fa-search" title="Submit Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Submit
							Sections Search</span>
					</button>
				</div>
			</form>
			<hr>

			<div class="reboot accordion" id="tagged-sections">
				<!-- Below is populated dynamically VIA JS -->
			</div>
		</div>



		<div id="help-menu" data-test="help-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">

			<div class="reboot mb-2">
				<span class="reboot lead">Help</span> <a id="help-menu-close" data-test="help-menu-close" class="reboot float-right click"> <i class="reboot fas fa-times-circle mt-2"></i>
				</a>
			</div>
			<div class="reboot accordion" id="help-sections">
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-getting-started">
								<span class="reboot font-size-1 ">Getting Started</span>
							</button>
						</h5>
					</div>
					<div id="help-getting-started" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Inline XBRL viewer allows a user
							to quickly and easily review details of the tagged information in
							an Inline document by automatically placing a top and bottom
							highlight border around each tagged numeric fact and left and
							right border for each block tagged fact. Hovering over a tagged
							fact will highlight (shade) all content related to the tagged
							fact, and clicking on a tagged fact will reveal its tagging
							details in the Fact Review Window. Navigation, search and filter
							options are also provided to easily refine and identify specific
							types of tagged information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-fact-review-window">
								<span class="reboot font-size-1">Fact Review Window</span>
							</button>
						</h5>
					</div>
					<div id="help-fact-review-window" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Fact Review Window shows the tagging
							details for the currently selected fact, which is highlighted
							with a solid blue border. There are four categories of fact detail
							which can be viewed; an "N/A" value indicates there is no
							available information for the item within the given category:</p>
						<ul class="reboot">
							<li class="reboot">Attributes - All primary information (as
								applicable) describing the tagged fact including period, sign,
								decimals, dimensional detail (axes and members), scale, measure
								and data type.</li>
							<li class="reboot">Labels - Detailed documentation
								(definition) for the tag used, and other labels.</li>
							<li class="reboot">References - Authoritative reference
								information (as applicable) for the selected tag.</li>
							<li class="reboot">Calculation - Balance and calculation
								hierarchy details (numeric non-dimensioned items only).</li>
						</ul>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-search">
								<span class="reboot font-size-1">Searching</span>
							</button>
						</h5>
					</div>
					<div id="help-search" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">There are two ways to search the
							document: FACTS AND SECTIONS. To search information, enter a
							keyword in a search box and select the magnifying glass icon to
							return matching results. Search operators "and" (via "AND" or
							"&amp;") and "or" (via "OR" or "|") are available to further refine a
							search.</p>
						<p class="reboot m-2">
							<strong>FACTS</strong>
						</p>
						<p class="reboot m-2">The Search Facts box can be used to find
							tagged facts matching entered keywords. By default, tag name, tag
							labels, and tagged content are included in Search. Tagged facts
							matching the search criteria are shown with a yellow-colored
							(default) shading on the page and appear in the Facts List.
							Select the "X" button to the left of the magnifying glass icon to
							clear the search.</p>
						<p class="reboot m-2">The content included in Search can be increased to
							included tag definitions, dimensions, and authoritative
							references by selecting the cog / wheel icon to the left of the
							search box. See Settings for more information.</p>

						<p class="reboot m-2">
							<strong>SECTIONS</strong>
						</p>
						<p class="reboot m-2">The Search Sections box can be used to
							filter the tagged sections of the financial statements.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-filter">
								<span class="reboot font-size-1">Filters</span>
							</button>
						</h5>
					</div>
					<div id="help-filter" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">Filters change the number of highlighted
							facts and items in the fact list by providing several ways to
							review and pinpoint certain tagged information. Multiple filters
							can be used at once.</p>
						<p class="reboot m-2">
							<strong>DATA FILTERS</strong>
						</p>
						<p class="reboot m-2">These filter options allow the user to
							refine the highlighted tagged facts by data type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Amounts Only - Numeric facts only</li>
							<li class="reboot">Text Only - Textual facts only</li>
							<li class="reboot">Calculations Only - Numeric facts
								participating in a calculation only</li>
							<li class="reboot">Negatives Only - Negative Numeric amounts
								only</li>
							<li class="reboot">Additional Items Only - Tagged facts
								without a corresponding HTML presentation (i.e., hidden facts)
								only</li>
						</ul>
						<p class="reboot m-2">
							<strong>TAGS FILTER</strong>
						</p>
						<p class="reboot m-2">These filters allow the user to refine
							the highlighted facts by tag type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Standard Only- Facts with standard tags
								from a common taxonomy (e.g., US_GAAP, IFRS, DEI).</li>
							<li class="reboot">Custom Only - Facts with extension
								"custom" tags unique to the entity's document.</li>
						</ul>
						<p class="reboot m-2">
							<strong>MORE FILTERS</strong>
						</p>
						<p class="reboot m-2">Additional filters that allow user to
							further refine the highlighted facts:</p>
						<ul class="reboot">
							<li class="reboot">Periods - List of all used context years
								and reporting periods</li>
							<li class="reboot">Measures - List of all used units of
								measure (e.g., US Dollars); as applicable</li>
							<li class="reboot">Axis - List of all used axis
								(dimensions); as applicable (dimensions); as applicable</li>
							<li class="reboot">Scale - List of all used scaled options
								(e.g., thousands, millions); as applicable</li>
							<li class="reboot">Balance - Debit, credit; as applicable</li>
						</ul>
						<p class="reboot m-2">Multiple filters work in conjunction
							with each other. For example, selecting the "Amounts Only" Data
							filter and "Custom Only" Tags filter will highlight only numeric
							tagged facts using custom tags and list them in the fact list.
							Active filters are displayed in the Filter toolbar as they are
							selected. Active filters can be removed individually by
							unchecking or selecting ALL option for each filter, or all at
							once via the "Reset All Filters" option.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-facts-results-list">
								<span class="reboot font-size-1">Facts List (Results)</span>
							</button>
						</h5>
					</div>
					<div id="help-facts-results-list" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">On the toolbar, select the "count" to
							the right of the word Facts (e.g., Facts 234) to reveal the Facts
							List results - a navigable listing of all currently highlighted
							tagged facts. The count represents the current number of facts.</p>
						<p class="reboot m-2">By default, all tagged facts are
							displayed in the Fact List Results. The list content and count
							reflects the currently highlighted facts (i.e., both Filters and
							Search criteria refine the list to match the highlighted tagged
							facts). Navigation controls are available to move through the
							list as well as move the current view to the corresponding
							highlighted fact location automatically. When a fact in the Facts
							Results List is selected, it will reveal the Fact Review Window.</p>
						<p class="reboot m-2">Certain letters may appear to the right
							of an item in the Fact Result list to indicate a certain
							property. If the letter "A" appears for a fact, it indicates the
							fact is additional data (i.e., hidden with potentially no
							corresponding HTML presentation). If the letter "C" appears, the
							fact is tagged with a custom tag. If the letter "D" appears, the
							fact is tagged with dimensional information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-sections">
								<span class="reboot font-size-1">Sections</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-sections" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The SECTIONS toolbar item provides a
							listing of the tagged sections of the Inline document. Sections
							are divided into three groups:</p>
						<ul class="reboot">
							<li class="reboot">Document &amp; Entity Information</li>
							<li class="reboot">Financial Statements</li>
							<li class="reboot">Notes to the Financial Statements</li>
						</ul>
						<p class="reboot m-2">By expanding a group and selecting a
							section item in the listing, Inline XBRL viewer will navigate to that section.
							When the Tagged Sections feature is open, the Search Sections box
							will additionally filter the list of sections to only those
							sections that match the entered criteria.</p>
					</div>
				</div>

				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-menu">
								<span class="reboot font-size-1">Menu</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-menu" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">
							<strong>Information</strong>
						</p>
						<p class="reboot m-2">The Information menu item provides
							additional detail about the current Inline document and
							customizable viewer settings.</p>
						<ul class="reboot">
							<li class="reboot">Company and Document - Basic company and document
								information</li>
							<li class="reboot">Tags - Fact and tag (standard and custom)
								information</li>
							<li class="reboot">Files - Files used</li>
							<li class="reboot">Additional Items - Additional hidden data
								that's been tagged but potentially does not have a corresponding
								location in the HTML</li>
						</ul>
						<p class="reboot m-2">
							<strong>Save XBRL Instance</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Instance menu item allows
							an XBRL instance document (*.xml) that is extracted from the
							Inline document to be saved locally for use by software
							supporting the XBRL format.</p>
						<p class="reboot m-2">
							<strong>Save XBRL Zip</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Zip menu item allows a zip
							file (*.zip) that contains the as-provided XBRL instance document
							and related custom taxonomy files to be saved locally.</p>
						<p class="reboot m-2">
							<strong>Settings</strong>
						</p>
						<p class="reboot m-2">The Settings menu item provides the
							ability to customize Viewer features.</p>
						<p class="reboot m-2">
							<strong>Tagged Fact Hover</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">On - Displays the hover fact review
								window for any tagged fact*</li>
							<li class="reboot">Off - Hides the hover fact review window
								for any tagged fact (default)</li>
						</ul>
						<p class="reboot m-2">* May impact performance with certain
							web browsers.</p>
						<p class="reboot m-2">
							<strong>Auto Scrolling Position </strong>(This setting will have
							no effect on IE 10 or Safari)
						</p>
						<ul class="reboot">
							<li class="reboot">Top - Selecting a fact from the Sections
								Menu or the Fact Menu will automatically scroll that element to
								the Top of the Inline XBRL viewer window (default)</li>
							<li class="reboot">Center - Selecting a fact from the
								Sections Menu or the Fact Menu will automatically scroll that
								element to the middle of the Inline XBRL viewer window</li>
						</ul>
						<p class="reboot m-2">
							<strong>Highlight Colors</strong> (Use the save and reset buttons
							to save the selected setting or reset to default)
						</p>
						<ul class="reboot">
							<li class="reboot">Tagged Data - Change the highlight color
								of the tagged fact border</li>
							<li class="reboot">Search Results - Change the background
								color of tagged items matching the Search results</li>
							<li class="reboot">Selected Fact - Change the color of
								highlight border used to identify the currently selected fact</li>
							<li class="reboot">Tag Shading (hover) - Change the color of
								the shading applied to tagged data on hover</li>
						</ul>
						<p class="reboot m-2">
							<strong>Search Options</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">Match Case - Matches the specific case of
								the entered Search keyword</li>
							<li class="reboot">Include Labels - Extends Search to
								include tag labels</li>
							<li class="reboot">Include Definitions - Extends Search to
								include tag definitions</li>
							<li class="reboot">Include Dimensions - Extends Search to
								include dimensional detail</li>
							<li class="reboot">Include References - Extends Search to
								include authoritative reference information. Optionally specify
								the reference parts to include in the search (e.g., topic,
								subtopic, section)</li>
						</ul>
						<p class="reboot m-2">
							<strong>Help</strong>(this content)
						</p>
						<p class="reboot m-2">
							<strong>Version</strong>
						</p>
						<p class="reboot m-2">Indicates the current build of the Inline XBRL viewer
							application.</p>
					</div>
				</div>

			</div>
		</div>



		<div data-test="taxonomies-menu" id="taxonomies-menu" class="reboot right-sidenav col-sm-3 bg-light invisible">
			<div class="reboot d-flex flex-column flex-fill h-100">
				<div class="reboot mb-2">
					<span class="reboot lead">Facts</span>
					<a id="taxonomy-menu-secondary-toggle" data-test="taxonomy-secondary-toggle" class="reboot float-right click">
						<i class="reboot fas fa-times-circle mt-2"></i>
					</a>
				</div>
				<div id="taxonomies-menu-list-pagination" class="reboot d-flex flex-column flex-fill h-100 w-100">
					<div class="reboot pagination"></div>
					<div class="reboot form-group">
						<select id="taxonomies-menu-page-select" class="reboot form-control" aria-label="Quickly jump to a page in the Fact Menu." tabindex="13">
							<option class="reboot">Select Page</option>
						</select>
					</div>
					<div class="reboot list-group list-group-flush overflow-x-auto w-100"><span class="text-center py-5">Loading.</span></div>
				</div>
			</div>
		</div>
		<div id="back-to-top" class="reboot d-none">
			<button id="back-to-top-btn" type="button" class="btn btn-sm btn-primary">
				<i class="reboot fas fa-arrow-up"></i>
			</button>
		</div>

		<div id="dynamic-xbrl-form" class="position-relative"><!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:e048f7a3-28f3-4092-a916-bde5dfced0f0,g:3190a302-79f3-4ce3-a4d9-ac703a7bb0fb,d:3cd151b5d83246a98b0e0ef4a9feb269--><meta http-equiv="Content-Type" content="text/html">


<title>lly-20210331</title><div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF81LTEtMS0xLTA_25bd029b-d269-4078-ade8-49a8fde5e6ab">FALSE</ix:nonnumeric><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF82LTEtMS0xLTA_470931e9-72e7-4323-abab-91652d95fd9d">2021</ix:nonnumeric><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF83LTEtMS0xLTA_dce5736d-1265-4056-b3ef-e0c487ee4dd8">Q1</ix:nonnumeric><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF84LTEtMS0xLTA_189acf29-f303-4b2d-952f-fafdaaf432ca">0000059478</ix:nonnumeric><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF85LTEtMS0xLTA_4fd04c6a-744f-4599-a012-ab066e0193a6">12/31</ix:nonnumeric><ix:nonnumeric contextref="i08bd92534c0942898d7deffdcc7f9938_D20191201-20191231" format="ixt-sec:durday" name="lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83My9mcmFnOmZjYWU3NTY3YWMyYTQ0NDliN2YxYjJiNjQ1YzI3Zjg3L3RleHRyZWdpb246ZmNhZTc1NjdhYzJhNDQ0OWI3ZjFiMmI2NDVjMjdmODdfNTA3_7b495efd-4927-4cb8-a7c3-719b42e6dcac">21</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="lly-20210331.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if8debecbe586414a933f775ea52cd38e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8777fbeb1d88449d8d60f606fd5c2c77_I20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bce3a2756434f739e7c3845a02a47cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ffc5bab7133436682aff62ddec1e376_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957ad33ccc1240e3948e9f141963844f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f3109e398cb4ebe87fb955a863b8ede_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e5e55c87bf4c9285d8bfe7ce6fd6d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i932abea342a94c46a25f33f1c8acc500_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdecec535fa14d78b9ef123144efa368_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibcf85b46974c4de78d45cca588cdb257_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i610527f799c444f999e77fc61f00e502_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id525ea543ffc4ac699696ae6133c1a3f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25f9462d4864ec48a45f240362e710e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e1e492a833a4874b74b3fb0b7f96fa5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id163dac405614d4ab0aab11d9539c9a8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife78f2b5881b4ab594c089c77d07dfdd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5e6fba402d49eda6d65097c72bd64e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2504bfe86b4fe3905a4c1dd6e8a31a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44d59353e664823911abf62eca2a0ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc56172f5f014bb48f88ac5499c1c0c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60d84be3db5c4d85abc4b594cd075e4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcdf0da7a8b34a378831b2abf856ab11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0582a765e6944e928d84c3bf2f09767c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf707b56bb5401397f3d1be8be7a6da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85d98868ecb4c1d9f33581b32035094_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002f042f1d494e298177c727853e4883_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6e502d3f77649d3b4966205297947db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i717123173f4f4d45a26fc171fcef135f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ffbb6496914f979518c442d56ddfdc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia95ec94014ed412d9ddf912309b31906_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336e60271cdd431887ad40e2953cb881_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8fa9dfe55240c8904822bb89d5d580_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54f7cb622be43a6a63855f304e93c8a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0151dc1fa445c680975efcbdc26506_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5b008047fc4f969d378bc0e8f5337b_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea0fcbeedbfb4018b173fba695dd9fc7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd152b8ae7b497f800f65a679736686_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b961987b212484fba2e55e3f8599292_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i00e2ad623e9f4f09a525954c7be34a38_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib696b72b79fd4a64a05a14552524fd57_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia9bcfbde64cf4e6885eff068fd1c0181_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3a64fdc1a7fc44278f9cf486b1d6c7cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i38bd7b2a836c4d14abc0e95512ba56c5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0b2a402409bd47ceb3efc76f535f0984_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iec6120b958de4ece8b0bb1b2c92eb827_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i14a1f7c9c8094a24b89b05adbfa13722_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1da1bf79aee54038ab5fb824f0b5459c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7879b1c8e8154d82951f06d7277606ca_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib22403656ba044288e3a7c9bd076149a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie60de7ffff384040bda8a7073de65757_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i35e2453e887841ba845624286f429037_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iac9fe39efa6e493c8fc3b5a5cb61875a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i12fc66e4003b4a108dafd95f3f948eae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaf36848406364477a5b09c68263549c0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0cec2d3e8980474dba0ccd4ba2f4be53_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ac183bd15654d9ea8bfb79ecfdabc21_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5d5411d889ea4b0c92badda1ff003164_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i80b19d05555b462299ff41542279ba37_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib8ce72672e984dc38dbee5c4872a819f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4bd74f7f91ca4076b9bc23d4ac7407c8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6cacb66e50b43a29e19d4cc6a18b475_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i82b9a6cc26eb4896a200c5b2d5ee6aa5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i23a99b86356248b7a363e089040850b1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1c94039dc776423e982d5e1215b9f0e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i57d3bc0a03b5400f848a8a445a06af73_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5c9abc35851840cd80b9598eb84e59be_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i68c425bf807b4ecfb4bfc4e63113b9a5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i991e0184719242bb9681a766c00e183e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9ad3a54cc6da48c7aabdfbd4ce0fd7d8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i97e8d103205d4d8a8ddce47720e2b0df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i37a9f92fe3be4a59bd100214c32741d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iab3763aca7de40e3bd3755d4afdf8ddd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i08fa42e2b3004f2c8d8c3d2949a77b62_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if05b79fd4afb4b3b85e0170d60701765_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i53e1ac90f1794867bdc0e1208a22454d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie5488586d175451ea3762d3e3427d7fb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6655e736bfc145ae9b61bcbd43ca3775_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i95a511f3e56540efaf67326c58f115f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3a8600a4d0ae48ac8eb847f76d72fb39_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5d683e3edb3b47769c30eadb5fc443db_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia92a87d280ea46c88caa7e96c7a0c2c6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3dc1168de1ac4bd892f4336105fe8d34_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib1eb5c54ee4f4ffd849c70b74454938b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i99351a29767e4c33b139db7c60592e0c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8c035a4a36d1475c87f42c50e4fe5b66_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ica6ff26a8f5c493bb678f8b8bdd2f5d0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9a84f264bd5f43d18f95d6449dbfd211_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3ad5e6e9c6b04e0ca3a23762ff4389d4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia3895e84ece4456f9fd7475f8330b5e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4bf54072320b4a95bcc03ebf93fd790b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a64b17a7372474b936176a48e73353e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1ca44d898d14b6ba06c659cc8685067_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaec1b41e2f1c429990d5463381ccb5b2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic305b0216fae4bc4be68a9c14511b14b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifc30d8c3304846bf98d3aff4faa90db6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i301b5063b45f4c778fa6be355225f1d2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6ac8015a990a47ac84766a6b061f5c80_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ice0f65e55bc14fb4a8b9c74295879c9f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iabd56efbd9ee475196495211900a4916_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib4990ade4fb749c5becfec40f273af6a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idc1ec2db8e1b4baa971e09c08d4342fd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i699a1a79461d4373af3cf037c5ca77a1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icbf8577a767f4b6fa45fbea9fc0008e8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9a65c960be0f46ebaab122d5eb8f5e3c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib410c05551594d84936a917166832ea9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8d36ff64df614dd2a64ea2e3cb167f9b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if30239ae11764340af612d6d0acb2802_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i10cbac4f340148c58e34434fbbf2a27f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5a346e0ad24144caac752ea7f4355d34_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia3156015f19b4add93eceadb6f839944_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i16d7bf43c3214967ae1523ebc568940c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a1925d8bba04bf5a88ae7c5a2c5a30e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i65134b9feaf3468bae4f56eb446cc39b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b08818da51f405ab315d6a7b99fcdb8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f8df345856f4facb882054634c50249_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b44fc5413ea4394a3af4e9ae8cc9357_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic6c1690f2a1044549cd196b5d0d49bad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5f2094304a9b41efa6498348dc920bd5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iccb5bb5fcf05439eafdaafbbf45b94dc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if46aa3d35d9f4f9e9f98c940d7063f27_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i27ef923c97994ad09a5131b38a10eff2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22ac5026b0df4c01a41cbb9fd7bf0ed4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e7b860d15e24b6d8a4c42caa07a07e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic9d2acfb73014f21b93868d591ba0055_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic86716e51463478c9178d57dbc0df5e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1eca7f391c9c4eb4bf1be4d2f78c64f1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i23a06e4fd12547b68a8c1fa847a573cd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2cdd8652ee714626a6ac6694e023589f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibe710610bc2745d6b62b94d3e5a59c49_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib5195f2602fa4de78f56cde487a199e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8e4a642cedfe46019dbf6bdbe6fbe49e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i82c451df337849a9aa0ebbd6efa659e5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id5d69a9f098946b99fd0dc8d1e98e66a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9d569029e59948f09619b73bf0efdca2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8ec2c9c0bb35428e84cb57a3987f75e0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ida0989eec65245df9b1682cf38ed4bd2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3bc0464b0bdb43f5a8e902cdb4b263da_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia8cb347768764c2b955eac4a8f4a17ad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98c884b95b7b4a8493c13f83a7b6caa7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5c53c31a3a5c43e680ca9bf03cd18bab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f23306ae00143a6a4003c6797529b59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if6964e815afd40a1a706fd094d27e141_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9ff073cd832f489a918e71ed9f2bc601_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icaab0628ba61471db8a691d30a7a5ae6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6540e5cb4f94023bd8a1a99cae7dd50_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if0244d48c6684b1d90aaffa07334e12c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3a035aacb6aa496e9aacfa82670a5f77_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2126f23f1b6c45da8eda485ea4fb0ffd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i476ff2f62e6e4dcd89e4d0e6f6e2e23a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icd995ff940774cf9958d9496ccefdd49_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i91bb5aef62c64ba6b7374026ad6cb167_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibc1a4bfd08874c51bd52ae124d146ed1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d060a91a83540adba28a86e89f8a0a9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d28979d157949e8beda765ff3ebba18_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i59a5e3ece3b2457d9dc9503670f62a19_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idcb95436aea141439b320a672d06798b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibbdb540b92834be9a1952a6988efe111_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id5ec8f6c1a2745b6aef8220c52179da0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifdac2859144646f497bdee29d8f1077c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6ecf74960c9f4004bfb28db9ceeee105_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibe3a395375b74608adcd0dcb2511ccb6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4e845118c19743509f235e3de1249c91_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i956b8eaf8bcc48e18a6392d104e3f82f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7f802e7b0b4c462498edd33fe1a08df8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i41bf8c2f57c2453187f38f71658035fd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iccd1e7bf99a04464a2be5ae2844e93c3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3a96f967a3e14ccfbf1709108752b15a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5e1de888a7434a7d8901d5d91e9a5662_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i805e06baf0334dd2a9272620abb71ef1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7bf6f39de92a477295091f337c5f246d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i87c3683c282e4dcab93976f033317191_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib781ea03fa4343ea9f43fe30bf85eaff_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib9004a4576d54acdab802ba18e5954b5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5b813d4b7f6a4ba8ab05eb62fa8c0d7e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6e00607e2514771bb461112b624c3c8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i678860fa552c43d4b4fcb6cefb64112a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i009fa3f9194b481097ec59ef54e9398c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic91d06961c624604bf888bc77f143328_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a70d046e3e04fe8814a35c37222c987_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5a1a9bda61764661a686cd2e6cdf4353_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2f37eacef6da488b9411e64b1e6f9bf8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46371b039efc4855ab60d1a0cfdee9ef_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iae0c3902df5443afaa207966c3c336ae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i01ed93e108f540d895209d6cd63a4196_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i02826dfbba6c48f19cdc43d704001dbe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0da8ce69328d41578d3e52a25ef5c637_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icf3afa843ed74fd3a1dccd7d9a340f73_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icdbb2ee92d984ead82d0bfe89b0b7e67_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5b635789ef4a4a3ea608c5ece8aad1d5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia0503e2189e0437c94e4365e2f5e1a42_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if7a3d52cbc5f4c36913820afde8b5ce0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i29a85ee0346840baa3213980b51c8392_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i48278fe6c84a480c993daadca8e14bec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id2da738de9a9496d82ebcd1ed1dfc349_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i72d5f436073e4013afbbcd703dec4745_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f47b5c8b6e647f7a98ae58501327a48_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ba01d74fb2f4bc0a8c1b64e3b1eef96_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i91fdfa6c20d94c5db431e71629735e62_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3bdeb0b05ca8485aae2687a910e899e8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibf27f4b868ff4ca6852de83fc00626db_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i725c25318b374568a7f6a1c522f751f5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic8f05f60f5234be3b895a985508995c8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iecc41b1e93894363b921a691b8c9ad5f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a8c46f072984025becf4f91f04a0ad4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i53a4c1fd0f0e411bbd983b92368c6662_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia8476fa283c5420a8c1cb44bf1886c3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8a141f4168094f93bc307eb5ebbf7392_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaf7492d96a0b4f29b67c7ffc8e4fc10e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2d6aaabb8fc4471fb4d955cbdc949682_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d1b2d8fe9744bfb992ea8ca03c8de17_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7fb432a8a93945a68250848e46684f98_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia3e93321ddf644359c1906deaf4915d8_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lly:right</xbrli:measure></xbrli:unit><xbrli:context id="icbcb632a5c694ec29deb85ebe3a2a2e9_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-02-01</xbrli:startdate><xbrli:enddate>2020-02-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i532d485d20654594a8b1a96d44626d00_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a359ced678146c9b9d8f9eb94adc1f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if0a60d23094d4089a16f414a2eb40222_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib490931de5a249db92647a2ab94af9ad_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie1c5831cc7174801a03a8b0a2fd91a4b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6460ea51b114fd5952c6937cbc22e89_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if871b5e2a0ea46059a74abfa4e82d02d_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-03-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5c7fcc42f3b34de0bb6bf706fa7541fa_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-03-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7cfe3973fd10441580375afacb0b0090_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-05-01</xbrli:startdate><xbrli:enddate>2020-05-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i787debb10db9449ebf355978b2cac4c9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d95635b39cc445ebd68b8eaacc4cf49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8356c279b93c42829023f67b564fd0f1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7898c22d6db548ba8e625e7b4cb51b1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie49f3b9fa84949058c66e2ccc6f1bafe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf3e061ab6a44e0b3e95b09ceec5863_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabb0222b012c480fa8a4b4033fb1c3b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i50e1340911c44726ba35205e9879816a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i661524a58a1c40ec97906a968e6f6aca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id9bf6a3d44b2458aabd053d1804a3283_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64aadc652c4343c1bcd2bfc5b72d6158_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3343c905d8554be69ab7b345fa893082_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec641d1b0e0486dba0286bc54d9f28f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cadf4d9d0bd4bf6b1d1bd9d0dc96dee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a54fd999064e8484fd5ca2af4dcc17_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied018ff88f6646e88340a81a87e88722_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d761f2cc36e4a03b6ad57e5ab13c540_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32a56f35ba84943ac17a6ae53d314e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">lly:OutsideUSAndJapanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24615d347773426cb44faa02b5f3a282_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6de8f942f44cf0aced4adc5181105e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee311292e604c2ba36873038aa0d41a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e55c79531a045a4849418d1e780b569_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd3d506e737426ca9f7d5071e2fe975_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6017620bc984fc3b23178c68fc11436_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c39357db5cc4a9cbcfd00adcb81f908_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fea589edc3e4ab08f9ed7052aad2e59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8fd6ec70f034998b9025e47bf69042a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsDollarSellEuroMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="iacc428f5b7444f79a59f33bd449c5b64_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i196a382db4dd474f9215758c00592480_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyBritishPoundandSellUSDollarsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i790e81260a954cde9599960f6c59fcd6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee91d9656eb3472e8cf1ac38a3807882_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifca25d1668f0447a8c0fb8e92c444a46_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd062c4f7c644c92a3bd0c5fc8d3cd2c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08261dc843c546e282dc7746c9935f3a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ae6e16034149ffab19351331c55b6a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5bc95e47cf6e4f3da137f20ede5e2282_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e9ced055f4647d1b7ac5f1b13d3dcdb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0675cae41ecf4fad80226860b67627c8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5cc6b325c96343679b6ae5ded2b4017a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ebf8484d97442a79f3fb0056a0a0636_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i48597227bfbf4037b23b06218e7f576b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i733a2380e7734f87b92e3f8aed9fe6ac_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie02bf6e1811a43e7a3d115fc98ca56c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic8a0cc4c13104fccbd1c69dcb601af62_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0468ac52ec0a40758c116186c956d819_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i259ea4a4728c4829bf5a1d53b88fe316_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379b7bdd53b04924a6915f7b6f539ae9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i502fd03d8e8b42f384a0637943ac9227_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110e7dd739b14882b203dd13e31a425d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b1fc639100545e8b40e4cfd5886def1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50db401e52d34c6bbb22d8b87c712ee3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9b74593ec94447a6448aee79dc1a4f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11210e6bf5044a31804dbf8297477c5b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c35346f0f3b44448000e57b1d0d71cf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e2ffab98d7f45a0a3b806e73e461745_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab695d20c84c457e96ce06476d8e182f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6474daeefd44828fcb9effa40e0c54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d22e93a3ad41848489c4810cedd352_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8aef2fe7df7413a99dc9b367490fdba_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ff33225cde42d38dd508e225243ffe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i094cfa08457b4639b53077e02b7b579b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39943827be2c4f9ea50a2cdfca84df2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaeb507e6d804976ad515b86786c2663_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd103e4954f440de8adec2b901b7d26f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2765888bb9a44e86856eb0e40a7a95a1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i937ee9f927b84aafaa8fd46c3071e390_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5623a1b5a79348899d40b0b51b54335e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i273c3175cdf54c6d9bd6414b446f3ab2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib521cd4c99774b97881a80a2a1c9c35d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b67199341a409fb3c610a89020e4e4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d997ddd2afa4e4aa435ed61a0039a79_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162abcddb00540a6b88917d1b8c94bc8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70666e8c06ae4150b3d53ba8f358e55b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b8e28324e994e5a9e7af4dd5abbfa4b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cef5c921b4d4a13aa14e51caae1e54c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45eb28a2afb843b5a7599d09796ba47a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c96a7e6ebdb4b5894e42f4f674afc2f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a6dbafa15745eabd7e346fc0404f3c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie03e1c230dbe49b5b1a23948beb4fdf8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4814dc5f3094945b14b09c32634e414_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5428a6a7e77a4afc87dbec371aa0e81b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b460fcffdff4102b1a5f350e775eb50_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68b41c9f5b24461e99ffaf90ae7df35e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07692a7baeb34e989f264a119af0c6a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc36d48d552416e883d9009bfca5133_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id251b7aadbd741c38319af027dda2015_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie57e8b8550a94ed3a3001f7258f40509_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie22efb639d76469d92d9d05b55c13b2e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5244871105b411bba98a34bdca3bb0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7364db11b9f4acc956a7d2db362e700_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc89d6e873484ce2a724580ab1fb0293_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib227796e6d934483a3898110d9a529dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99278c5824b4d0d9f4dabbc783d760a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i173d02bf976949bb9c2fff706b29e7c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca67a3e336f480dbf5c62f2d4887602_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2385ee7845f44db9928643d251ba010f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674d272a65ea4e939a918cbd40640fad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8e950975814a17bb0570d6ed036339_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab6a22cd5a3647489cfa1868842fce27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id94556bfa50648c6896a229ad967ebdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba9c3716f03494583ac46573df6d898_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f1ae733c62431ea7747e533857a063_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f60e22ff78453692beb5eecfca6ffc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7549721eee45bb8a3527258d461fd4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9525a450be44ef9048544d4294da74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65bf701b377c4beda33939db2d2f21ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55aec24c88d44f4fa43277cc7538aab2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853e5949474b4d67b1db52061559bac8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0f7206c077458c83a576a665d51173_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb18caa1f88e42d389a9b17c85b0d9bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43215dcd05be459096efcec752179430_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c52e457bd4422ca65d6e22cb0ade48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1389fc9ec68d4b2db27d6a8e3bbd4bf1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c4f4f185ab4ad881bcc56455b80c21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79853a9b5da14a6fac53703381e9a418_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33320e06f4274ef9845c5efab8d73bb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2eb8a9c98a498ca9bf40a99de8f49a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04cc817383740faa1e617ece927631a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id384954fa3fa4e6095584ab30e130a4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8955bee463a4261b77faca6da120420_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e8796c582de405f85453b6be2e3dc09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57b6463cf5a4132bbba6db81c527ec0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65887bb8147d4233b2936ee964d36760_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45624739b2404896b6fe384552b5797f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bd77315f3640e2b75151bd1a403bd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i095078139e5147baa3f7c5a93913c9f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41723e47817543c98de3be1e9ac4e77b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide25b210128b49279f9dcc009920c562_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed173a5c7554ed8a6efa974dce7de56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8841002a34004d4d894ac4dd47bba8cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd5d2cfe7b1c4e6293342168871eb584_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1862e16eb5894cbb872c6ebca5ff8dda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8f781677394edcb970a7db2a230211_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0320b4ac23843468622fdd30e513355_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df56ec982804883a504fffec19bec2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i818be88d8b754d358fa8f0f48530989d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff50ed7383624a5dabf03016acb58cb4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22a911ebb564c3e8e5e11aebe36daf2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3791d236011c495c9a6bc09f31e0e651_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eef9a676fef442f8cc0df6224b88661_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4f985dfc4c4913b6b477e42c5b7abf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f888ed727b47c4969964bbc26cee74_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc00ea5651d44a68866912b87e772f32_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9728137c063040fdb217c0c575d24e90_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5691e9a962e48b9bab39a38eebafc58_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i083270152267493cab8ef4a98752605d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4db963049a418ebc24c7b6962c9c42_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df54907b9c740578baa39b1f16db346_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9868066d4bf64c67b21b80f50a543d09_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3477ea907754af1b237c11ecd845a8c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5579461ee30641f5866f90f7f973fc2d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c522dc4d3644e6b89e1c04ae748b784_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4028304ed5344f378d4d8453889c1244_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i835b04928dc34e3d9eb5b6a882d6a434_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59341bae0f284bb79a7771c86ff861f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253bfddb6f414fe3a582437856252d99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd815ed694bb4b1da50025622caa47df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39cd3b104234bdfbcbaedb52a41b15c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f25e4c5e4b42cca659ef04248013aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541afb2da75d43639f7fec2ae5748d7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014bd38c39aa4b1895340e1de5390e79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79425d230e734042bd4df00c16901373_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2553d800f08240b1b782fd37f8f03377_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf6391061294c348287bce4418a7767_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i326c763bfd9e49bdb908141c5104c4c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if72250a4fe7543458ef88e49f913f39a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ee22718d2249e6932918034d9479f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11784cd0180b4240bfe628b8a935091b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b7165b4f9f4b159f2f118447ef21b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492cf935c87d44ea908c1584da4f932b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86f5f0213b924cf4a2443b1755e0e558_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie913be1662fb496dadd88c102ecc6d7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9d49fc86e54fa4aef040dc305765cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c34c5498af462390f43272c1214aad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80e1536360e0467e919e75a282b9c273_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="i9472948bb7f947afa49886afa824b300_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7408050434b1433f9057403b967bc044_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-02-01</xbrli:startdate><xbrli:enddate>2020-02-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1dfd4b4b1d2a4b459b67e2e9c72eac8d_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-03-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i19d9bfc8635f470e9a7adb121100256d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fbb93a5eb8140d2b2faeef2de2e7c59_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9877de074e3b4cd68f3e14e738b53b96_I20120731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac89cba080843258ae570efc0620a18_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad757e1928624ece99a2023c2b06db4a_I20130131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92b96cca8ef435288a260a7692a4296_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>lly:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i87320df79b3f461da082a107fa7a8e57_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i15f9ce4e2e9f47789b45d86896781f54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6776f7310a5341a3b3f6bfdef846dfea_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib44052b397dc4098a69265e6060b79a8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121dcf9b52ce46eead9ac16494dd1642_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib73e27481f2e44bcb74fda4f3cecf682_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa2b0f3392543f2b160709e35c124d7_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b029559694b48b08c94d12ad381445e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02307f1292e42dd8aa0a8c7f88d014f_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ccdd965fb0d44ed8eaa51cd4f6af3a8_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id5a9904ee8fe4ee9900bba9f1c855eb9_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>lly:claimant</xbrli:measure></xbrli:unit><xbrli:context id="i0ac86530d3c243cca63aa23529e06624_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f7430fd06b947ef84b255b6fb8aee26_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>lly:site</xbrli:measure></xbrli:unit><xbrli:context id="ida0a952118b340e6ba680f7df96d7075_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="ib5001859aff84e2dbe43c4543f7e5dbc_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-07-01</xbrli:startdate><xbrli:enddate>2018-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-03-31</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i877919e055e34b8eb3844514babacc6f_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-07-01</xbrli:startdate><xbrli:enddate>2019-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaa67ffc334f74fdd88aeff3e17eb06fd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69f451428d3e45a3a75cd744529fea05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="request"><xbrli:measure>lly:request</xbrli:measure></xbrli:unit><xbrli:context id="i08bd92534c0942898d7deffdcc7f9938_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:DrReddysLabMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-12-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b10da171de74c8882000a2f696152fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5614d38977b64c168c1b9fc251c757ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd75cb32c5543a891d689e8933d4949_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa91bb6c1a24ffcb202a27011d73dd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2845560a0ba2491a904c84ba82f35819_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743947277250425485ee1e0a26d90120_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9655bade5b00400dba7752533cb6743c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i577b7fef6c2c49bf87fe8cb8121248ce_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23fc76e1a5a432a8db78dd624ef5cc1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7caab5ff3a4d4ca8a64128cbbeb05cdd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8b459cd1fc47f6baa6f11b48145ac4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1eeb66393264479aecf1f1d2fcd51b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc74d110d0145598aeabdd970d87f17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa58ad2146314403b3eff9eaf3e10324_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ebe01e7039a44a4888856db6e4a7d39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffabc6d5c4614780a93ce1b21d701159_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ce660d25654b37a7243b236eca576b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i55b8fd6090834514913a2977fd43623e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icd5fe3b1199247e6a91eb8d01efc2392_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d912b5241343a9b988106cef8e0215_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33afbb7d73484c0a83d56114c6756d5c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194e7735259d438eb363e7d9f3ae1523_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i986fb3e559c0490ca09848e9ac9bf901_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf742f7aff334b05a91842e894677604_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i02045ea33c7d43d4a34c42a37721b125_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if48b9be7413d42df903afc9bf15c3c13_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i492583e2c9b044f29ac4a51092ddfbe8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibfdc30c8362d4397a4020c9b938662fa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2917edad81e5463e9d61cceea8f62ea4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if82cce099c354dd78182619455a05af1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i191727da20c34eae98d4dbc93f0337fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9638221883d14af2935d735e8cc9a360_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i37bfd76d6ecb46708142e81e2d19a33c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9c0ff30fbf7f474f9b43c59d3bc7e538_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMx_c2b9ed78-63cc-4402-9b93-0d368b9aa5bf">10-Q</ix:nonnumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl80OTQ3ODAyMzI3MDg3_50524f91-7466-4ed1-8a0e-4ce3dec76b0b"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl80OTQ3ODAyMzI3MDg3_ed6a6b1d-7d90-4454-9a97-2f44f6fac31d">Quarterly</ix:nonnumeric></ix:nonnumeric> Report Pursuant to Section&nbsp;13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDU_54d3768c-fcb0-4dfe-a940-17fc80e0a257">March&nbsp;31, 2021</ix:nonnumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM3_941c6df3-644e-4aee-a032-e86c79125d81">001-6351</ix:nonnumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMy_eafa7129-abe9-4396-85ac-0509a8a791db">ELI LILLY AND COMPANY</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6MTMzMGExNWNjZmMwNDI3NmE0NjU5NzBiMzgxZDlmMmEvdGFibGVyYW5nZToxMzMwYTE1Y2NmYzA0Mjc2YTQ2NTk3MGIzODFkOWYyYV8wLTAtMS0xLTA_5ba4d629-ef82-4d8c-9fcf-ff68042ea2ae">Indiana</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6MTMzMGExNWNjZmMwNDI3NmE0NjU5NzBiMzgxZDlmMmEvdGFibGVyYW5nZToxMzMwYTE1Y2NmYzA0Mjc2YTQ2NTk3MGIzODFkOWYyYV8wLTItMS0xLTA_d4bbb31a-df75-48cd-b8b9-306cf3d83247">35-0470950</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></tbody></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMz_27dbb615-7f0c-415d-99ef-cb4d12b161b0">Lilly Corporate Center</ix:nonnumeric>, <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM4_477fb1e2-e68e-4a77-8667-f1aaeb4f6608">Indianapolis</ix:nonnumeric>, <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM0_1d8d3687-6efb-46f3-a252-33f8569fffb0">Indiana</ix:nonnumeric> <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDI5_67048238-f05e-46fa-94fb-89c7384b062a">46285</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrants telephone number, including area code (<ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM5_0f54f8d1-891a-4573-93cf-0745c6d91461">317</ix:nonnumeric>)&nbsp;<ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMw_73cce34b-600d-420a-9c6b-b59b8b5171a1">276-2000</ix:nonnumeric> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&nbsp;12(b) of the Exchange Act:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbols</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTAtMS0xLTA_5852ea3e-abe5-46df-8885-e1ff73dd97c9">Common Stock (no par value)</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTEtMS0xLTA_32af1ca8-ec20-4bb1-b2a7-3b7a3b6ec007">LLY</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTItMS0xLTA_a6e4c6d9-81fc-4c24-8399-e83077bae5fd">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTAtMS0xLTA_02a9f67b-f920-46ba-bedd-a609ff4ba425">1.000% Notes due 2022</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTEtMS0xLTA_55876694-6a66-457e-8c0c-11de8b5f3b9d">LLY22</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTItMS0xLTA_eb74693f-0c5a-446c-b927-bc5be1003f72">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTAtMS0xLTA_d8b50eae-ed90-4d86-a091-ff0573a57d9a">7 1/8% Notes due 2025</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTEtMS0xLTA_01faa47f-63d7-46ec-ad8d-321e3e04bada">LLY25</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTItMS0xLTA_5be754f0-9d9d-404c-8baf-9f91d7df91f8">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTAtMS0xLTA_62ccd249-293e-4394-a1ee-2ff65d4a3668">1.625% Notes due 2026</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTEtMS0xLTA_d649d9e3-810f-4f88-b11c-5af5437046c5">LLY26</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTItMS0xLTA_31e4cd36-ac40-4fbe-b189-c65c92f1feeb">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTAtMS0xLTA_0d331ad7-b4c1-48a5-81e0-23cd986ebe3c">2.125% Notes due 2030</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTEtMS0xLTA_647c3c2d-dd00-4092-b7ba-12447200608b">LLY30</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTItMS0xLTA_f67af9d2-a1a2-45b9-99c8-68565551dddc">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTAtMS0xLTA_1af55436-1efb-4d22-add3-749d55e1acd1">0.625% Notes due 2031</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTEtMS0xLTA_8c5d9633-0fbc-44ba-95ea-bfd8bec2c49d">LLY31</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTItMS0xLTA_6906eeb0-ca8f-46e1-8a49-0e2b75ab686f">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTAtMS0xLTA_bfd3ae83-1f34-4d48-b4c7-3ceff96c5453">6.77%&nbsp;Notes due 2036</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTEtMS0xLTA_ac233df6-c8ae-4368-9082-b9bd752f8f97">LLY36</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTItMS0xLTA_d3dc6bff-572e-4d8a-9f9b-203d8eb0d68f">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if8debecbe586414a933f775ea52cd38e_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTAtMS0xLTA_cc65f1d5-af80-44f1-b7d9-7c97935d37cd">1.700% Notes due 2049</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if8debecbe586414a933f775ea52cd38e_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTEtMS0xLTA_994a0125-366c-4068-abb3-25aba8111495">LLY49A</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if8debecbe586414a933f775ea52cd38e_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTItMS0xLTA_03a472e8-842f-426c-99e2-543f449c964e">New York Stock Exchange</ix:nonnumeric></span></td></tr></tbody></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&nbsp;has been subject to such filing requirements for the past 90 days.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDQw_8316d960-0856-4a7e-8b1d-ee51109c64fb">Yes</ix:nonnumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM1_c638c031-3805-48a3-9c9f-ad1df8425815">Yes</ix:nonnumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8wLTAtMS0xLTA_6fcdb110-1ea5-4f3f-9769-81e29600c2ad">Large accelerated filer</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&nbsp;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"></span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8xLTctMS0xLTA_26fe7f6e-5b13-4a6e-aa31-43601438e047"></ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8yLTctMS0xLTA_5943a540-b02b-47db-ae6c-851d80537700"></ix:nonnumeric></span></td></tr></tbody></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM2_55615946-59d6-4dae-b2f9-bc6a2db335fc"></ix:nonnumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April&nbsp;27, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Shares Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i8777fbeb1d88449d8d60f606fd5c2c77_I20210427" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6ZGQ4N2E0ZWZkOWUyNDA4Y2I3ZTM2YTgzOTYxZGUxMmIvdGFibGVyYW5nZTpkZDg3YTRlZmQ5ZTI0MDhjYjdlMzZhODM5NjFkZTEyYl8xLTItMS0xLTA_2e4c175a-d277-48bd-9ae6-fd9d9db41429">959,025,446</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended March&nbsp;31, 2021 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_13">PART I. Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_13">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_16">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_19">Consolidated Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_22">Consolidated Condensed Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_25">Consolidated Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_28">Consolidated Condensed Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_31">Consolidated Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_34">Notes to Consolidated Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_85">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_85">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_85">34</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_88">Executive Overview</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_88">34</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_91">Revenue</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_91">44</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_97">Gross Margin, Costs, and Expenses</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_97">47</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_103">Financial Condition and Liquidity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_103">48</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_106">Financial Expectations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_106">49</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_109">Available Information on our Website</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_109">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_112">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_112">50</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_115">PART II. Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_115">51</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_118">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_118">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_121">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_121">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_124">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_124">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_130">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_130">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_130">52</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_136">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_136">52</a></span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under Management's Discussion and Analysis of Results of Operations and Financial Condition includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as may, believe, will, expect, project, estimate, intend, anticipate, plan, continue, or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of the evolving COVID-19 pandemic and the global response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">uncertainties related to our efforts to develop potential treatments for COVID-19;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of acquisitions and business development transactions and related integration costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">market uptake of recently launched products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our IT systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">issues with product supply and regulatory approvals stemming from manufacturing difficulties or disruptions, including as a result of regulatory actions relating to our facilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory changes or other developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory actions regarding currently marketed products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">devaluations in foreign currency exchange rates or changes in interest rates, and inflation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">asset impairments and restructuring charges;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of global macroeconomic conditions and trade disruptions or disputes; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory compliance problems or government investigations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2020, particularly under the caption Risk Factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this Quarterly Report on Form 10-Q. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Quarterly Report on Form 10-Q. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART I. Financial Information</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;1. Financial Statements</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars and shares in millions, except per-share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue (Note 2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMi0xLTEtMS0w_cdc049d5-2d49-4700-9596-113c5a6bdda8">6,805.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMi0zLTEtMS0w_dacb8a1f-5e19-46c6-9a11-2a2c57bae91d">5,859.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNC0xLTEtMS0w_9ba2fceb-ee49-4a8b-8346-76e081a31a3f">1,878.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNC0zLTEtMS0w_87ad829e-e05d-41bd-ae98-2f91a74a2b62">1,215.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNS0xLTEtMS0w_f8b4cd4a-2076-4e6b-8580-772d97f02af6">1,684.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNS0zLTEtMS0w_025feed4-c178-4e39-ab60-2494910cdcd0">1,392.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNi0xLTEtMS0w_e9da96b3-fff1-4c26-be72-dc12179ab88b">1,576.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNi0zLTEtMS0w_da1c1dee-53f6-481d-bfa1-65b9d3399c1f">1,549.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNy0xLTEtMS0w_f22b0665-a414-427f-a392-d550ff6a24db">299.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNy0zLTEtMS0w_e596da16-5335-4bd7-a836-7c3abf06b559">52.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOC0xLTEtMS0w_867dc0f3-4934-4403-bb1c-95f003c7ea49">211.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOC0zLTEtMS0w_61e9d0f7-00f1-4631-bc7a-178c42842cd9">59.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Othernet, (income) expense (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOS0xLTEtMS0w_49172d7c-4713-4a2f-973b-380bc431025b">321.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOS0zLTEtMS0w_db66b2b8-dfdf-4080-ba6b-e3e254491d0a">89.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTAtMS0xLTEtMA_d0032acc-81f7-437b-ba30-aedbaaa5b406">5,329.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTAtMy0xLTEtMA_070ba26f-5648-4913-b04c-09e4be48ac68">4,179.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTEtMS0xLTEtMA_dd4bee67-0886-4a2a-9b4a-487c6a1d8f0c">1,476.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTEtMy0xLTEtMA_2a049c13-51fa-4014-b603-b30c60c21d65">1,679.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTItMS0xLTEtMA_939aec93-1f5e-428f-84e7-ca213f434238">121.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTItMy0xLTEtMA_f7a2b37d-1475-4fc4-9d8c-34d43b09a8fe">223.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTMtMS0xLTEtMA_cc339fb1-a3d8-40fe-bd5a-d7d496f2ee0b">1,355.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTMtMy0xLTEtMA_be444e07-fef8-45e6-aa2a-4663cf497616">1,456.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTgtMS0xLTEtMA_6dae2d9a-054e-4ba3-a878-91126bff5d82">1.49</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTgtMy0xLTEtMA_a412d89f-0c49-4153-b210-3917b8f07278">1.60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjItMS0xLTEtMA_abf07fd6-089c-478d-86a2-347b71efc313">1.49</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjItMy0xLTEtMA_03a4aa9a-eba9-4fea-8fbb-7fe5d08add7a">1.60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjctMS0xLTEtMA_3c35c5a9-73e4-4f0c-ac6d-e930b74dc741">908.8</ix:nonfraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjctMy0xLTEtMA_895ee77e-373c-4d4b-a6e4-f46c3819ee3f">908.2</ix:nonfraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjgtMS0xLTEtMA_da1d0de4-5bcc-447d-8960-719067847d15">912.4</ix:nonfraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjgtMy0xLTEtMA_4c301199-0d52-4f7f-b99d-f82add56f70d">911.7</ix:nonfraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&nbsp;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfMi0xLTEtMS0w_cc339fb1-a3d8-40fe-bd5a-d7d496f2ee0b">1,355.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfMi0zLTEtMS0w_be444e07-fef8-45e6-aa2a-4663cf497616">1,456.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNS0xLTEtMS0w_a79a99fe-4b1e-44a8-a984-c93057b5c890">100.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNS0zLTEtMS0w_82ff9c03-fc22-4abb-93c4-d85c797465a2">362.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNi0xLTEtMS0w_897f99ac-b4ae-4368-95aa-9a941897260c">1,456.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNi0zLTEtMS0w_09eecf62-c95e-4973-9cf2-1ac3c1956e81">1,094.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_25"></div><hr style="page-break-after:always"><div style="min-height:27pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 6)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMy0xLTEtMS0w_034f9e93-900e-4fb4-8ad3-cdd9bf5ecf03">3,002.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMy0zLTEtMS0w_69ace194-1e38-44a0-b337-1996cc5d86d1">3,657.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNC0xLTEtMS0w_442e9d67-69bf-4e3f-b9b1-29d1fded794e">49.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNC0zLTEtMS0w_34125e58-651a-4c6a-a066-f4d405257885">24.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0wLTEtMS0wL3RleHRyZWdpb246NDZjNmI0Y2EzOTJhNGRmZTlmNzdkNDhkY2ZmMDA1ZmRfNDc_1d325f81-0281-4300-a333-ff1fee095d03">23.9</ix:nonfraction> (2021)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and $<ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0wLTEtMS0wL3RleHRyZWdpb246NDZjNmI0Y2EzOTJhNGRmZTlmNzdkNDhkY2ZmMDA1ZmRfNjE_d50d661c-f008-4799-96a3-ec599f5664ad">25.9</ix:nonfraction> (2020)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0xLTEtMS0w_8346b42f-e329-40c0-9f85-47311fed5b74">5,592.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0zLTEtMS0w_a524cd36-3168-4ddd-8cd1-0c45e977037a">5,875.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNi0xLTEtMS0w_24df703d-80b8-4e64-8cd0-0061c234dcf7">1,065.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNi0zLTEtMS0w_9201bac2-3ffc-4783-9889-ed9d7c50d6dc">1,053.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNy0xLTEtMS0w_cec099a5-ce58-44a8-9836-a02f318df379">3,660.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNy0zLTEtMS0w_a92ddf93-bb71-42ea-a458-397c3cf21504">3,980.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOC0xLTEtMS0w_7bb5cdcc-af37-403a-be67-49a7c67fa27a">3,233.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOC0zLTEtMS0w_2e14d297-3829-42da-b5e0-6b89a044d785">2,871.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOS0xLTEtMS0w_ff560519-b78c-4506-b7a1-6cd75bcae2af">16,604.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOS0zLTEtMS0w_3b9e257c-b4f0-4a4a-bec1-01e6d8166461">17,462.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTAtMS0xLTEtMA_5f709141-2822-4a7b-a241-db41dd0c099e">3,232.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTAtMy0xLTEtMA_a767f40c-70db-4008-ae4b-88d702843af9">2,966.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTEtMS0xLTEtMA_c58376a8-4d20-456d-9a96-b1e3957cd079">3,877.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTEtMy0xLTEtMA_313289d1-34ef-44cd-978b-7bf1803a0e60">3,766.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTItMS0xLTEtMA_67c308b5-6d09-4964-b9f7-964f3c398e1e">8,087.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTItMy0xLTEtMA_1cfc3905-b15c-4fb3-a57d-c193a31ee036">7,450.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTMtMS0xLTEtMA_8a0dc432-cf32-41f7-8eb6-b34f6d40d71d">2,649.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTMtMy0xLTEtMA_1283a6f0-fec8-4a79-a915-738152bf6282">2,830.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMjA2NmYwNDMyMjRhZDVhOWM3Mjc3NDAzMzdkYjdjXzYz_05ccbfcf-5761-451b-b76d-3d7b3f4f7208">9,643.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2021) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and $<ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMjA2NmYwNDMyMjRhZDVhOWM3Mjc3NDAzMzdkYjdjXzc3_d952a318-4574-4d1b-b8d7-88ede913ff9e">9,570.7</ix:nonfraction> (2020)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMS0xLTEtMA_dc5ec02b-146f-455d-914c-ab68f74ce807">8,630.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMy0xLTEtMA_490bad88-3732-458b-8c7e-c6e65c4a5008">8,681.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTUtMS0xLTEtMA_75703814-703c-468f-8d09-98d359c7c032">3,756.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTUtMy0xLTEtMA_d89b4823-f88e-49cd-93d5-c8a9b8d12ded">3,475.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTYtMS0xLTEtMA_0415647e-435e-4299-b5e2-0d4829261b63">46,838.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTYtMy0xLTEtMA_d6978284-b968-4dc4-86fc-9b1b71a4db78">46,633.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTktMS0xLTEtMA_23f4c3fe-b9f1-4774-a007-033a7e650e04">4.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTktMy0xLTEtMA_a6a294f9-36eb-461a-ab90-21ea90d5c4f0">8.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjAtMS0xLTEtMA_1e429c67-bd7e-4ccc-a1d2-d28302ce40fa">1,639.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjAtMy0xLTEtMA_12ae1353-3677-49be-9afa-862ba08f4f67">1,606.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjEtMS0xLTEtMA_2ebde5b6-8fef-47d4-b426-b626cf00e0e2">649.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjEtMy0xLTEtMA_67faf49b-20c0-422c-837d-a608fd8e6372">997.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:SalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjItMS0xLTEtMA_d9ca682d-9455-4e50-aa36-c0693e6fb6d5">5,821.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:SalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjItMy0xLTEtMA_57d73291-4974-4d25-a5bd-bf6a59492e91">5,853.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjMtMS0xLTEtMA_78b8a931-1340-4301-b518-97e4aff9487d"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjMtMy0xLTEtMA_89812fa7-98c8-4285-a6e3-db0a3caeeed5">770.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjQtMS0xLTEtMA_8bd63a24-fe57-4d97-97e0-8207844b9a1a">791.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjQtMy0xLTEtMA_770468c6-042d-45d4-be29-cb09bf822891">495.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjUtMS0xLTEtMA_d0b1c191-bbed-4c21-a776-bed48a1ad5df">2,806.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjUtMy0xLTEtMA_766a78e7-cc0e-492f-8039-ceabf5bf8511">2,750.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjYtMS0xLTEtMA_e8d21695-899b-4c59-aee6-c79d52de7d6f">11,714.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjYtMy0xLTEtMA_b1eb52d3-b3d5-41f3-82fe-054caa817bfa">12,481.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjgtMS0xLTEtMA_71fb1798-e563-4adc-88f4-30795d1922db">16,199.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjgtMy0xLTEtMA_3c04221c-244c-4a10-b24b-169f3b87da89">16,586.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjktMS0xLTEtMA_fcb2b670-6441-4559-a93a-6d562cc2d101">3,969.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjktMy0xLTEtMA_fad1d723-a179-43d5-88a2-b43d1d27d780">4,094.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzAtMS0xLTEtMA_0a5a8745-70ba-4e14-9918-027ef227844e">3,917.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzAtMy0xLTEtMA_27ab968b-a764-46a9-84ea-7ba8970b5da1">3,837.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzEtMS0xLTEtMA_b9915539-b00c-4b33-8344-1677059b5e1e">2,200.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzEtMy0xLTEtMA_d4d13d47-c4bf-40ac-9893-703717bdc702">2,099.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzItMS0xLTEtMA_79aa0d32-c818-4dcd-bfb8-a4a0cc7972b8">1,737.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzItMy0xLTEtMA_bfa0f893-cffa-4109-b416-2724a56acf68">1,707.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzMtMS0xLTEtMA_0de7255c-da6a-4975-95e5-55546a09e56e">28,024.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzMtMy0xLTEtMA_ce3d877d-8429-4ba7-8393-9248fa26e178">28,326.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzQtMS0xLTEtMA_1430d540-ea80-491d-af71-87513bb9824a"></ix:nonfraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzQtMy0xLTEtMA_cff7caa8-a783-4578-a425-3a848eece547"></ix:nonfraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzYtMS0xLTEtMA_7f7c3cad-f765-439b-9b92-3ae56712ddfc">599.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzYtMy0xLTEtMA_d1dedd7b-9125-43e6-9ce7-608d90369ecf">598.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzctMS0xLTEtMA_1afeeafb-607b-4647-b92f-ea8716703329">6,579.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzctMy0xLTEtMA_a5015b02-4133-489e-98ae-1d2672f0b72c">6,778.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzgtMS0xLTEtMA_f281b49e-e72a-4036-b9fe-592174303a44">9,181.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzgtMy0xLTEtMA_c961505c-154a-4637-a02b-f51dac7f9cf5">7,830.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzktMS0xLTEtMA_5dd4d647-217d-4ab7-90f0-28a13d698817">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzktMy0xLTEtMA_51734cc1-6ea5-4bf0-8e2a-398e9ea3e162">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDAtMS0xLTEtMA_639e9003-c830-4c07-883f-c0597984374d">6,395.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDAtMy0xLTEtMA_1e77ebaa-a100-4485-9488-6819d91787fd">6,496.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDEtMS0xLTEtMA_0f1a838d-bd9d-48a6-b7a1-9e46b3cdd4cd">52.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDEtMy0xLTEtMA_8589a315-f65e-405a-909b-10c9fad292f9">55.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDItMS0xLTEtMA_0f8ec0ee-a6bf-4170-a295-ea85a65cb488">6,898.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDItMy0xLTEtMA_d4ec8dd4-0412-45cf-8201-dd528b951a6d">5,641.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDMtMS0xLTEtMA_dc16b1c7-7859-4e91-a67f-e58e294a4258">200.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDMtMy0xLTEtMA_cbdaf687-1576-471b-958f-67f5516ee4dc">183.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDQtMS0xLTEtMA_c5cec4f2-e4e6-46f5-beae-1a937d9b975d">7,099.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDQtMy0xLTEtMA_a6649690-4901-4147-a160-beffc79b0ae0">5,825.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDUtMS0xLTEtMA_30ec29c8-6ed0-4486-9a97-10ec81476ee2">46,838.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDUtMy0xLTEtMA_8391f9c8-ea95-4c2b-8afc-3442797380ac">46,633.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Dollars in millions and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br>Paid-in<br>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i5bce3a2756434f739e7c3845a02a47cf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xLTEtMS0w_9c1b04ea-872d-4a06-afe7-fc4e379fe744">958,056</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5bce3a2756434f739e7c3845a02a47cf_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0zLTEtMS0w_5ce40ca3-4adf-41de-ba30-eff791195989">598.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3ffc5bab7133436682aff62ddec1e376_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy01LTEtMS0w_8b4ed52b-d8a9-4996-bce0-f6f74f0c4b93">6,685.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i957ad33ccc1240e3948e9f141963844f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy03LTEtMS0w_e445cf97-c62d-41ac-9b33-3826bbed0dc9">4,920.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7f3109e398cb4ebe87fb955a863b8ede_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy05LTEtMS0w_fb52eddc-d19f-499d-a27e-fe55841bf227">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i46e5e55c87bf4c9285d8bfe7ce6fd6d3_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xMS0xLTEtMA_c9b95bb8-785b-4ce8-85b2-2e7ef11d1695">6,523.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i932abea342a94c46a25f33f1c8acc500_I20191231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xMy0xLTEtMA_7e73863e-9cb2-4626-b057-57e3085d9eb7">530</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i932abea342a94c46a25f33f1c8acc500_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xNS0xLTEtMA_896c20ea-1137-46b1-b06d-3cfc73c9a19c">60.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifdecec535fa14d78b9ef123144efa368_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xNy0xLTEtMA_4020e14d-dd44-48ad-a24c-18016e40e376">92.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNC03LTEtMS0w_061c9e8d-e6f4-4340-af12-8f82b634b072">1,456.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNC0xNy0xLTEtMA_f6557702-9e71-4c8e-9da5-1296046877ca">26.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibcf85b46974c4de78d45cca588cdb257_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNS0xMS0xLTEtMA_98ca8388-f71b-4f97-8a7a-32a63cd7130c">362.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xLTEtMS0w_8bab93fd-bc14-4b2f-8243-0d9167876dd8">3,627</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0zLTEtMS0w_6bb74d66-56d6-4e79-83ed-019a0b014199">2.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy03LTEtMS0w_145a0233-bcbf-4f90-baaa-f63a1c879372">497.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xMy0xLTEtMA_fa34a8c6-acd0-4dd6-b1f0-f8bf46aa4b63">3,627</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xNS0xLTEtMA_588282b7-d96e-49e6-b9b3-6a61a0e391a6">500.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOC0xMy0xLTEtMA_76263621-d7db-43c7-9a4b-2c8ce236b352">3,627</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOC0xNS0xLTEtMA_cb394133-c64f-4a76-8f37-d79b3621fe3c">500.0</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xLTEtMS0w_f1ee94fa-5aa6-4b96-b149-edd2ede0336e">2,500</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0zLTEtMS0w_ccf810f7-601c-4236-8d4c-f9e538d5295e">1.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS01LTEtMS0w_d3f2ec52-6485-44cd-94ad-82147ff606fd">201.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xMy0xLTEtMA_c510d9f3-bc28-4070-8865-f7a0fe2dbd73">43</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xNS0xLTEtMA_062c3330-5553-4be1-aa49-20efe7e43411">5.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTAtNS0xLTEtMA_7c1614b3-2d10-46d8-91e3-2c010e71c751">71.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTMtNy0xLTEtMA_2c25eb19-bad4-4277-b227-e28d5d92621e">0.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonfraction unitref="usd" contextref="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTMtMTctMS0xLTA_e7d28129-b3a8-47dc-8c13-25ab5d8ee729"></ix:nonfraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="id525ea543ffc4ac699696ae6133c1a3f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMS0xLTEtMA_a1efb309-54ae-4022-9d60-41ba30c599be">956,929</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id525ea543ffc4ac699696ae6133c1a3f_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMy0xLTEtMA_6aefc5f1-297a-4155-978b-c3f81077f45e">598.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie25f9462d4864ec48a45f240362e710e_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtNS0xLTEtMA_1fc861ef-e719-4608-a8e6-5d9b97a44c4a">6,556.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3e1e492a833a4874b74b3fb0b7f96fa5_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtNy0xLTEtMA_98830ab4-71fb-407f-8cde-864d345bb8cf">5,879.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id163dac405614d4ab0aab11d9539c9a8_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtOS0xLTEtMA_a167bd24-69ba-41ba-afda-bbf93b82b7c1">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ife78f2b5881b4ab594c089c77d07dfdd_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTEtMS0xLTA_e882d840-3e3b-4741-99e8-066e76382c23">6,885.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i4a5e6fba402d49eda6d65097c72bd64e_I20200331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTMtMS0xLTA_60b33594-c5f1-4c72-8b2c-f2c91e7eae87">487</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4a5e6fba402d49eda6d65097c72bd64e_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTUtMS0xLTA_02e5eef2-b0a6-47ee-8ec3-455237f458df">55.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a2504bfe86b4fe3905a4c1dd6e8a31a_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTctMS0xLTA_264fb1be-6682-4895-850f-737d7443e544">118.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="ib44d59353e664823911abf62eca2a0ec_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMS0xLTEtMA_6364214a-064b-4e14-8ea5-e4ab5d6cbeca">957,077</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib44d59353e664823911abf62eca2a0ec_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMy0xLTEtMA_43ea76a6-364f-4f91-809d-4562c757f477">598.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc56172f5f014bb48f88ac5499c1c0c8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtNS0xLTEtMA_336e9203-62f3-4643-bbf0-064f47f20caf">6,778.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i60d84be3db5c4d85abc4b594cd075e4e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtNy0xLTEtMA_7abb21c8-7bf3-4214-ac06-b9f071dac6ce">7,830.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idcdf0da7a8b34a378831b2abf856ab11_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtOS0xLTEtMA_0fde597f-1d4e-459a-9cc4-bf63677962e4">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0582a765e6944e928d84c3bf2f09767c_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTEtMS0xLTA_eaf3c92a-ed87-4dac-a63f-6b53a6e6d2a2">6,496.4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="iaaf707b56bb5401397f3d1be8be7a6da_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTMtMS0xLTA_75b3c8b2-21ed-4ad7-aabc-e741d28250b3">487</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iaaf707b56bb5401397f3d1be8be7a6da_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTUtMS0xLTA_ff57fea3-796e-44c4-89ea-0f44504b2776">55.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia85d98868ecb4c1d9f33581b32035094_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTctMS0xLTA_d30ea7f3-281c-4efb-9ba2-b0809b98bdd1">183.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i002f042f1d494e298177c727853e4883_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTctNy0xLTEtMA_883c9ba3-03f2-4b07-9836-0f25eff17743">1,355.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTctMTctMS0xLTA_9349dda0-e39a-4217-b527-76e1dc5b4888">16.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6e502d3f77649d3b4966205297947db_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTgtMTEtMS0xLTA_6acfa60a-464f-4735-8c2b-559ac2392fd9">100.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMS0xLTEtMA_6b4a8131-b98e-4717-be4d-30549319d681">2,405</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMy0xLTEtMA_a5b62b9c-0d44-4684-aa93-f61bc6c852af">1.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItNS0xLTEtMA_fe592fd7-c0d6-4ac8-bac4-daecc8749730">283.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="shares" contextref="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMTMtMS0xLTA_ed2669e1-f56f-4a0f-90c2-8b8e603ce075">24</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMTUtMS0xLTA_750ec208-8831-46fe-ab4b-fd9f77971ab1">3.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjMtNS0xLTEtMA_a9ae4bd5-d1d0-4fcf-b7d4-7d1732ea9fc4">85.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtNS0xLTEtMA_eff4418b-9f6e-4bea-97c2-66bc61fbb52c">0.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i002f042f1d494e298177c727853e4883_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtNy0xLTEtMA_153cde31-f440-455a-9b6e-dd4598b71513">4.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtMTctMS0xLTA_146a58fe-01e5-40bd-9725-d358cf6e8aa6">0.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i717123173f4f4d45a26fc171fcef135f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMS0xLTEtMA_0519d9a4-9de4-43ca-b1e8-17e424dc890c">959,482</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i717123173f4f4d45a26fc171fcef135f_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMy0xLTEtMA_9e192271-604d-4b0f-bcd8-5fee2a23d64b">599.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i19ffbb6496914f979518c442d56ddfdc_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtNS0xLTEtMA_a5912e6a-35a9-44fc-b9e9-96d1b1b8ce8c">6,579.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia95ec94014ed412d9ddf912309b31906_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtNy0xLTEtMA_e098123b-d178-4987-bbdc-250e984fa2de">9,181.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i336e60271cdd431887ad40e2953cb881_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtOS0xLTEtMA_c9d9f0ed-8cbc-4642-92a2-33f72e9abcd3">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iaf8fa9dfe55240c8904822bb89d5d580_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTEtMS0xLTA_62f91c8d-d804-4763-890d-d11c3067fc2b">6,395.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="ia54f7cb622be43a6a63855f304e93c8a_I20210331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTMtMS0xLTA_85488785-e26b-45f8-b3c8-8d6b78d135e6">463</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia54f7cb622be43a6a63855f304e93c8a_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTUtMS0xLTA_e46dcc18-cf01-4074-9b97-4f814d5cf7f1">52.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9b0151dc1fa445c680975efcbdc26506_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTctMS0xLTA_b204493d-1f36-497c-9d6b-8cfe503871da">200.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RleHRyZWdpb246YTMwNDZiY2ZiZjAyNDg5N2FmN2ViMWVmZmE2NzMzMmZfNDIz_c5e5909a-8548-407b-aee5-ee9ea5f20454" footnoterole="http://www.xbrl.org/2003/role/footnote">As of March&nbsp;31, 2021, there was $<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RleHRyZWdpb246YTMwNDZiY2ZiZjAyNDg5N2FmN2ViMWVmZmE2NzMzMmZfMTI3_f031e19e-8127-4a8f-8d2a-c700b0d97016">1.00</ix:nonfraction> billion remaining under our $<ix:nonfraction unitref="usd" contextref="ice5b008047fc4f969d378bc0e8f5337b_I20180630" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RleHRyZWdpb246YTMwNDZiY2ZiZjAyNDg5N2FmN2ViMWVmZmE2NzMzMmZfMTUw_d403757c-0ecd-4915-a9d9-f760002d89a4">8.00</ix:nonfraction> billion share repurchase program authorized in June 2018.</ix:footnote> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_31"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMy0xLTEtMS0w_ae7ee78c-bc2a-4a56-8162-6b0384fdf98f">1,355.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMy0zLTEtMS0w_f158bb6a-1289-4b50-9341-e6fd06c0b0c5">1,456.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNi0xLTEtMS0w_899d8243-13d3-49a8-baab-59805438dc16">350.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNi0zLTEtMS0w_45fb5017-a964-4749-b022-4336855051c5">273.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNy0xLTEtMS0w_c5a37435-e612-4242-a7d3-6fda0e8ea615">119.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNy0zLTEtMS0w_44d0fa7a-9262-4e7a-8b74-2c1d160feb2e">11.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfOS0xLTEtMS0w_289e0aec-9861-46d1-854a-c93c7a316019">85.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfOS0zLTEtMS0w_3928ef4b-17e2-4e5d-a12c-2653d5e524a7">71.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTEtMS0xLTEtMA_6c502d6e-b3e4-45a6-93c5-b341df7383e2">302.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTEtMy0xLTEtMA_27208db8-e473-4ff6-9fad-e29823183e0b">186.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTItMS0xLTEtMA_d69046f9-685d-4939-9370-816b77c86a76">299.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTItMy0xLTEtMA_5da87cc2-3e07-4dac-8cb3-0ca427a092cf">52.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTMtMS0xLTEtMA_edd17af3-f84f-4e30-8c38-95163872eeeb">102.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTMtMy0xLTEtMA_353f55d6-c299-4b0e-b96c-7ae59d5fc2df">1,408.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash operating activities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTQtMS0xLTEtMA_2206b6ad-6444-4caf-b752-c62fcac9b413">131.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTQtMy0xLTEtMA_f015a202-6238-41b2-90ac-d8cf5a56bf5e">111.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTUtMS0xLTEtMA_9871c9fb-7ff5-4e79-9516-056db5f18943">1,697.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTUtMy0xLTEtMA_02557f3b-a2d5-4f74-967a-7cda6a90d707">382.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTctMS0xLTEtMA_ea76a953-9d1b-4e58-9ab4-894286ac61cf">300.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTctMy0xLTEtMA_862e91fe-247d-4537-ac49-1f418013ad0a">258.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTgtMS0xLTEtMA_0c2b1814-56c6-49a6-bb3a-b300096af45f">4.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTgtMy0xLTEtMA_f50132f9-410a-4b26-bac0-6925aea9f013">36.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTktMS0xLTEtMA_d4860695-0b8e-4d98-821b-0da7602614c4">19.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTktMy0xLTEtMA_fd3db003-2441-4469-8ee0-aa4025160ec0"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of noncurrent investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjAtMS0xLTEtMA_a2daba93-2536-49c9-8501-8081497c690e">284.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjAtMy0xLTEtMA_9656bcf8-0fed-41e7-9d33-192783cb3f99">54.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjEtMS0xLTEtMA_ad1fdbe8-fdf7-48fa-bbb0-b37192a6622d">291.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjEtMy0xLTEtMA_ad5b0792-48d0-4aa0-bb2a-9a58065a35d0">83.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired (Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjItMS0xLTEtMA_71e42b07-63bf-494b-a7b6-8b25546e0d90">747.4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjItMy0xLTEtMA_35952610-324c-45b7-9ca4-89e51ef4a9ab">849.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjQtMS0xLTEtMA_dd3195b0-1a74-4524-a625-ce8f9e25d894">191.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjQtMy0xLTEtMA_87988fb2-237a-459a-9868-912b8de8e45c">13.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjUtMS0xLTEtMA_d577ec7a-7cd0-4309-8d48-15dcc3ea5846">21.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjUtMy0xLTEtMA_9f7f2452-e907-4ea4-974b-1cc804a04046">51.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjYtMS0xLTEtMA_db111105-b95e-4418-a567-252f99a4f5ae">1,283.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjYtMy0xLTEtMA_e8baff8e-15f8-470c-b669-fab0965698e1">1,060.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjgtMS0xLTEtMA_d3e8f006-e6c5-439e-a21c-6a2f1dbf2f41">774.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjgtMy0xLTEtMA_7eac4258-65f4-477c-b3d2-5e9c0ad9d66e">671.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjktMS0xLTEtMA_ff8f3835-9afd-4747-abdf-43eb11be0a69">3.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjktMy0xLTEtMA_980128f1-cb67-42c3-8f93-236c77fce4d6">1,748.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzEtMS0xLTEtMA_252516be-9ad6-4b33-a9a3-6115af6854be"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzEtMy0xLTEtMA_715cab77-5188-4b46-b3d5-2254e2ccccca">276.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzItMS0xLTEtMA_0bcaec84-4534-4129-a36d-8248dbd3df6e"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzItMy0xLTEtMA_75c398ce-1ad4-4696-9a32-dd934c3f96cc">500.0</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzQtMS0xLTEtMA_b265bb6b-3b03-4af4-ab0f-15918d9f82d9">279.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzQtMy0xLTEtMA_d2fb53c3-da61-44ef-bc78-e7ae3b2216ce">194.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash (Used for) Provided by Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzUtMS0xLTEtMA_768671b4-a1cf-4af2-9214-71dfa20f6d83">1,058.4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzUtMy0xLTEtMA_c5fa09a2-23af-4249-93b2-899c00bbfdc0">106.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzYtMS0xLTEtMA_3d063542-ea23-41b9-89b3-79d7274c33bb">10.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzYtMy0xLTEtMA_204c10d1-cb08-417a-a74d-f1229c65e219">66.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzgtMS0xLTEtMA_0804902c-2f69-4417-a853-8139e4858909">654.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzgtMy0xLTEtMA_1d836a92-775c-47fe-820f-039a1cfacaa7">638.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at January&nbsp;1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzktMS0xLTEtMA_aee31920-0162-4fa0-aed1-d404307d4974">3,657.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea0fcbeedbfb4018b173fba695dd9fc7_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzktMy0xLTEtMA_10ae2936-d0bb-453f-861d-9b269eaf4005">2,337.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at March 31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNDAtMS0xLTEtMA_3b4ae334-c242-4ec8-a83a-e7d10052e40b">3,002.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9dd152b8ae7b497f800f65a679736686_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNDAtMy0xLTEtMA_d7f7f66a-9b33-44ab-9a42-55af35b3a70c">1,699.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></tbody></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br></span></div><div style="margin-top:9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Condensed Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_37"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zNy9mcmFnOmViNDAyMmNkMGRiMTQ3MGY4MDYyMThhNzc2ODBmMjBlL3RleHRyZWdpb246ZWI0MDIyY2QwZGIxNDcwZjgwNjIxOGE3NzY4MGYyMGVfMjc1Mw_3fb1f345-b9e4-4a93-9eba-3c4a64f1819f" continuedat="ia466a7485e494f25bde27141d8733768" escape="true">Basis of Presentation </ix:nonnumeric></span></div><ix:continuation id="ia466a7485e494f25bde27141d8733768"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2020. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div style="margin-bottom:3pt"><span><br></span></div><div style="margin-bottom:3pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_40"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM4MA_cc163449-fa82-412a-bdac-5ea120741e96" continuedat="id6d2f14c7b96409c963ae83958d9ec09" escape="true">Revenue</ix:nonnumeric></span></div><ix:continuation id="id6d2f14c7b96409c963ae83958d9ec09" continuedat="i5ddc236a48f34365b503b4aceff610fc"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM3OA_298eb2a7-7132-4b14-92b7-0934812fbef6" continuedat="i8080887e51394ba18b07f4e0f5622673" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b961987b212484fba2e55e3f8599292_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMi0xLTEtMS0w_03785b25-56a0-4de7-9429-0c09b0fe5ab5">6,320.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00e2ad623e9f4f09a525954c7be34a38_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMi0zLTEtMS0w_933928b0-4b7d-46c5-8150-d6ada1d5d9e1">5,403.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib696b72b79fd4a64a05a14552524fd57_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMy0xLTEtMS0w_abeffc77-ed9f-49a2-921b-99f934035343">485.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia9bcfbde64cf4e6885eff068fd1c0181_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMy0zLTEtMS0w_b5f92ba6-f837-44bb-af82-4c369008a91e">456.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfNC0xLTEtMS0w_e2466254-4b1c-42d5-84e3-adb2cd00661d">6,805.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfNC0zLTEtMS0w_346c0333-f621-411c-8941-80d8dc8eb8a3">5,859.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonfraction unitref="usd" contextref="i3a64fdc1a7fc44278f9cf486b1d6c7cf_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMjM4_5b90024e-dd78-49cb-b2a9-0cdd52c79720">43.0</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i38bd7b2a836c4d14abc0e95512ba56c5_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMjQ1_a2540f76-d446-46f1-bec0-a2e20ace801d">35.4</ix:nonfraction> million during the three months ended March&nbsp;31, 2021 and 2020, respectively.</span></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than <ix:nonfraction unitref="number" contextref="i0b2a402409bd47ceb3efc76f535f0984_D20200101-20200331" decimals="2" format="ixt:numdotdecimal" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMTA5OTUxMTYzMjUyNQ_64f45f88-44e1-419f-b95c-9b78b4662655">2</ix:nonfraction> percent of U.S. revenue during the three months ended March&nbsp;31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM5Mg_a20590c0-f11a-4876-b466-d92fce9f433f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjI0ZTcwNzA2YTA0MjQxM2E4YTE4Njc5ZjI2NGU4M2ExL3RhYmxlcmFuZ2U6MjRlNzA3MDZhMDQyNDEzYThhMTg2NzlmMjY0ZTgzYTFfMS0xLTEtMS0w_98e0a090-0409-41a6-9ae9-98b31c749fcc">346.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjI0ZTcwNzA2YTA0MjQxM2E4YTE4Njc5ZjI2NGU4M2ExL3RhYmxlcmFuZ2U6MjRlNzA3MDZhMDQyNDEzYThhMTg2NzlmMjY0ZTgzYTFfMS0zLTEtMS0w_52b8aa3b-2191-40f4-9407-b94416773d3a">276.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i5ddc236a48f34365b503b4aceff610fc" continuedat="i960f332faeab45d386014048a8eb364c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><ix:continuation id="i8080887e51394ba18b07f4e0f5622673" continuedat="i824163b5c1774b82bd45421d3163d1fb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenueto unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iec6120b958de4ece8b0bb1b2c92eb827_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0xLTEtMS0w_4f66f567-9c0a-4c9f-8128-b5251d29f0a3">1,116.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i14a1f7c9c8094a24b89b05adbfa13722_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0yLTEtMS0w_7955e0e6-4e9f-4dd0-bb80-8c03f038c307">335.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1da1bf79aee54038ab5fb824f0b5459c_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0zLTEtMS0w_8319a666-4a1c-4502-ad7e-5a9199b95737">1,452.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7879b1c8e8154d82951f06d7277606ca_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS01LTEtMS0w_86ab1026-90ea-489b-ab46-db48ee563ba7">929.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib22403656ba044288e3a7c9bd076149a_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS02LTEtMS0w_c26c050d-7c65-480c-8c0e-573b699cc69c">299.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie60de7ffff384040bda8a7073de65757_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS03LTEtMS0w_04113082-064a-4a2a-ba83-375e8581eb8a">1,229.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35e2453e887841ba845624286f429037_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0xLTEtMS0w_f5e08274-e4f7-4510-a9ef-38d7e3057cf0">332.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iac9fe39efa6e493c8fc3b5a5cb61875a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0yLTEtMS0w_b6bf08c3-968a-49da-8052-b0501f0f2d42">284.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12fc66e4003b4a108dafd95f3f948eae_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0zLTEtMS0w_020d842b-3727-431f-b1f6-39468a0b167f">617.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf36848406364477a5b09c68263549c0_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi01LTEtMS0w_90d63d05-c14a-456f-a582-b94fc4e7c615">398.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0cec2d3e8980474dba0ccd4ba2f4be53_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi02LTEtMS0w_bb8211b0-a021-49bc-b488-f459ea381b90">297.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ac183bd15654d9ea8bfb79ecfdabc21_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi03LTEtMS0w_17472488-fa01-4361-8d8d-547d412c09d4">695.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d5411d889ea4b0c92badda1ff003164_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0xLTEtMS0zNjMx_65f93c6d-1cca-49e3-9f59-332ada8a4fd7">219.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i80b19d05555b462299ff41542279ba37_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0yLTEtMS0zNjMx_03770a81-b3dc-4328-9a11-75daa539f75d">102.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib8ce72672e984dc38dbee5c4872a819f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0zLTEtMS0zNjMx_eeffdfe7-4d39-4737-bf1e-abd17ef8ff56">321.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bd74f7f91ca4076b9bc23d4ac7407c8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy01LTEtMS0zNjMx_75182754-2b34-4afa-ac3b-d49eec86db1b">214.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6cacb66e50b43a29e19d4cc6a18b475_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy02LTEtMS0zNjMx_0d67ab58-520f-4f65-b075-84220d858c05">101.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82b9a6cc26eb4896a200c5b2d5ee6aa5_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy03LTEtMS0zNjMx_14e7bcee-661d-4c56-bb6e-36f9a1c31d5d">315.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i23a99b86356248b7a363e089040850b1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0xLTEtMS0w_96876aeb-d36d-454b-b8bc-814dcc1ed10f">151.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1c94039dc776423e982d5e1215b9f0e7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0yLTEtMS0w_07a03a6f-447b-4c2b-95b8-6761e349e362">160.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0zLTEtMS0w_aafa8472-ae8a-4bc6-80be-9b15648fda23">312.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57d3bc0a03b5400f848a8a445a06af73_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy01LTEtMS0w_d8e2c058-6d7d-4c3c-b864-5ea1a7228f6a">144.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c9abc35851840cd80b9598eb84e59be_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy02LTEtMS0w_4cae0cc0-9247-471f-8a9d-4804c0607ac4">122.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy03LTEtMS0w_5bd7fdb7-0e99-4719-bc21-00d331b9d6a9">267.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i68c425bf807b4ecfb4bfc4e63113b9a5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0xLTEtMS0w_33595673-891d-46f9-a7c4-70bd0b328ad7">175.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i991e0184719242bb9681a766c00e183e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0yLTEtMS0w_f47ed12a-e32e-4385-a129-f72d431ed912">71.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0zLTEtMS0w_dbc0725d-fc85-44cd-9fd8-4b1bfe2430d3">246.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ad3a54cc6da48c7aabdfbd4ce0fd7d8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS01LTEtMS0w_52650033-a694-4c97-aa1b-ef47a2b5083c">230.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97e8d103205d4d8a8ddce47720e2b0df_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS02LTEtMS0w_32b5f669-6b71-4b03-bec4-11314720cbfb">73.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS03LTEtMS0w_5b2e845f-3e4b-4b3a-86bc-2680bbf4e4bd">303.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i37a9f92fe3be4a59bd100214c32741d5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMS0xLTEtMA_926932e5-593e-4b7f-b823-28104204d1bd">66.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab3763aca7de40e3bd3755d4afdf8ddd_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMi0xLTEtMA_57fb056b-d37f-459c-8d2f-448d9d609137">94.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i08fa42e2b3004f2c8d8c3d2949a77b62_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMy0xLTEtMA_6f77ea1f-35a9-42dd-aafa-c90a65001536">161.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if05b79fd4afb4b3b85e0170d60701765_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNS0xLTEtMA_12938704-05e5-4c98-9b39-5e62117d230b">74.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i53e1ac90f1794867bdc0e1208a22454d_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNi0xLTEtMA_d2cfea7b-68a1-43ab-b710-c91e566eb514">82.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5488586d175451ea3762d3e3427d7fb_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNy0xLTEtMA_d64b51de-c125-4335-afca-9fc26f294da5">156.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6655e736bfc145ae9b61bcbd43ca3775_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMS0xLTEtMA_a02eec77-6333-40c3-86c9-18c580b355f8">2,061.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i95a511f3e56540efaf67326c58f115f8_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMi0xLTEtMA_0cbab2a4-4c15-4df7-a6fa-de79571bfb40">1,049.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a8600a4d0ae48ac8eb847f76d72fb39_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMy0xLTEtMA_c9234a1f-32e5-46f7-ae41-27f7c3d56ef9">3,111.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d683e3edb3b47769c30eadb5fc443db_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNS0xLTEtMA_cfe347ee-828c-4227-839b-c1b12f726954">1,991.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia92a87d280ea46c88caa7e96c7a0c2c6_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNi0xLTEtMA_bc717e06-5720-43cf-9d94-671003e27840">977.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dc1168de1ac4bd892f4336105fe8d34_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNy0xLTEtMA_c51ffb0f-c259-462a-897b-e047713186c8">2,968.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1eb5c54ee4f4ffd849c70b74454938b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMS0xLTEtMA_4b9d1937-f406-4ef4-8362-b4ad3878c888">261.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i99351a29767e4c33b139db7c60592e0c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMi0xLTEtMA_b041014b-b937-4571-9868-935fd56a1d3b">297.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8c035a4a36d1475c87f42c50e4fe5b66_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMy0xLTEtMA_a19d5740-7f55-4a7e-bc3f-fa40b87c9d93">559.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ica6ff26a8f5c493bb678f8b8bdd2f5d0_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNS0xLTEtMA_f47b8149-c703-46a3-97e1-7fdb4d02eb89">324.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9a84f264bd5f43d18f95d6449dbfd211_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNi0xLTEtMA_caf6095c-800d-4aa0-a54e-53f03654fec4">235.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3ad5e6e9c6b04e0ca3a23762ff4389d4_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNy0xLTEtMA_53dc05fd-0e58-4197-968b-174390ecfd61">560.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia3895e84ece4456f9fd7475f8330b5e2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMS0xLTEtMzYzOQ_6fb149a7-b32e-4029-b23c-d8c65860c785">172.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bf54072320b4a95bcc03ebf93fd790b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMi0xLTEtMzYzOQ_fe82de4d-d533-424e-ac03-4488aa9147dd">96.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a64b17a7372474b936176a48e73353e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMy0xLTEtMzYzOQ_2fe831bf-95a2-4b0c-874e-ee25f4ee2298">269.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id1ca44d898d14b6ba06c659cc8685067_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNS0xLTEtMzYzOQ_586f8119-f23d-411e-bab7-3690733e6087">129.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaec1b41e2f1c429990d5463381ccb5b2_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNi0xLTEtMzYzOQ_07bd4b8c-c15d-47f9-8ee8-c3829c8fd847">58.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic305b0216fae4bc4be68a9c14511b14b_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNy0xLTEtMzYzOQ_25753e2f-fb7f-44d6-9469-a4a5740f2c55">188.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifc30d8c3304846bf98d3aff4faa90db6_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMS0xLTEtMA_a1e43dcf-daab-480b-933e-b8858367c67f">80.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i301b5063b45f4c778fa6be355225f1d2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMi0xLTEtMA_44f909dc-bded-4dc4-90af-62e00831ff0f">160.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6ac8015a990a47ac84766a6b061f5c80_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMy0xLTEtMA_124c656e-0fa3-46fd-9d3e-eb02c58aaa83">240.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice0f65e55bc14fb4a8b9c74295879c9f_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNS0xLTEtMA_b08dd4d2-5cfa-4138-ac24-923a056cdf49">89.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabd56efbd9ee475196495211900a4916_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNi0xLTEtMA_25477350-7944-4a5f-9201-dab4b3849e69">149.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4990ade4fb749c5becfec40f273af6a_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNy0xLTEtMA_f0514538-f30a-4f4f-9e66-d9386fe75291">239.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idc1ec2db8e1b4baa971e09c08d4342fd_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMS0xLTEtMA_e892bae4-aaab-4387-b900-f69a86cfd6ad">107.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i699a1a79461d4373af3cf037c5ca77a1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMi0xLTEtMA_ec723406-69a8-450e-8401-daca49d88901">14.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="icbf8577a767f4b6fa45fbea9fc0008e8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMy0xLTEtMA_5a2d0784-2491-4bd5-99e3-5f2db37cda1f">122.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9a65c960be0f46ebaab122d5eb8f5e3c_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNS0xLTEtMA_8c37255d-902f-4885-9e28-ea339b8abaa1">117.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib410c05551594d84936a917166832ea9_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNi0xLTEtMA_c758f8ee-e6a5-4cec-81cf-4977fdd964fa">13.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8d36ff64df614dd2a64ea2e3cb167f9b_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNy0xLTEtMA_80b4b6c3-fc00-479b-8587-88f6ed1636ed">130.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if30239ae11764340af612d6d0acb2802_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMS0xLTEtNTkwOQ_dd13c573-a839-4cdf-be82-18ed024672d9"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMi0xLTEtNTkwOQ_b1fa3217-3b4b-4488-be3c-9a95a7c78d93">109.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10cbac4f340148c58e34434fbbf2a27f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMy0xLTEtNTkwOQ_1494f895-e1dc-4797-a905-5c54a4bd2f9a">109.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5a346e0ad24144caac752ea7f4355d34_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNS0xLTEtNTkxMg_730ab310-6c00-4dda-a369-75dc317202d0"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNi0xLTEtNTkxMg_0f70f948-9ad1-4927-a458-413ccdf9f113">57.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia3156015f19b4add93eceadb6f839944_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNy0xLTEtNTkxMg_c2095b64-e688-40c2-a2c4-425ccf0506cd">57.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i16d7bf43c3214967ae1523ebc568940c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMS0xLTEtMA_e3821a8e-0522-4d9c-ae02-c470701ee86e">20.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a1925d8bba04bf5a88ae7c5a2c5a30e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMi0xLTEtMA_4a13c13b-011a-4f81-9958-3b706f8fa620">51.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i65134b9feaf3468bae4f56eb446cc39b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMy0xLTEtMA_6d72189b-6ae0-4552-b604-9c3ac0ade6dd">71.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6b08818da51f405ab315d6a7b99fcdb8_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNS0xLTEtMA_021d56da-a8f7-4857-853c-7f4c7b0b1cf6">2.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f8df345856f4facb882054634c50249_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNi0xLTEtMA_3ca7b4cd-f2dd-4e26-bc4c-ff99aa9515b4">28.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b44fc5413ea4394a3af4e9ae8cc9357_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNy0xLTEtMA_45bd42f8-67c4-4009-8b9b-79362f426b07">26.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic6c1690f2a1044549cd196b5d0d49bad_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMS0xLTEtMA_d62dbc9b-63d6-40ef-bd33-d5d6b43d7120">642.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5f2094304a9b41efa6498348dc920bd5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMi0xLTEtMA_f39017a6-86f6-4f77-96b8-54b72a79a22e">729.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iccb5bb5fcf05439eafdaafbbf45b94dc_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMy0xLTEtMA_3efabe92-683f-4d77-9f06-5ece818aca4c">1,372.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if46aa3d35d9f4f9e9f98c940d7063f27_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNS0xLTEtMA_207a841e-6a29-493c-a10c-a6be02b90d7d">657.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i27ef923c97994ad09a5131b38a10eff2_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNi0xLTEtMA_48fb196d-b7f8-4e0b-921a-7be87b6aba7b">543.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22ac5026b0df4c01a41cbb9fd7bf0ed4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNy0xLTEtMA_556d4b96-7732-49d7-9eb3-9eb503c906a7">1,201.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e7b860d15e24b6d8a4c42caa07a07e9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMS0xLTEtMA_821a1405-f33e-438a-875c-db72c58fbc51">249.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic9d2acfb73014f21b93868d591ba0055_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMi0xLTEtMA_9a1ade00-ee6a-4490-b4ff-cc840a222285">153.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic86716e51463478c9178d57dbc0df5e9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMy0xLTEtMA_7b833611-ad34-40b6-8565-e2cc8bcc0cea">403.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1eca7f391c9c4eb4bf1be4d2f78c64f1_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNS0xLTEtMA_e245bfb9-d929-4354-9bd7-1d42774957d0">327.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i23a06e4fd12547b68a8c1fa847a573cd_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNi0xLTEtMA_b28c6d9c-c21c-41dc-b5d0-47a2ba434d18">116.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2cdd8652ee714626a6ac6694e023589f_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNy0xLTEtMA_ab1185d0-0961-41f9-8a95-52888c0756cc">443.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibe710610bc2745d6b62b94d3e5a59c49_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMS0xLTEtMA_9e543814-3451-44fb-973b-c0ed60e63dd6">24.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib5195f2602fa4de78f56cde487a199e9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMi0xLTEtMA_4d810de1-2f5f-42f5-bcb4-a82d890e20a8">169.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMy0xLTEtMA_43dfdcb5-e735-4121-ad47-147da4f5a662"><ix:nonfraction unitref="usd" contextref="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMy0xLTEtMA_ba60441b-b236-48e2-9d7f-ff80305eb163">193.8</ix:nonfraction></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e4a642cedfe46019dbf6bdbe6fbe49e_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNS0xLTEtMA_1f7cad31-7de3-4f61-b43b-386a96321e7a">11.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82c451df337849a9aa0ebbd6efa659e5_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNi0xLTEtMA_5f9beb2b-cffd-4dae-996d-bcb53c4c5b86">128.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNy0xLTEtMA_72d5363b-b180-417d-b6c7-91b3343689d9"><ix:nonfraction unitref="usd" contextref="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNy0xLTEtMA_eff31ee2-fe9a-417e-9b48-e79b1e0348ce">139.7</ix:nonfraction></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5d69a9f098946b99fd0dc8d1e98e66a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMS0xLTEtMA_8daf5991-22ef-48a0-8471-ffc68d24bec8">10.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9d569029e59948f09619b73bf0efdca2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMi0xLTEtMA_0e64a3b5-21ed-4a2f-91d5-028001e680d8">6.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8ec2c9c0bb35428e84cb57a3987f75e0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMy0xLTEtMA_d88ee19d-b17a-440c-8274-0c2591d1119e">16.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ida0989eec65245df9b1682cf38ed4bd2_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNS0xLTEtMA_eb9d6fc3-bed2-4a79-aa4e-e45e895a4220">2.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bc0464b0bdb43f5a8e902cdb4b263da_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNi0xLTEtMA_92a84263-a5df-46e5-b0d4-a8947cea3aaf"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia8cb347768764c2b955eac4a8f4a17ad_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNy0xLTEtMA_2eff3293-2a61-4971-b25a-9166f6b56ee3">2.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i98c884b95b7b4a8493c13f83a7b6caa7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMS0xLTEtMA_6d5b2d5f-8334-4484-bc00-1cb47c3576b1">284.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c53c31a3a5c43e680ca9bf03cd18bab_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMi0xLTEtMA_2bb5d873-800b-403d-972c-86c6d680cbb5">329.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f23306ae00143a6a4003c6797529b59_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMy0xLTEtMA_a395506b-e34e-4b22-9107-01577b0a6eca">613.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if6964e815afd40a1a706fd094d27e141_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNS0xLTEtMA_c96d7e64-4aff-40cb-9424-c6a24499364f">341.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ff073cd832f489a918e71ed9f2bc601_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNi0xLTEtMA_92e8db33-91f8-4811-80dc-660bcc762e95">244.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icaab0628ba61471db8a691d30a7a5ae6_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNy0xLTEtMA_03583474-a9e5-4836-9303-3471aeae8d96">585.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6540e5cb4f94023bd8a1a99cae7dd50_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMS0xLTEtMA_1709741e-a5c7-437c-8cbf-9812972e95e5">11.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if0244d48c6684b1d90aaffa07334e12c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMi0xLTEtMA_377c945d-0c51-402b-b471-64631d0eb054">165.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a035aacb6aa496e9aacfa82670a5f77_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMy0xLTEtMA_aa7d3802-acbb-4c50-a36d-8ff9f7c90599">176.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2126f23f1b6c45da8eda485ea4fb0ffd_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMA_9e1e9b22-fda7-475e-8582-e40580488905">11.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i476ff2f62e6e4dcd89e4d0e6f6e2e23a_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMA_e81f2805-12ac-457f-9502-c33d3bd09114">198.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icd995ff940774cf9958d9496ccefdd49_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNy0xLTEtMA_1c33885e-dfd8-4327-b85a-47194c584e1c">210.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i91bb5aef62c64ba6b7374026ad6cb167_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMS0xLTEtMzY0Nw_a7e20e58-02e0-478e-8040-b75b11d1b42d">101.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc1a4bfd08874c51bd52ae124d146ed1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMi0xLTEtMzY0Nw_fdc60b3a-825d-416c-a68c-2e28976a2af1">18.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d060a91a83540adba28a86e89f8a0a9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMy0xLTEtMzY0Nw_87d3660d-5c73-4ab8-af0c-4b9e97561451">119.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMzY0Nw_468e6097-73e2-485f-962f-e485d6fc19a4"><ix:nonfraction unitref="usd" contextref="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMzY0Nw_ec2bdabf-07de-46f0-9126-e195a820151c">67.3</ix:nonfraction></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMzY0Nw_68cc054c-472c-4e86-ba72-7d30c5262036"><ix:nonfraction unitref="usd" contextref="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMzY0Nw_de70a077-08ed-49c6-9944-08a28e4fbe48">6.7</ix:nonfraction></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d28979d157949e8beda765ff3ebba18_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNy0xLTEtMzY0Nw_5cb3666b-706e-4437-b613-183f14e15ba5">74.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59a5e3ece3b2457d9dc9503670f62a19_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMS0xLTEtMA_14b3a014-62b6-4f30-824c-3281b096a49b">6.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idcb95436aea141439b320a672d06798b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMi0xLTEtMA_6556d913-23e3-4039-a647-94131b19b45b">88.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibbdb540b92834be9a1952a6988efe111_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMy0xLTEtMA_537d2206-f07a-4fd0-b455-5b4712c4a9fe">95.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5ec8f6c1a2745b6aef8220c52179da0_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNS0xLTEtMA_2a898070-554b-49a4-90a7-8834f3abfb70">11.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifdac2859144646f497bdee29d8f1077c_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNi0xLTEtMA_5965c6b7-a80d-49f5-8169-b104d98022f3">87.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6ecf74960c9f4004bfb28db9ceeee105_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNy0xLTEtMA_d1286232-001d-496d-9ea9-184f578d75e9">98.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibe3a395375b74608adcd0dcb2511ccb6_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMS0xLTEtMA_cabd0fa4-bc12-40c0-8aad-b0de68273fde">22.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e845118c19743509f235e3de1249c91_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMi0xLTEtMA_2507100c-1886-4840-b16d-183d3cbc4541">51.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i956b8eaf8bcc48e18a6392d104e3f82f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMy0xLTEtMA_fc8b4dd9-aaba-4637-b01d-dc14a57f26fe">73.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7f802e7b0b4c462498edd33fe1a08df8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNS0xLTEtMA_d5c8f589-9d63-468f-93bd-a9f31322c4dc">20.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i41bf8c2f57c2453187f38f71658035fd_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNi0xLTEtMA_ecec1dcc-bca2-4e5b-9fdc-44e0c771ae8d">60.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iccd1e7bf99a04464a2be5ae2844e93c3_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNy0xLTEtMA_57a1733f-5d72-416c-90bc-68dee9467df1">80.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a96f967a3e14ccfbf1709108752b15a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMS0xLTEtMA_58db5dec-c3f2-4bad-8685-0ea3321bfae2">141.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e1de888a7434a7d8901d5d91e9a5662_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMi0xLTEtMA_4d506696-6955-48af-915e-59f46f157a3d">323.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i805e06baf0334dd2a9272620abb71ef1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMy0xLTEtMA_9f3ccbbb-3813-44ba-8bee-2d93c852fce5">465.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7bf6f39de92a477295091f337c5f246d_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNS0xLTEtMA_cf22b358-6e57-40ed-ae3f-80ca874dcfc7">110.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i87c3683c282e4dcab93976f033317191_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNi0xLTEtMA_6fc5e62a-736f-4ac8-8130-e838a28f1eae">353.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib781ea03fa4343ea9f43fe30bf85eaff_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNy0xLTEtMA_d950276b-5811-44d1-b69a-755d4eac702f">463.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib9004a4576d54acdab802ba18e5954b5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMS0xLTEtMzYwOA_60affd60-a097-4595-a747-dca3ae7397ff">650.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5b813d4b7f6a4ba8ab05eb62fa8c0d7e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMi0xLTEtMzYwOA_0b8eaeaf-9a60-4300-a57f-19f1e07bf504">159.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMy0xLTEtMzYwOA_287208df-52a7-4065-8892-5d3b6e35705c">810.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6e00607e2514771bb461112b624c3c8_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNS0xLTEtMzYwOA_0e2cae64-98d9-4c66-9bb1-587c5733f421"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i678860fa552c43d4b4fcb6cefb64112a_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNi0xLTEtMzYwOA_0bbff655-0788-4ea7-aeff-9125460078e1"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i009fa3f9194b481097ec59ef54e9398c_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNy0xLTEtMzYwOA_fb8da522-d627-4243-b500-71cfb89b670e"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic91d06961c624604bf888bc77f143328_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMS0xLTEtMA_cb3102df-a6bc-41e5-9ce5-708bc2e1baca">97.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a70d046e3e04fe8814a35c37222c987_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMi0xLTEtMA_1de89ddf-6d15-49b9-b555-98ad2189865c">100.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5a1a9bda61764661a686cd2e6cdf4353_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMy0xLTEtMA_25e677b0-e5e0-4d99-8fcf-71b705d40801">198.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f37eacef6da488b9411e64b1e6f9bf8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNS0xLTEtMA_71290bb5-bbc1-4c1f-a640-45a4f20217fd">122.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46371b039efc4855ab60d1a0cfdee9ef_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNi0xLTEtMA_8dbcb534-f565-4a67-9347-d19780bcb521">149.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iae0c3902df5443afaa207966c3c336ae_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNy0xLTEtMA_f3925561-5ba8-440f-af56-e8792f167a71">272.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i01ed93e108f540d895209d6cd63a4196_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMS0xLTEtMA_8c8f637a-c30a-4af6-b994-a67ea3fbec43">8.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i02826dfbba6c48f19cdc43d704001dbe_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMi0xLTEtMA_a78c5581-be87-4fde-9d0f-5a606d50cfc3">118.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0da8ce69328d41578d3e52a25ef5c637_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMy0xLTEtMA_0755f358-1bb3-4252-bffc-88acdde89d9b">126.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icf3afa843ed74fd3a1dccd7d9a340f73_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNS0xLTEtMA_96ed555a-4c5e-4106-b682-d783869558c4">26.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdbb2ee92d984ead82d0bfe89b0b7e67_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNi0xLTEtMA_aa6ed3e0-ada1-4fe7-865a-183e48ce5e3c">167.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5b635789ef4a4a3ea608c5ece8aad1d5_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNy0xLTEtMA_5bf6594a-65ef-47d8-b9c7-2c89179a8b68">193.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia0503e2189e0437c94e4365e2f5e1a42_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMS0xLTEtMA_897b229e-37a9-4f90-a795-2c16677de794">54.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7a3d52cbc5f4c36913820afde8b5ce0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMi0xLTEtMA_dec1123b-9fb4-46f3-ada1-71582f018212">53.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i29a85ee0346840baa3213980b51c8392_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMy0xLTEtMA_33338d0c-7c8e-44b5-9399-dca215404a26">107.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i48278fe6c84a480c993daadca8e14bec_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNS0xLTEtMA_830f38e5-eeb1-4afe-9399-d429ef2187bc">79.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id2da738de9a9496d82ebcd1ed1dfc349_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNi0xLTEtMA_c2893e08-2554-4cc8-b63d-a99cc13b006a">95.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i72d5f436073e4013afbbcd703dec4745_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNy0xLTEtMA_62f00c01-f336-45d3-943c-79ee36be5b52">174.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f47b5c8b6e647f7a98ae58501327a48_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMS0xLTEtMA_d12c39f3-2f9b-4c52-ad42-8c3411ea8d51">811.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ba01d74fb2f4bc0a8c1b64e3b1eef96_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMi0xLTEtMA_88f090ca-62a0-45f3-924a-f8e7d8e9c86c">431.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i91fdfa6c20d94c5db431e71629735e62_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMy0xLTEtMA_944790e6-c38b-470e-97fb-b50bfa9b7ebe">1,242.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bdeb0b05ca8485aae2687a910e899e8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNS0xLTEtMA_1b32ac05-2480-4752-9b92-d3e2ac19eb5f">228.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibf27f4b868ff4ca6852de83fc00626db_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNi0xLTEtMA_92b1a8b2-2227-40d8-8085-82c004008439">412.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i725c25318b374568a7f6a1c522f751f5_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNy0xLTEtMA_bd1638e2-761f-4aea-9948-a760e4bddf72">640.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMS0xLTEtMA_a1d0804d-182d-4dbf-8f9c-6e154fa32ebd">3,941.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic8f05f60f5234be3b895a985508995c8_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMi0xLTEtMA_adc413f7-cec7-400f-8bf3-e5dc03a65a66">2,864.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMy0xLTEtMA_4b6e8fa4-7d70-4f2a-a5d4-22aff23211dc">6,805.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNS0xLTEtMA_0d977cc7-613d-4854-ba8d-997ae56f3841">3,328.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iecc41b1e93894363b921a691b8c9ad5f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNi0xLTEtMA_0cb0ffd8-9857-458f-91c2-2c0c8b2646b5">2,531.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNy0xLTEtMA_63f76030-5ba4-4b9c-8f25-fa75b15dd0b4">5,859.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs). </span></div></ix:continuation></ix:continuation><div style="margin-top:3pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i960f332faeab45d386014048a8eb364c"><ix:continuation id="i824163b5c1774b82bd45421d3163d1fb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenueto unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfMy0xLTEtMS0w_69d784ca-1c74-435b-be92-ca91c961dd02">3,941.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfMy0zLTEtMS0w_9c7065da-483f-4a4e-8fb6-5b4c4b4435d3">3,328.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a8c46f072984025becf4f91f04a0ad4_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNC0xLTEtMS0w_10d6e43d-1d95-492a-bf90-8939490e3bc5">1,321.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i53a4c1fd0f0e411bbd983b92368c6662_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNC0zLTEtMS0w_b23a1060-ce44-49f1-bd3c-1e9e1f9894d0">1,061.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia8476fa283c5420a8c1cb44bf1886c3e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNS0xLTEtMS0w_f038800b-140c-4413-b5e0-80017bbf49c4">571.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a141f4168094f93bc307eb5ebbf7392_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNS0zLTEtMS0w_67bb26be-6ac7-4e3a-89b1-6557422ddefe">592.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf7492d96a0b4f29b67c7ffc8e4fc10e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNi0xLTEtMS0w_5309b16d-74d1-4958-85e6-5d89bef7fff1">362.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2d6aaabb8fc4471fb4d955cbdc949682_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNi0zLTEtMS0w_76331d3d-5faa-4c9e-baf4-2981aa689a53">267.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d1b2d8fe9744bfb992ea8ca03c8de17_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNy0xLTEtMS0w_69443a3e-aac5-40d3-b5a6-025df928ff3e">609.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7fb432a8a93945a68250848e46684f98_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNy0zLTEtMS0w_3c591930-d0c1-4d95-95b1-67a6d9a848b2">610.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfOC0xLTEtMS0w_8090a2ef-b28f-4707-a0ab-9ca08a41ba3a">6,805.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfOC0zLTEtMS0w_8d0e9611-a5e6-4efb-8ef5-5fba0c98e408">5,859.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:12pt;margin-top:3pt"><span><br></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_46"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&nbsp;3:&nbsp;<ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI5Mw_65c4c3c3-765a-4151-ac9a-b89405a6752d" continuedat="ia371c93e293f4dd087767565e289ef31" escape="true">Acquisitions</ix:nonnumeric></span></div><ix:continuation id="ia371c93e293f4dd087767565e289ef31" continuedat="i44ee3174d18344e1a646c1b677b5bd26"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI5NQ_660d065c-49eb-43df-b468-9119d86187ab" continuedat="ib7ba92052bc6492e86c635684b6d0d7a" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.</ix:nonnumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. <ix:continuation id="ib7ba92052bc6492e86c635684b6d0d7a">Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;D) was immediately expensed because the compound had no alternative future use.</ix:continuation> We recognized $<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTA5OTUxMTYzNTI5Nw_c1726182-6323-41a7-ab12-320e1c94ecf2">299.3</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTM4Mg_9587bc0b-3486-4772-9d87-da9a861caf6c">52.3</ix:nonfraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of acquired IPR&amp;D charges for the three months ended March&nbsp;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $<ix:nonfraction unitref="usdPerShare" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc0MQ_adf8230b-a63f-438d-b5ac-4ebef0d49e25">22.50</ix:nonfraction> per share in cash (or an aggregate of $<ix:nonfraction unitref="usd" contextref="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTA5OTUxMTY2MDY3NQ_e1639a03-a0de-40c9-a68a-914a2f8fc235">747.4</ix:nonfraction> million, net of cash acquired) plus <ix:nonfraction unitref="right" contextref="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131" decimals="INF" format="ixt-sec:numwordsen" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1MDQ1Mw_99f2580c-5b75-4669-ae75-fe6a66c34996">one</ix:nonfraction> non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders to up to an additional $<ix:nonfraction unitref="usdPerShare" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc1NQ_ef6771c6-8094-469d-8e1f-805780b3eff2">4.00</ix:nonfraction> per share in cash (or an aggregate of approximately $<ix:nonfraction unitref="usd" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc2Mg_2c276e04-a8b7-48f7-83a8-98f44af3801e">160</ix:nonfraction>&nbsp;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately <ix:nonfraction unitref="usdPerShare" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="3" name="lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM2MDkwMQ_6bb9b1e9-c864-4b6b-937f-92d3fda3b645">8.3</ix:nonfraction> cents per month until December 1, 2028, at which point the CVR will expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that will be anchored by Prevails portfolio of assets. Prevails lead gene therapies in clinical development are PR001 for patients with Parkinsons disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i44ee3174d18344e1a646c1b677b5bd26" continuedat="i861bda280f1544cc9df0970276b5df6e"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM2MDkwMg_12b29c0d-c796-4cad-ac1e-0b6dc66c5370" continuedat="ie5eff5dcf6de431ba284955ac134a7cc" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMS0xLTEtMS03OTc2_86525dbf-0f39-4901-98f3-0e12836ff32e">90.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMi0xLTEtMS03OTk1_701e81f5-27d8-4080-8673-4f3ee872dc74">834.0</ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMy0xLTEtMS04MDAx_90f88061-c9e8-41e1-913f-e84fd79313d7">111.0</ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNC0xLTEtMS04MDEw_81132a22-3980-4ff0-8605-f81c8cf743d2">100.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNS0xLTEtMS04MDE3_7e868679-3ce8-4652-9c4a-7882cec79228">31.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNi0xLTEtMS04NTc4_c951eb16-7415-40e3-aa4d-1ad3581787b0">903.8</ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfOC0xLTEtMS04MDQw_fc9e256c-cb16-4390-a5d1-60ae62329edf">90.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfOS0xLTEtMS04MDM1_96c4f215-44a6-4c2d-bf12-5dfff74a99ef">65.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMTAtMS0xLTEtODU4MQ_4a3f43de-e613-4b73-9f48-465c4eabae38">747.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div></ix:nonnumeric><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="ie5eff5dcf6de431ba284955ac134a7cc" continuedat="ibd85c98b37994a01aa4355a7566d62a7">(3) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ibd85c98b37994a01aa4355a7566d62a7">See Note 6 for a discussion on the estimation of the CVR liability.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $<ix:nonfraction unitref="usd" contextref="icbcb632a5c694ec29deb85ebe3a2a2e9_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTY1NQ_6ff5a115-2354-408c-aebb-1be9fe7fb083">849.3</ix:nonfraction> million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the three months ended March&nbsp;31, 2021, we decided to sell the rights to Qbrexza. See Note 5 for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $<ix:nonfraction unitref="usd" contextref="i532d485d20654594a8b1a96d44626d00_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMjkwNg_f7a3f23a-fc30-42eb-a690-c30dba993546">86.8</ix:nonfraction> million, other intangibles of $<ix:nonfraction unitref="usd" contextref="i532d485d20654594a8b1a96d44626d00_I20200229" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMjkzMQ_5a6fb229-69c3-4faa-bdf9-212dc068ac1d">1.20</ix:nonfraction> billion primarily related to lebrikizumab, deferred income tax liabilities of $<ix:nonfraction unitref="usd" contextref="i532d485d20654594a8b1a96d44626d00_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzAwNA_b5d48ad5-ba9f-4645-b4fa-f9fba4a6e252">49.5</ix:nonfraction> million, and long-term debt of $<ix:nonfraction unitref="usd" contextref="i532d485d20654594a8b1a96d44626d00_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzAzMA_1f0fda30-5c03-42dd-bac4-4d3bf04004a7">375.5</ix:nonfraction> million. After the acquisition, we repaid $<ix:nonfraction unitref="usd" contextref="i1a359ced678146c9b9d8f9eb94adc1f8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzA2Nw_bdb3a1e3-da09-4039-80d6-6775cc221b40">276.2</ix:nonfraction> million of long-term debt assumed as part of our acquisition of Dermira.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i861bda280f1544cc9df0970276b5df6e"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI4NA_696c362c-47d4-4f87-a851-b553d2a25903" continuedat="icb7c243339b24baca288f603996b9df9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our asset acquisitions during the three months ended March&nbsp;31, 2021 and 2020:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s) or Therapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development of potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if0a60d23094d4089a16f414a2eb40222_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMS02LTEtMS0xNzg0_23bcdc46-58f6-4403-9f71-8c36c4ce8bda">107.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib490931de5a249db92647a2ab94af9ad_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMi02LTEtMS0xNzcz_8a893286-42d6-4b00-bd50-3e730c38bb2c">46.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie1c5831cc7174801a03a8b0a2fd91a4b_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMy02LTEtMS0xNzY4_c441e7e6-126d-45cd-af5b-57d921f6a5a4">20.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id6460ea51b114fd5952c6937cbc22e89_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfNC02LTEtMS0xNzk4_ef3cb04d-7268-4d7a-b416-4422385a8966">125.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if871b5e2a0ea46059a74abfa4e82d02d_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMS02LTEtMS0w_4717fb67-fdcd-4428-af0d-f26f1e352184">52.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c7fcc42f3b34de0bb6bf706fa7541fa_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMi02LTEtMS0w_20723a11-eb11-4077-85b0-91f946b85d1c">25.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div></ix:nonnumeric><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="icb7c243339b24baca288f603996b9df9" continuedat="i32d3acfdedf941e0b4989dc25664605a">(2)</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i32d3acfdedf941e0b4989dc25664605a"> We recognized an acquired IPR&amp;D expense of $<ix:nonfraction unitref="usd" contextref="i7cfe3973fd10441580375afacb0b0090_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNTI2MA_6fa1f3b0-daa4-4b87-88af-0fef5b91a60e">25.0</ix:nonfraction> million in May 2020 upon closing of the transaction.</ix:continuation> </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div></ix:continuation><div id="i3cd151b5d83246a98b0e0ef4a9feb269_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfMTAwODk_99ca6efb-3712-4f6c-b910-5f4d58db5b43" continuedat="i2d615b4acd384fd0ba9122c932d07a45" escape="true">Collaborations and Other Arrangements</ix:nonnumeric></span></div><ix:continuation id="i2d615b4acd384fd0ba9122c932d07a45" continuedat="ic541bc53cb314ea1aa5120c8988d7f41"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheims oral diabetes products: Jardiance,  Glyxambi, Synjardy, Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="ic541bc53cb314ea1aa5120c8988d7f41" continuedat="i686abc669804468e921aee8abff5a888"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfMTAwOTM_5e29e693-ec19-4791-803c-fad41b8c15bc" continuedat="i74e546f17e8a4e0ba9af4687d825859c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the net amount of significant milestones (deferred) capitalized at March 31, 2021 and December 31, 2020 for the compounds included in this collaboration: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones (Deferred) Capitalized </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i787debb10db9449ebf355978b2cac4c9_I20210331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0xLTEtMS04MzEx_0361397f-01c7-4de2-997a-88e0ac9ad3ab">151.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d95635b39cc445ebd68b8eaacc4cf49_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0yLTEtMS04MzEx_aa18fde8-72f4-43c2-9573-2aae2451a8a8">156.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8356c279b93c42829023f67b564fd0f1_I20210331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0xLTEtMS01MDM3_ca961c16-e81e-499a-b1c0-581a629f4d8a">108.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7898c22d6db548ba8e625e7b4cb51b1c_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMS0yLTEtMS0w_4fb1a185-7395-46e9-9cd4-35d8b9a2d5b2">114.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie49f3b9fa84949058c66e2ccc6f1bafe_I20210331" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfNC0xLTEtMS01MDM3_f2921045-378c-4d32-90a1-ff887f74aac6">163.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iecf3e061ab6a44e0b3e95b09ceec5863_I20201231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMy0yLTEtMS0w_f32badb5-5d80-47b8-8642-20f7ef2b9441">168.0</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue.  Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><ix:continuation id="i74e546f17e8a4e0ba9af4687d825859c" continuedat="i026dfac012d64444bba0d47947deb0b9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0xLTEtMS04MzMz_aafa8472-ae8a-4bc6-80be-9b15648fda23">312.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0zLTEtMS04MzMz_5bd7fdb7-0e99-4719-bc21-00d331b9d6a9">267.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0xLTEtMS0w_dbc0725d-fc85-44cd-9fd8-4b1bfe2430d3">246.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0zLTEtMS0w_5b2e845f-3e4b-4b3a-86bc-2680bbf4e4bd">303.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabb0222b012c480fa8a4b4033fb1c3b4_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfNC0xLTEtMS0w_7ef61ed1-ad75-442b-b0da-806f8d9af6df">94.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i50e1340911c44726ba35205e9879816a_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfNC0zLTEtMS0w_60603f4f-6ee6-4292-a88f-0de106a7fe4d">93.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on global net sales with rates ranging up to <ix:nonfraction unitref="number" contextref="i661524a58a1c40ec97906a968e6f6aca_D20210101-20210331" decimals="2" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjI1Mw_971163d5-a212-4916-9914-af3cd3cf4e56">20</ix:nonfraction> percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $<ix:nonfraction unitref="usd" contextref="id9bf6a3d44b2458aabd053d1804a3283_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjUwOA_75191053-25b1-4459-ad43-6db8ad11885e">210.0</ix:nonfraction> million were capitalized as intangible assets as of March 31, 2021 and December 31, 2020 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, Incyte is eligible to receive up to $<ix:nonfraction unitref="usd" contextref="i64aadc652c4343c1bcd2bfc5b72d6158_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjgxOQ_0dcae872-c3af-42fb-a209-7c7c28c86e6b">100.0</ix:nonfraction> million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $<ix:nonfraction unitref="usd" contextref="i3343c905d8554be69ab7b345fa893082_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjk3MQ_19489ce0-3fb9-4522-910f-6b707b34fd61">150.0</ix:nonfraction> million of potential sales-based milestones.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i686abc669804468e921aee8abff5a888" continuedat="i5673fc1096ea41a6a58f1af382a310ac"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="i026dfac012d64444bba0d47947deb0b9" continuedat="i7579c930bf4a4fcd86f20810dee6e07f">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="i7579c930bf4a4fcd86f20810dee6e07f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0xLTEtMS0w_43dfdcb5-e735-4121-ad47-147da4f5a662"><ix:nonfraction unitref="usd" contextref="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0xLTEtMS0w_ba60441b-b236-48e2-9d7f-ff80305eb163">193.8</ix:nonfraction></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0zLTEtMS0w_72d5363b-b180-417d-b6c7-91b3343689d9"><ix:nonfraction unitref="usd" contextref="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0zLTEtMS0w_eff31ee2-fe9a-417e-9b48-e79b1e0348ce">139.7</ix:nonfraction></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of Greater China (which includes mainland China, Hong Kong and Macau Special Administrative Regions and Taiwan) and for which Junshi Biosciences maintains all rights in Greater China. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) in the U.S. and Europe, milestone payments of $<ix:nonfraction unitref="usd" contextref="i3ec641d1b0e0486dba0286bc54d9f28f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg3OA_e328a81f-6023-4d4c-bb97-f9359f674143">60.0</ix:nonfraction> million were capitalized as intangible assets as of March&nbsp;31, 2021 and are being amortized to cost of sales over the estimated useful life of etesevimab. As of March&nbsp;31, 2021, Junshi Biosciences is eligible to receive up to $<ix:nonfraction unitref="usd" contextref="i9cadf4d9d0bd4bf6b1d1bd9d0dc96dee_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg2NA_71ed43c5-b39e-42f9-bb9e-f1dd1d8becd4">15.0</ix:nonfraction> million of additional payments contingent upon certain success-based regulatory milestones and up to $<ix:nonfraction unitref="usd" contextref="i44a54fd999064e8484fd5ca2af4dcc17_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg2OQ_6bfe2c41-a48d-4c7b-a34a-dae460326a01">120.0</ix:nonfraction> million of potential sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs, we recognized $<ix:nonfraction unitref="usd" contextref="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTk2NQ_287208df-52a7-4065-8892-5d3b6e35705c">810.1</ix:nonfraction> million of net product revenue associated with our sales of our COVID-19 antibodies during the three months ended March&nbsp;31, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tyvyt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize Tyvyt (sintilimab injection) in China. In 2019, we and Innovent began co-commercializing Tyvyt in China. We record our sales of Tyvyt to third parties as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We also report as revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. Our Tyvyt revenue in China, which is primarily recorded as net product revenue, was $<ix:nonfraction unitref="usd" contextref="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTY4Nw_b1fa3217-3b4b-4488-be3c-9a95a7c78d93">109.7</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTY3MQ_f9954cb6-a22d-425c-a088-134ad2d685fd">57.4</ix:nonfraction> million during the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we obtained an exclusive license for Tyvyt from Innovent for geographies outside of China. Innovent, with collaboration from us, will pursue the initial registration of Tyvyt in the U.S., and we will pursue initial registration of Tyvyt in other markets and all other subsequent registrations of Tyvyt. We have exclusive commercialization rights outside of China.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, Innovent is eligible to receive up to $<ix:nonfraction unitref="usd" contextref="ied018ff88f6646e88340a81a87e88722_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg4OA_ad2281d6-a9e6-4001-a984-47b8469128ee">825.0</ix:nonfraction> million for geographies outside of China and up to $<ix:nonfraction unitref="usd" contextref="i2d761f2cc36e4a03b6ad57e5ab13c540_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg5Mw_a1337b91-4c92-4b78-ad4f-890665ad5b1f">235.0</ix:nonfraction> million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tanezumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. The companies equally share the ongoing development costs and, if successful, in the U.S. will co-commercialize and equally share in gross margin and certain commercialization expenses. As a result of an amendment to the agreement in 2020, Pfizer will be responsible for commercialization activities and costs outside the U.S., and we have the right to receive tiered royalties in percentages from the high teens to mid-twenties for net sales in Japan as well as low double digit royalties on annual net sales greater than $<ix:nonfraction unitref="usd" contextref="ia32a56f35ba84943ac17a6ae53d314e0_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNDk0NzgwMjM0NTYzOQ_8a0e07cc-289f-43d3-ab41-e429dd02c103">150.0</ix:nonfraction>&nbsp;million in all other territories outside of the U.S. and Japan. As of March&nbsp;31, 2021, Pfizer is eligible to receive up to $<ix:nonfraction unitref="usd" contextref="i24615d347773426cb44faa02b5f3a282_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODA5Mw_7a5b96ac-6595-439e-885b-4f61c456cfdb">147.5</ix:nonfraction> million in success-based regulatory milestones based on current development plans and up to $<ix:nonfraction unitref="usd" contextref="i3b6de8f942f44cf0aced4adc5181105e_I20210331" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODE4MA_4992ab14-7f3e-4803-8581-3143b6bf1ec9">1.23</ix:nonfraction> billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i5673fc1096ea41a6a58f1af382a310ac" continuedat="i8520b90efb954b96a309bdd9f66cf802"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of March&nbsp;31, 2021, Roche is eligible to receive up to $<ix:nonfraction unitref="usd" contextref="i4ee311292e604c2ba36873038aa0d41a_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODc2NQ_2197898d-1c35-48a0-86c8-40da352577c1">180.0</ix:nonfraction> million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonfraction unitref="usd" contextref="i2e55c79531a045a4849418d1e780b569_I20210331" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODg3MA_77e1fb01-e28e-493e-9d42-c474a09ec427">1.03</ix:nonfraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of March&nbsp;31, 2021, we are eligible to receive additional payments of $<ix:nonfraction unitref="usd" contextref="i1bd3d506e737426ca9f7d5071e2fe975_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfOTUyNg_db3476fb-d847-445a-8fc5-f48a832c7a6d">85.0</ix:nonfraction> million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonfraction unitref="usd" contextref="ia6017620bc984fc3b23178c68fc11436_I20210331" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfOTYyNA_4372d029-f890-4b0d-a4d3-7784585ca72a">1.25</ix:nonfraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8520b90efb954b96a309bdd9f66cf802">As of March&nbsp;31, 2021 and December 31, 2020, $<ix:nonfraction unitref="usd" contextref="i5c39357db5cc4a9cbcfd00adcb81f908_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDkwMw_46e412e0-d89f-4983-86aa-a650444a5dae">23.3</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i6fea589edc3e4ab08f9ed7052aad2e59_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1ODY3NA_820362df-11ab-42bc-915e-58e9962906ba">29.7</ix:nonfraction> million, respectively, were recorded as contract liabilities on the consolidated condensed balance sheet and are expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the three months ended March&nbsp;31, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_58"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNzc4_36abbb79-574f-414e-b791-2864374b5292" continuedat="i5bec616772c74dee9962071bd9a87384" escape="true">Asset Impairment, Restructuring, and Other Special Charges</ix:nonnumeric></span></div><ix:continuation id="i5bec616772c74dee9962071bd9a87384" continuedat="i40676bd2921a49fe82c7ec5fd2df15cf"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNzg1_d9ee5252-7669-466e-beb3-eda60f33990a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMi0xLTEtMS0w_6d174d88-bd85-4952-b4cc-f3df9bff93b9">11.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMi0zLTEtMS0w_b4e78399-dba1-4aae-8ccc-3528e952767e">9.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMy0xLTEtMS0w_0987e5e5-2fc3-494a-8f25-22f0cd050e33">200.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMy0zLTEtMS0w_26bb8512-cc99-4be1-aa04-8de2e2d65491">50.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfNC0xLTEtMS0w_867dc0f3-4934-4403-bb1c-95f003c7ea49">211.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfNC0zLTEtMS0w_61e9d0f7-00f1-4631-bc7a-178c42842cd9">59.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the three months ended March&nbsp;31, 2021 were primarily related to an intangible asset impairment of $<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNDk0NzgwMjMzMTA1NQ_ab77e7a4-3bae-4da2-9fc0-bb1eeb0c06f9">108.1</ix:nonfraction>&nbsp;million resulting from the decision to sell the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. During the three months ended March&nbsp;31, 2021, we entered into an agreement to sell our rights to Qbrexza, subject to closing conditions which are expected to be completed in the second quarter of 2021. The assets associated with Qbrexza were written down to fair value less cost to sell, which were determined based upon a discounted cash flow valuation. The remaining book value of assets associated with Qbrexza subsequent to the impairment charge is not material.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i40676bd2921a49fe82c7ec5fd2df15cf">Asset impairment, restructuring, and other special charges recognized during the three months ended March&nbsp;31, 2020 were primarily related to acquisition and integration costs associated with the acquisition of Dermira.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_61"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4OTg_77a10609-7cb8-4d05-9dde-2c32f7d2eea0" continuedat="i69cef6e845a54239a64f47b3895fb085" escape="true">Financial Instruments</ix:nonnumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i69cef6e845a54239a64f47b3895fb085" continuedat="idd07b0134f874dcf88622b40618ea8d9">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="idd07b0134f874dcf88622b40618ea8d9" continuedat="i4a20beb0043942df95fd20c36916059e"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4Mjk_40b19818-1fc9-4819-a30b-6ed9b2b414d2" continuedat="i3eb8245f5510494a9e0e8ada2bf8ff08" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3eb8245f5510494a9e0e8ada2bf8ff08">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in othernet, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</ix:continuation> At March&nbsp;31, 2021, we had outstanding foreign currency forward commitments to purchase <ix:nonfraction unitref="usd" contextref="if8fd6ec70f034998b9025e47bf69042a_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDMwNw_8be969a2-8fe0-4880-82ff-1005831944be">1.11</ix:nonfraction> billion U.S. dollars and sell <ix:nonfraction unitref="eur" contextref="if8fd6ec70f034998b9025e47bf69042a_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDMzMg_6a7555b9-1f54-4db3-aaf1-3f84d1eea9c9">941.7</ix:nonfraction> million euro, commitments to purchase <ix:nonfraction unitref="eur" contextref="iacc428f5b7444f79a59f33bd449c5b64_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDM2NQ_67d67f1b-3a87-44dc-be01-d12b6a1e0b21">4.19</ix:nonfraction> billion euro and sell <ix:nonfraction unitref="usd" contextref="iacc428f5b7444f79a59f33bd449c5b64_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDM4Mg_fd0805d8-975b-40fb-acc4-d9fe68fdb67a">4.98</ix:nonfraction> billion U.S. dollars, commitments to purchase <ix:nonfraction unitref="usd" contextref="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQyMw_76a0d582-3444-414c-9051-da55b8a5f3b9">140.7</ix:nonfraction> million U.S. dollars and sell <ix:nonfraction unitref="jpy" contextref="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQ0OA_cf717cae-fa36-4235-8b99-b2d2cd207e92">15.47</ix:nonfraction> billion Japanese yen, and commitments to purchase <ix:nonfraction unitref="gbp" contextref="i196a382db4dd474f9215758c00592480_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQ5Mw_40187227-e041-4000-b2c6-4cfa926f665a">285.2</ix:nonfraction> million British pounds and sell <ix:nonfraction unitref="usd" contextref="i196a382db4dd474f9215758c00592480_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDUyMA_863c582d-9f72-44fe-9a20-9f8c8ec2e42e">396.5</ix:nonfraction> million U.S. dollars, which all settled within <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:durday" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDU2Ng_69718dcf-f14e-4ae0-8b38-43c80559d386">30</ix:nonnumeric> days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $<ix:nonfraction unitref="usd" contextref="i790e81260a954cde9599960f6c59fcd6_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDc2MQ_7c437e4b-194d-43d8-ad4a-9e541eac160d">5.72</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="iee91d9656eb3472e8cf1ac38a3807882_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDc2OA_fe04fae3-298e-4961-a3d7-a00e04179265">6.02</ix:nonfraction> billion as of March&nbsp;31, 2021 and December&nbsp;31, 2020, respectively, of which $<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDgxMQ_d228b96e-a9fd-481d-afe9-265751887a71">4.30</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDgxOA_7cacecac-dad8-4076-969e-14cb318f9f66">4.50</ix:nonfraction> billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations as of March&nbsp;31, 2021 and December&nbsp;31, 2020, respectively. At March&nbsp;31, 2021, we had outstanding cross currency swaps with notional amounts of $<ix:nonfraction unitref="usd" contextref="ifca25d1668f0447a8c0fb8e92c444a46_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNTA2MA_f68a4f95-40c5-4b24-a7bf-2b2bda01656b">3.79</ix:nonfraction> billion swapping U.S. dollars to euro and $<ix:nonfraction unitref="usd" contextref="icd062c4f7c644c92a3bd0c5fc8d3cd2c_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNTA5Nw_f783611f-44ac-4387-acda-a0a0b17e922f">1.00</ix:nonfraction> billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i4a20beb0043942df95fd20c36916059e" continuedat="i5a4a5e658e7749f285b927855e6cc7fd"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At March&nbsp;31, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonfraction unitref="number" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="2" format="ixt:numdotdecimal" name="lly:DescriptionOfDerivativeActivityVolumePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNjg4MA_c0501b28-d2d1-4e34-84c7-4030225792fb">13</ix:nonfraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of March 31, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonfraction unitref="usd" contextref="i08261dc843c546e282dc7746c9935f3a_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNzYwMQ_264bf1da-2105-4b73-a0bc-69c24b6fc7ed">1.75</ix:nonfraction> billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MzA_a9f88747-6636-408d-abdd-7e994387c2e3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in othernet, (income) expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i40ae6e16034149ffab19351331c55b6a_D20210101-20210331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfMy0xLTEtMS0w_091d97c9-6ec4-4d84-b4c8-e69aed54569e">81.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5bc95e47cf6e4f3da137f20ede5e2282_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfMy0zLTEtMS0w_91b5e364-0421-4d52-bdce-b7bfd05366e5">117.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNC0xLTEtMS0w_e8d47989-4b87-453f-8cb5-d018ce9c4ce9">81.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNC0zLTEtMS0w_e09c8394-16c2-4554-b58e-7187a7bc84eb">117.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNi0xLTEtMS0w_ecb3f3e2-92a4-44b0-8e06-cc815d661450">4.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNi0zLTEtMS0w_d91e23e2-1e04-4c14-a32c-97c35600eeb4">4.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e9ced055f4647d1b7ac5f1b13d3dcdb_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNy0xLTEtMS0w_ab927ed0-044d-41d0-988f-11ddc7f04ed3">71.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0675cae41ecf4fad80226860b67627c8_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNy0zLTEtMS0w_43004df9-1d6f-4c61-8d58-ab58bd2c47cb">12.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5cc6b325c96343679b6ae5ded2b4017a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOC0xLTEtMS0w_929d33de-317f-4130-bb31-cac405be335f">133.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1ebf8484d97442a79f3fb0056a0a0636_D20200101-20200331" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOC0zLTEtMS0w_13bee5ee-39f7-4f2f-a482-8de94bd1039a">5.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOS0xLTEtMS0w_51e24626-faf7-4389-b313-c1588fa23c2d">208.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOS0zLTEtMS0w_568c8bdc-9a39-492c-9d09-e2ca30f6d94a">14.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2021 and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MjM_d444bfe7-d7a5-45b7-8f18-91271a909470" escape="true"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTU_f2563394-95a8-40f8-960d-2c2f01b65ead" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i48597227bfbf4037b23b06218e7f576b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfMy0xLTEtMS0w_4cf4ac8e-05de-4dc8-b6e4-a163850f5cc9">207.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i733a2380e7734f87b92e3f8aed9fe6ac_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfMy0zLTEtMS0w_79c330e7-f109-4bd0-90e2-6e13af8dd268">67.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNC0xLTEtMS0w_2a1dcbdd-bcdb-45b8-afcb-ab620dc55d96">150.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNC0zLTEtMS0w_b99945b8-2f81-42cf-8481-656b648458f8">115.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie02bf6e1811a43e7a3d115fc98ca56c9_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNy0xLTEtMS0w_7fcba855-c0d2-4984-8c93-0329ffa7b396">295.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic8a0cc4c13104fccbd1c69dcb601af62_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNy0zLTEtMS0w_bca4f9a9-69af-400f-9a10-1b14d65eab4a">369.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfOC0xLTEtMS0w_08a7ac18-daff-4724-af5d-f2f5ee314191">26.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfOC0zLTEtMS0w_0c7b6d49-b939-41ca-834c-3fa2dfabac83">69.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:nonnumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&nbsp;months, we expect to reclassify $<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfODkyOQ_e4ca65fe-9ca3-488e-9af9-b7ce78764d0b">16.9</ix:nonfraction>&nbsp;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to othernet, (income) expense. During the three months ended March&nbsp;31, 2021 and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div></ix:continuation><div style="margin-top:9pt"><span><br></span></div><div style="margin-top:9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i5a4a5e658e7749f285b927855e6cc7fd" continuedat="i64ded331eb5a429a8a17f28c70a6cac3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTA_b38730a1-9e8f-499a-98d2-1a61a5fc301a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at March&nbsp;31, 2021 and December&nbsp;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br>Observable Inputs<br>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Unobservable<br>Inputs<br>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0xLTEtMS0w_305307bc-3e5e-4f81-b0d7-b14e9cbf2786">1,554.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i259ea4a4728c4829bf5a1d53b88fe316_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0zLTEtMS0w_ab5c1787-e111-481f-bcde-2c43c950ce72">1,554.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i379b7bdd53b04924a6915f7b6f539ae9_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy01LTEtMS0w_1b44dc38-278c-4fe2-8504-843ff8eea6f0">1,554.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i502fd03d8e8b42f384a0637943ac9227_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy03LTEtMS0w_cee65b4d-1992-489d-9d97-c6341118c48a"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i110e7dd739b14882b203dd13e31a425d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy05LTEtMS0w_d8363081-4d3d-4407-b24c-e15a832e8561"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b1fc639100545e8b40e4cfd5886def1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0xMS0xLTEtMA_08e0db31-f09c-4ade-8fcf-8f9a05fa040d">1,554.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i50db401e52d34c6bbb22d8b87c712ee3_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0xLTEtMS0w_5001c7cf-479f-444f-b868-632ccefc2172">20.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9d9b74593ec94447a6448aee79dc1a4f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0zLTEtMS0w_a4d29ff9-e3db-4b60-b4b3-54987a8e32ef">20.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11210e6bf5044a31804dbf8297477c5b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi01LTEtMS0w_444894d1-5db3-48c5-82fa-3d9b9aa7991d">20.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi03LTEtMS0w_76e9970c-c30a-43d0-bcd5-c8b234d4587a"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3c35346f0f3b44448000e57b1d0d71cf_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi05LTEtMS0w_c17ed7a8-d156-4aef-a74e-0d0ee0287a21"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e2ffab98d7f45a0a3b806e73e461745_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0xMS0xLTEtMA_8b507bd8-f009-49db-b88e-19e4e97d7bf3">20.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab695d20c84c457e96ce06476d8e182f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0xLTEtMS0w_c8f0cd03-6171-40cf-b0c7-f313ac338a91">7.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c6474daeefd44828fcb9effa40e0c54_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0zLTEtMS0w_c3ae9805-60a7-4394-b476-49532a51b9d0">7.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC01LTEtMS0w_8296b48b-6da1-4553-a42d-848fdf9cb558"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC03LTEtMS0w_3f38441b-e0db-4fb3-ae63-5e5a49bdfbba">7.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC05LTEtMS0w_4a8c1046-4ad0-4750-b68d-8f5cdc53ba84"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0xMS0xLTEtMA_75316296-594f-49e9-a6ac-8bbb3472b260">7.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i94d22e93a3ad41848489c4810cedd352_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0xLTEtMS0w_43e593c4-52ad-404c-b177-c95af62823a8">2.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8aef2fe7df7413a99dc9b367490fdba_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0zLTEtMS0w_0e339da6-ca0f-48eb-b0ec-2056d473139f">2.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i21ff33225cde42d38dd508e225243ffe_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS01LTEtMS0w_0eec8368-0515-4fd7-b894-e33dc599f5cd"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i094cfa08457b4639b53077e02b7b579b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS03LTEtMS0w_85db2fa0-f1da-4d49-b36f-768b89c1fd1f">2.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39943827be2c4f9ea50a2cdfca84df2b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS05LTEtMS0w_bbb57532-4d72-404e-bbec-f1c1bddc89b8"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idaeb507e6d804976ad515b86786c2663_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0xMS0xLTEtMA_cc18196e-23a7-4093-a913-1255b3415609">2.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd103e4954f440de8adec2b901b7d26f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMS0xLTEtMA_6c33b19e-dd1f-4f0f-8059-e24d5ef0cf39">18.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2765888bb9a44e86856eb0e40a7a95a1_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMy0xLTEtMA_bdae86e9-270f-4789-a4ed-dab0c91d6798">18.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i937ee9f927b84aafaa8fd46c3071e390_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtNS0xLTEtMA_bf96ca64-0d7f-4879-bde3-a724ef9f18f9">18.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5623a1b5a79348899d40b0b51b54335e_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtNy0xLTEtMA_915ac37f-a9eb-4127-89a9-b8d8593ed452"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i273c3175cdf54c6d9bd6414b446f3ab2_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtOS0xLTEtMA_2b2a6575-0455-4d5d-8faf-bfbfef2418bd"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib521cd4c99774b97881a80a2a1c9c35d_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMTEtMS0xLTA_af9df4bd-b40e-44d8-b1e0-3c4751883e4e">18.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTItMS0xLTEtMA_630e609a-c67e-43e4-8681-b578671c2d0f">49.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i50db401e52d34c6bbb22d8b87c712ee3_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMS0xLTEtMA_c657e494-da39-4bde-b0b5-93f55008ebbc">109.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9d9b74593ec94447a6448aee79dc1a4f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMy0xLTEtMA_8415a7c8-5d4b-4a15-aeba-12171ebb931b">108.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11210e6bf5044a31804dbf8297477c5b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtNS0xLTEtMA_7985bec2-d53e-409e-bdd5-e5ff093e49f9">109.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtNy0xLTEtMA_09b1cbda-25b9-4e55-a37f-c9bd524ceea4"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3c35346f0f3b44448000e57b1d0d71cf_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtOS0xLTEtMA_5fe18368-4f6e-45c8-b4d5-fc68bfcff512"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e2ffab98d7f45a0a3b806e73e461745_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMTEtMS0xLTA_48baff9d-d3eb-48ac-8702-c7ab12810e14">109.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab695d20c84c457e96ce06476d8e182f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMS0xLTEtMA_4455579c-d0ca-446f-8732-328ba91caa80">177.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c6474daeefd44828fcb9effa40e0c54_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMy0xLTEtMA_ee61749e-aebf-4e38-a1db-3315c64b67d7">175.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctNS0xLTEtMA_a2867d81-a71e-4476-9c72-ec2b236370bc"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctNy0xLTEtMA_086816f0-0921-49ff-8a89-8b39908b22d3">177.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctOS0xLTEtMA_67dbe50e-b0cd-4afe-8fae-7efc580d6b21"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMTEtMS0xLTA_e922801e-bc1e-41bf-832c-09ace39ebae4">177.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i49b67199341a409fb3c610a89020e4e4_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMS0xLTEtMA_ddf23040-3a23-4b79-99c5-a7c7c082f80f">102.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8d997ddd2afa4e4aa435ed61a0039a79_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMy0xLTEtMA_6071b5fd-2d65-425a-896e-273ed0c73de8">99.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i162abcddb00540a6b88917d1b8c94bc8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtNS0xLTEtMA_7470e1a4-f8f9-4699-84a6-0f4ac50e5781"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i70666e8c06ae4150b3d53ba8f358e55b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtNy0xLTEtMA_18179c9f-996f-459c-bbea-6c05c4013ad7">102.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0b8e28324e994e5a9e7af4dd5abbfa4b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtOS0xLTEtMA_a14ff7dd-d173-4ddb-ab67-e7956567f0b6"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9cef5c921b4d4a13aa14e51caae1e54c_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMTEtMS0xLTA_683cab71-6b95-4d41-8aca-b124efc7afad">102.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i94d22e93a3ad41848489c4810cedd352_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMS0xLTEtMA_eeba3c59-197e-4460-bb85-361047755a32">23.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8aef2fe7df7413a99dc9b367490fdba_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMy0xLTEtMA_6585d34d-02aa-4827-b473-a3aaf46b2244">23.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i21ff33225cde42d38dd508e225243ffe_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktNS0xLTEtMA_e3300b37-d303-4379-b4f0-7271b1e31a99"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i094cfa08457b4639b53077e02b7b579b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktNy0xLTEtMA_d8efcf92-3bc8-4a66-9568-5f3838c7ff76">23.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39943827be2c4f9ea50a2cdfca84df2b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktOS0xLTEtMA_7c511fbe-9544-4989-a4d6-335e365268fe"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idaeb507e6d804976ad515b86786c2663_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMTEtMS0xLTA_f0af32d1-6642-442b-b28f-ef8b20323e6c">23.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i45eb28a2afb843b5a7599d09796ba47a_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMS0xLTEtMA_f1f2a827-a7bd-4404-bca9-071a301ee27c">110.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8c96a7e6ebdb4b5894e42f4f674afc2f_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMy0xLTEtMA_2155c07a-ee33-440a-a18a-bb40e3ca9646">30.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35a6dbafa15745eabd7e346fc0404f3c_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtNS0xLTEtMA_02a4de54-2cfa-433c-a29c-2382746976fa"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie03e1c230dbe49b5b1a23948beb4fdf8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtNy0xLTEtMA_9466ec16-967b-4045-9b07-5d3b6007219e"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic4814dc5f3094945b14b09c32634e414_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtOS0xLTEtMA_79bf8922-6baa-476b-be66-90b689dedf0c">110.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5428a6a7e77a4afc87dbec371aa0e81b_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMTEtMS0xLTA_182e5dd5-b07f-41ca-a545-889c72e4a758">110.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5b460fcffdff4102b1a5f350e775eb50_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMS0xLTEtMA_d80e48d9-7dae-4684-8ec8-fbaffad9d186">1,645.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i68b41c9f5b24461e99ffaf90ae7df35e_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMy0xLTEtMA_3c94ee45-f007-4d98-a54b-6e2ec1433d83">386.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07692a7baeb34e989f264a119af0c6a3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtNS0xLTEtMA_8e82fbd1-fac4-4a1e-98ce-ff673eb202fa">1,645.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cc36d48d552416e883d9009bfca5133_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtNy0xLTEtMA_6b6c4f8e-5b17-4f54-be54-44653ac9a75f"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id251b7aadbd741c38319af027dda2015_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtOS0xLTEtMA_9dfa2938-0e29-4296-9b4e-d6b31c7aef7a"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie57e8b8550a94ed3a3001f7258f40509_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMTEtMS0xLTA_d47ab838-3910-4a6a-9cb9-766161dfde1a">1,645.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjItMS0xLTEtMA_56f5323f-f7a3-4992-9b64-853bb18725c7">384.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie22efb639d76469d92d9d05b55c13b2e_I20210331" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjMtMS0xLTEtMA_570f0405-9674-4d15-a351-e7db8b3fec1f">679.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjQtMS0xLTEtMA_b1f7147f-a7af-4e0a-a124-f6b449bc6db0">3,232.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMS0xLTEtMA_3b56f49c-2559-4d49-9964-c155d7dd316e">2,097.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id7364db11b9f4acc956a7d2db362e700_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMy0xLTEtMA_a72d586c-c4e3-42de-924c-16a634e54c58">2,097.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc89d6e873484ce2a724580ab1fb0293_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctNS0xLTEtMA_d84f1b00-8057-4800-b5b0-f119a95d2b53">2,097.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib227796e6d934483a3898110d9a529dd_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctNy0xLTEtMA_cf853136-5202-4e92-8fe8-393a021304b8"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic99278c5824b4d0d9f4dabbc783d760a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctOS0xLTEtMA_674c70b6-6f9f-4672-8e60-fe4493994ed6"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i173d02bf976949bb9c2fff706b29e7c8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMTEtMS0xLTA_bbbc985b-9e6b-4a70-9356-3b886ad1dcab">2,097.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaca67a3e336f480dbf5c62f2d4887602_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMS0xLTEtMA_e605251d-cf6a-4e6f-86b3-df45b2fdf25d">9.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2385ee7845f44db9928643d251ba010f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMy0xLTEtMA_b7ba7d81-4620-4df7-928c-f9edd416d250">9.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtNS0xLTEtMA_61e620d8-c63b-4de4-a787-10963787c0bb">9.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i674d272a65ea4e939a918cbd40640fad_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtNy0xLTEtMA_d82a5741-bc5a-4e1e-b28e-6b3bf2ad2155"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtOS0xLTEtMA_5f750a51-2f0b-4418-aeff-f726d04329d2"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea8e950975814a17bb0570d6ed036339_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMTEtMS0xLTA_988f0318-c280-4e45-8a18-105c6049bdfd">9.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab6a22cd5a3647489cfa1868842fce27_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMS0xLTEtMA_9520042f-813a-4413-a18a-6d8abe4e6a1c">2.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id94556bfa50648c6896a229ad967ebdb_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMy0xLTEtMA_392b6ac7-c081-480c-a4c7-cdc70f32f2a5">2.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ba9c3716f03494583ac46573df6d898_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtNS0xLTEtMA_8f224b66-824e-49ba-ab34-d1cf93893309"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3f1ae733c62431ea7747e533857a063_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtNy0xLTEtMA_7b1fbba1-1785-46be-b96a-15d1ee3d4663">2.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtOS0xLTEtMA_80d8ce9d-0064-4469-9b23-9ac8477ab784"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i15f60e22ff78453692beb5eecfca6ffc_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMTEtMS0xLTA_854c0199-4848-4295-bcc9-29505a7b4a36">2.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd7549721eee45bb8a3527258d461fd4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMS0xLTEtMA_6dcfd230-d788-4d0a-bccb-44788dc5f576">1.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f9525a450be44ef9048544d4294da74_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMy0xLTEtMA_445a44a8-1d00-488a-bd4c-5fc40974eda7">1.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i65bf701b377c4beda33939db2d2f21ff_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItNS0xLTEtMA_480fc4bb-7966-45db-b254-21bee997941d"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i55aec24c88d44f4fa43277cc7538aab2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItNy0xLTEtMA_484e2818-3659-4d91-b278-43f536981550">1.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItOS0xLTEtMA_d7d89220-7dd7-4451-94d1-3d7069b0d618"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i853e5949474b4d67b1db52061559bac8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMTEtMS0xLTA_8a3f7853-de78-481c-8005-40e968e76b64">1.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb0f7206c077458c83a576a665d51173_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMS0xLTEtMA_210b37b2-fa22-4b66-b53d-1047e827621a">10.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb18caa1f88e42d389a9b17c85b0d9bd_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMy0xLTEtMA_1e950c07-af93-4ae2-8003-f7fd961ce22b">10.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i43215dcd05be459096efcec752179430_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtNS0xLTEtMA_8269aa0f-7754-44e4-ab90-173d93e2bba2"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i54c52e457bd4422ca65d6e22cb0ade48_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtNy0xLTEtMA_06f65f5d-505e-4cda-9379-b69c6c9f2b27"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1389fc9ec68d4b2db27d6a8e3bbd4bf1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtOS0xLTEtMA_9c8fba3a-50aa-47a6-819c-c5e0928d3482">10.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib3c4f4f185ab4ad881bcc56455b80c21_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMTEtMS0xLTA_34f80914-83a2-4238-bab2-fcc13ae39c16">10.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzUtMS0xLTEtMA_bef91bd3-e4cb-472c-b643-99379d7b920c">24.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaca67a3e336f480dbf5c62f2d4887602_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMS0xLTEtMA_970a8ca8-e7c3-49b1-9245-4b59c910a902">78.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2385ee7845f44db9928643d251ba010f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMy0xLTEtMA_b932469e-39b9-4ccd-b808-f2f64898e09b">74.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtNS0xLTEtMA_ba5ad492-fefe-4689-9d01-deeb83bdeef9">78.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i674d272a65ea4e939a918cbd40640fad_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtNy0xLTEtMA_bf664bef-9459-4093-b1a3-20c667ae9267"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtOS0xLTEtMA_ef1d6cb6-756c-406b-85a1-b21bcfc17fa4"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea8e950975814a17bb0570d6ed036339_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMTEtMS0xLTA_d821f161-d7aa-4c96-abad-d77974949bb1">78.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab6a22cd5a3647489cfa1868842fce27_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMS0xLTEtMA_5199021c-b611-47f7-b995-fab6c6b6910f">137.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id94556bfa50648c6896a229ad967ebdb_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMy0xLTEtMA_d9cea973-06e8-446f-b32b-726e052a891e">126.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ba9c3716f03494583ac46573df6d898_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktNS0xLTEtMA_eea61346-585c-4b51-80ad-17bad380ec69"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3f1ae733c62431ea7747e533857a063_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktNy0xLTEtMA_6474128e-b873-4556-8c5e-5b5174ee949f">137.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktOS0xLTEtMA_302433ad-7cce-44ab-9380-1c14040bd15f"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i15f60e22ff78453692beb5eecfca6ffc_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMTEtMS0xLTA_aea5a02e-4edf-4c31-9a42-c2b6654c03f5">137.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i79853a9b5da14a6fac53703381e9a418_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMS0xLTEtMA_cbc05334-f109-40c1-8b9c-d08705942e39">106.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i33320e06f4274ef9845c5efab8d73bb1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMy0xLTEtMA_1ab017d1-c28c-42c5-a265-21a9f55d7122">101.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2b2eb8a9c98a498ca9bf40a99de8f49a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtNS0xLTEtMA_64851bc3-1a16-4d34-9feb-6c08dd391cad"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib04cc817383740faa1e617ece927631a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtNy0xLTEtMA_1dde1e21-4f0f-41c4-8356-7daa8dd30677">106.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id384954fa3fa4e6095584ab30e130a4e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtOS0xLTEtMA_da4e22fd-ec6f-4dc1-ada8-6d9f95497cf4"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic8955bee463a4261b77faca6da120420_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMTEtMS0xLTA_fc1dde88-c332-419a-9986-c8a188e08c25">106.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd7549721eee45bb8a3527258d461fd4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMS0xLTEtMA_f22b66ff-3ad3-41b2-8c58-42eb20000f72">24.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f9525a450be44ef9048544d4294da74_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMy0xLTEtMA_f142f20d-8cee-40d4-be59-ba554646d9a7">23.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i65bf701b377c4beda33939db2d2f21ff_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtNS0xLTEtMA_ac588570-9bae-4a63-a80d-a011e15d99d5"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i55aec24c88d44f4fa43277cc7538aab2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtNy0xLTEtMA_d7b59a16-ef0c-4904-9023-c9ee619fda65">24.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtOS0xLTEtMA_2bee3c94-7f9a-4c29-a422-7ed2451318c4"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i853e5949474b4d67b1db52061559bac8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMTEtMS0xLTA_b2cce36a-89d0-4ef6-8d26-a56b8220f244">24.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3e8796c582de405f85453b6be2e3dc09_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMS0xLTEtMA_47f0261e-1a0f-46d6-acd6-58796897fb68">110.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if57b6463cf5a4132bbba6db81c527ec0_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMy0xLTEtMA_fe9a1c65-048a-4007-ac7f-8d9410ab9f7a">31.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i65887bb8147d4233b2936ee964d36760_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItNS0xLTEtMA_117ec505-425a-492a-add4-be46679dee5d"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i45624739b2404896b6fe384552b5797f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItNy0xLTEtMA_42eb1b7c-3056-4b85-a1b9-1cbd6c785c47"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18bd77315f3640e2b75151bd1a403bd6_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItOS0xLTEtMA_2bbcb288-22d1-4837-9f97-259a30ab10a0">110.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i095078139e5147baa3f7c5a93913c9f2_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMTEtMS0xLTA_da18f102-f9a8-45c3-9b19-6c518346062c">110.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i41723e47817543c98de3be1e9ac4e77b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMS0xLTEtMA_97a97ecc-1927-4a58-8fef-0003df5cd589">1,664.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide25b210128b49279f9dcc009920c562_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMy0xLTEtMA_07c1d570-71a7-43ea-96cf-b19e5fdbe5f1">311.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2ed173a5c7554ed8a6efa974dce7de56_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtNS0xLTEtMA_99f26ccd-48ba-478f-b792-d0265d6e6810">1,664.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8841002a34004d4d894ac4dd47bba8cf_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtNy0xLTEtMA_f0fdfca5-b7e7-4449-a26f-bdd29661abc8"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd5d2cfe7b1c4e6293342168871eb584_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtOS0xLTEtMA_e9097022-477c-4449-a44b-6a43697da0d7"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1862e16eb5894cbb872c6ebca5ff8dda_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMTEtMS0xLTA_bc6bc761-a47b-4980-8b13-89cd76a2f9d7">1,664.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDQtMS0xLTEtMA_b55220ed-5538-4faa-89d3-ab7ab161c67c">373.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2a8f781677394edcb970a7db2a230211_I20201231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDUtMS0xLTEtMA_86d1ff83-be72-44a8-b004-7431f6cce0b5">471.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDYtMS0xLTEtMA_ab120fab-f284-4bb7-8a70-307bb77701ff">2,966.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonnumeric></ix:continuation><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4ODY_62bbef02-549b-410e-ab88-b58c8704c202" continuedat="if6f44c3e90d94250ac5b37e16e1910c8" escape="true"></ix:nonnumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i64ded331eb5a429a8a17f28c70a6cac3" continuedat="i1d62df419fa945308db6f1acecd83e81"><ix:continuation id="if6f44c3e90d94250ac5b37e16e1910c8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:38.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Other Observable Inputs<br>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Unobservable<br>Inputs<br>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi0xLTEtMS0w_aa7ed7bc-3614-499b-8c28-8aae4291562d">16,204.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i379b7bdd53b04924a6915f7b6f539ae9_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi0zLTEtMS0w_677ab780-b0ce-4862-835a-8c58a0af7c19"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i502fd03d8e8b42f384a0637943ac9227_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi01LTEtMS0w_bafb101a-287a-44d9-baa5-549e58618d49">17,462.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i110e7dd739b14882b203dd13e31a425d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi03LTEtMS0w_31d6fce1-e1a8-4a28-baca-203f72940ff7"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1b1fc639100545e8b40e4cfd5886def1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi05LTEtMS0w_b0708977-c750-4bda-904f-fa1cd373b3f4">17,462.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy0xLTEtMS0w_fba37efc-19b8-4f59-bf1c-a01c094ecf7b">16,595.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc89d6e873484ce2a724580ab1fb0293_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy0zLTEtMS0w_e63b4510-a86e-49de-b880-36904010d300"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib227796e6d934483a3898110d9a529dd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy01LTEtMS0w_6a0437b5-45cd-4060-8b06-1e25e901bf7c">19,038.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic99278c5824b4d0d9f4dabbc783d760a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy03LTEtMS0w_0bf073e6-1fe1-4ec1-83fc-8989bb1ec36c"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i173d02bf976949bb9c2fff706b29e7c8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy05LTEtMS0w_74eb80c7-fae0-4ebb-89a0-45fea65cc1dd">19,038.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></ix:continuation></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTI_418f5d28-67f4-4993-b6f1-46d1bb1738db" continuedat="id115a781d8614a49a5fc47709721b2fc" escape="true"></ix:nonnumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i1d62df419fa945308db6f1acecd83e81" continuedat="iefeeeb2db2294664bccd8c84b545e9e8"><div style="margin-top:11pt"><ix:continuation id="id115a781d8614a49a5fc47709721b2fc"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Other Observable Inputs<br>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Unobservable<br>Inputs<br>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib0320b4ac23843468622fdd30e513355_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi0xLTEtMS0w_1c36095a-1ac3-4f2a-a70e-72eeaa7ab1ac">87.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi0zLTEtMS0w_953271b3-eadf-4b6d-82c0-198ee835ab6c"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9df56ec982804883a504fffec19bec2b_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi01LTEtMS0w_06874db9-8311-429a-a113-a993e69c65bf">87.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i818be88d8b754d358fa8f0f48530989d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi03LTEtMS0w_6b1beb08-608e-480e-8932-e14e458b0c22"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi05LTEtMS0w_8f699b1d-ebaa-4357-928d-7104912569f5">87.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib0320b4ac23843468622fdd30e513355_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC0xLTEtMS0w_7dbae019-a024-4457-9032-74013df60bea">9.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC0zLTEtMS0w_afa251bd-85f0-4975-a2e8-7bef580087ab"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9df56ec982804883a504fffec19bec2b_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC01LTEtMS0w_6df1c79f-3d4f-4d12-8939-708bd7d328bd">9.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i818be88d8b754d358fa8f0f48530989d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC03LTEtMS0w_f7676b95-0f38-4b50-9af3-42b7a6b2d014"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC05LTEtMS0w_38e13996-c331-4a63-a093-6f59891567e6">9.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iff50ed7383624a5dabf03016acb58cb4_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItMS0xLTEtMA_c6f712b5-13b0-4388-83e7-f024dd5a290b">235.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic22a911ebb564c3e8e5e11aebe36daf2_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItMy0xLTEtMA_b826fac3-2586-4cc5-b4fc-7219e12cb2c7"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3791d236011c495c9a6bc09f31e0e651_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItNS0xLTEtMA_f826691c-1c93-4c8a-99dc-5d57c016feff">235.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1eef9a676fef442f8cc0df6224b88661_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItNy0xLTEtMA_851f1258-42b6-45ea-ab20-a7663f61b7eb"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7f4f985dfc4c4913b6b477e42c5b7abf_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItOS0xLTEtMA_340bc596-6b1e-409a-ae23-498108bcacff">235.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97f888ed727b47c4969964bbc26cee74_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtMS0xLTEtMA_a94e044c-d8a7-433a-b313-294d535a3f0e">12.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtMy0xLTEtMA_d79d385a-bb9b-42b4-a79f-0eaf18c9c894"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc00ea5651d44a68866912b87e772f32_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtNS0xLTEtMA_eadd6b5a-c837-4f1c-b569-cfa6257ae56a">12.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9728137c063040fdb217c0c575d24e90_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtNy0xLTEtMA_1999e081-f4af-4b86-9aab-16c129289bfa"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia5691e9a962e48b9bab39a38eebafc58_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtOS0xLTEtMA_b21aadb2-0bfd-4b1c-ac59-c6532071e6d2">12.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97f888ed727b47c4969964bbc26cee74_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtMS0xLTEtMA_f07fc2c8-4da0-40d8-a700-691bb87b77e3">39.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtMy0xLTEtMA_f1715ef5-1023-40e4-926d-45e0d19c41da"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc00ea5651d44a68866912b87e772f32_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtNS0xLTEtMA_e38d1b8c-18fd-46a2-a975-2d578d822fc6">39.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9728137c063040fdb217c0c575d24e90_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtNy0xLTEtMA_5631ebc0-d01d-4225-96f7-f2d6fd6ea0d0"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia5691e9a962e48b9bab39a38eebafc58_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtOS0xLTEtMA_5cb98137-7c44-43f5-a6d6-f72d893c2777">39.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i97f888ed727b47c4969964bbc26cee74_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctMS0xLTEtMA_87e2c300-8796-4e2d-9969-d2722bdd4ba9">45.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctMy0xLTEtMA_faaeb623-8962-4d77-a897-228e0bd658eb"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibc00ea5651d44a68866912b87e772f32_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctNS0xLTEtMA_16cf1f95-ca19-47e0-a2e1-e5cbfab5f8dc">45.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9728137c063040fdb217c0c575d24e90_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctNy0xLTEtMA_d0e8946d-f687-43c7-8f68-1ab6df90d93a"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia5691e9a962e48b9bab39a38eebafc58_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctOS0xLTEtMA_60c5d0a2-9886-48a7-90b6-79e016fe84f6">45.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i97f888ed727b47c4969964bbc26cee74_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtMS0xLTEtMA_42beaf6d-45c1-4c25-83be-788d38339c67">19.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtMy0xLTEtMA_1d5dd257-81af-4633-abbd-6f02e83788c7"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibc00ea5651d44a68866912b87e772f32_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtNS0xLTEtMA_daa52edc-3907-4a79-b637-09161544f8a5">19.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9728137c063040fdb217c0c575d24e90_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtNy0xLTEtMA_1abec63d-78ce-42a5-84a9-0e93cc5f8654"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia5691e9a962e48b9bab39a38eebafc58_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtOS0xLTEtMA_442b2f8c-b002-4e46-8e2f-43de3868dd1b">19.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtMS0xLTEtMA_f5ffaa5c-bd09-4305-80b1-15f790dd40e0">3.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i083270152267493cab8ef4a98752605d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtMy0xLTEtMzI4Mg_f788c07e-0e7d-4472-836e-025b0261a946"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idb4db963049a418ebc24c7b6962c9c42_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtNS0xLTEtMA_92692327-e6a7-4b60-8662-9b8d499d7bee">3.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2df54907b9c740578baa39b1f16db346_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtNy0xLTEtMzI4Mg_7e5fd5db-0b26-4043-ba61-c251ecb7fc72"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9868066d4bf64c67b21b80f50a543d09_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtOS0xLTEtMA_42ded5ab-0eba-423b-a190-8ceb2ff7c96b">3.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtMS0xLTEtMA_826331c7-e264-447d-82c4-f5853f31a466">16.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i083270152267493cab8ef4a98752605d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtMy0xLTEtMA_ae2c15e2-becb-475b-bbeb-f8880c0cae45"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idb4db963049a418ebc24c7b6962c9c42_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtNS0xLTEtMA_dcddb1e6-27cb-4854-961f-da0ef48f179b">16.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2df54907b9c740578baa39b1f16db346_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtNy0xLTEtMA_6979ccf7-670d-4e36-8852-1b32798acc4e"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9868066d4bf64c67b21b80f50a543d09_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtOS0xLTEtMA_1324c55e-9db6-419a-bbfa-1e59f2e6c675">16.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id3477ea907754af1b237c11ecd845a8c_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtMS0xLTEtMA_3dadf9e3-90e2-4eca-bb48-bf31562f2835">14.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5579461ee30641f5866f90f7f973fc2d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtMy0xLTEtMA_28ebe9b2-fc77-49a0-96cf-3e46e08c0a0b"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c522dc4d3644e6b89e1c04ae748b784_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtNS0xLTEtMA_72da6b88-ecce-41bc-acfc-775a3d774f59">14.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4028304ed5344f378d4d8453889c1244_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtNy0xLTEtMA_cb1e3809-7c08-41cc-beca-4c5cd19e4c32"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtOS0xLTEtMA_c7d668d3-e879-4b6d-ab8e-6f5f82677006">14.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id3477ea907754af1b237c11ecd845a8c_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtMS0xLTEtMA_2b6834f0-7d7c-4ec1-b624-b1c8221ea16a">66.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5579461ee30641f5866f90f7f973fc2d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtMy0xLTEtMA_ec9a237e-9be6-43f1-aa89-0db903fbcf66"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0c522dc4d3644e6b89e1c04ae748b784_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtNS0xLTEtMA_7ebba9a8-6f27-44c4-9b48-655920986ed5">66.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4028304ed5344f378d4d8453889c1244_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtNy0xLTEtMA_a1e101b8-427b-4d43-9725-a45a66ffefb4"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtOS0xLTEtMA_675cf999-46bd-4391-9fc5-03ff0d642205">66.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktMS0xLTEtNzY4NQ_84da6db7-cdbb-4006-a62c-9962566b886d">71.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i379b7bdd53b04924a6915f7b6f539ae9_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktMy0xLTEtNzY4NQ_4cb0aa99-ee22-4980-8fdb-e634405a4abe"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i502fd03d8e8b42f384a0637943ac9227_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktNS0xLTEtNzY4NQ_1cfa9373-5edd-4bbf-a7ed-f90d9bcbd758"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i110e7dd739b14882b203dd13e31a425d_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktNy0xLTEtNzY4NQ_ba6bdddb-8fd6-4353-897c-ab0885682359">71.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1b1fc639100545e8b40e4cfd5886def1_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktOS0xLTEtNzY4NQ_ba0c4b2c-2d34-4d66-98cb-f43c116ae983">71.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i835b04928dc34e3d9eb5b6a882d6a434_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtMS0xLTEtMA_7462ab78-c251-4a85-8c1b-064be14e96cd">158.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59341bae0f284bb79a7771c86ff861f4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtMy0xLTEtMA_52a151a4-bca3-4334-bbe0-22ef4d0b3aa4"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i253bfddb6f414fe3a582437856252d99_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtNS0xLTEtMA_32e2bb8c-d58b-41f6-8069-d3ebf953b843">158.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icd815ed694bb4b1da50025622caa47df_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtNy0xLTEtMA_eeef826e-c79c-4769-9135-3ac87867518a"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie39cd3b104234bdfbcbaedb52a41b15c_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtOS0xLTEtMA_372bcab0-0e55-4d66-97d0-d0bb8a0be136">158.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i94f25e4c5e4b42cca659ef04248013aa_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktMS0xLTEtMA_f0965049-e4be-4f0e-9c68-ea23d3510745">38.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktMy0xLTEtMA_c646d7cc-a4ed-4d7e-9ec0-b12dce3d3dc4"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i541afb2da75d43639f7fec2ae5748d7f_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktNS0xLTEtMA_786d6733-2a45-41c5-9fba-28eb2a6223c8">38.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i014bd38c39aa4b1895340e1de5390e79_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktNy0xLTEtMA_da61d7da-2328-467a-be32-3d43211ca3c0"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i79425d230e734042bd4df00c16901373_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktOS0xLTEtMA_ad139b9e-e51d-40a5-88a5-7aaae14db0a6">38.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i94f25e4c5e4b42cca659ef04248013aa_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtMS0xLTEtNTQ1Nw_24f78da9-27cd-47e5-a7b9-a94d064d6ca8">97.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtMy0xLTEtNTQ1Nw_7f405576-7e71-4676-923f-9304bb35d1fc"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i541afb2da75d43639f7fec2ae5748d7f_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtNS0xLTEtNTQ1Nw_bef65268-7a52-42aa-ba56-48878e6ae59b">97.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i014bd38c39aa4b1895340e1de5390e79_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtNy0xLTEtNTQ1Nw_c496a71f-34ab-4c86-ae11-12e0cb6a4426"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i79425d230e734042bd4df00c16901373_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtOS0xLTEtNTQ1Nw_c06cbc78-c248-47f0-ab6e-9cb276e795d6">97.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2553d800f08240b1b782fd37f8f03377_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtMS0xLTEtMA_5b1c93cf-c133-47bd-9a3d-d5c537c1c107">92.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdf6391061294c348287bce4418a7767_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtMy0xLTEtMA_4591e762-167e-45bf-91ab-a1a3b69a03a9"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i326c763bfd9e49bdb908141c5104c4c6_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtNS0xLTEtMA_8ce13888-830e-43b6-ac05-3e6d1a40ebea">92.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if72250a4fe7543458ef88e49f913f39a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtNy0xLTEtMA_0ebd982c-b3b0-446a-ad3a-5cc9e6b88620"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i53ee22718d2249e6932918034d9479f7_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtOS0xLTEtMA_e2ef42d6-e39d-472e-9a5e-6fbe3a885160">92.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2553d800f08240b1b782fd37f8f03377_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtMS0xLTEtMA_8739e0bd-701a-498a-be78-7702ac7f2bf2">97.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdf6391061294c348287bce4418a7767_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtMy0xLTEtMA_bead6971-afb8-454c-b2cb-12c627ec6f42"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i326c763bfd9e49bdb908141c5104c4c6_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtNS0xLTEtMA_4107cc8e-ded8-49e8-8e22-fe4e0788aa3b">97.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if72250a4fe7543458ef88e49f913f39a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtNy0xLTEtMA_18dcc2ba-1c9c-4232-bcb5-e521ab9b92e8"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i53ee22718d2249e6932918034d9479f7_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtOS0xLTEtMA_bd2fa48f-21f3-4f56-bca1-02c13ca20b19">97.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11784cd0180b4240bfe628b8a935091b_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtMS0xLTEtMA_4d0231af-1c84-41fd-9169-202558746e6c">34.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id2b7165b4f9f4b159f2f118447ef21b2_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtMy0xLTEtMA_a9a33290-14b2-409c-a41a-cd02e1b57508"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtNS0xLTEtMA_bd4a307e-0928-4ddc-8c12-376d4be1b443">34.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i492cf935c87d44ea908c1584da4f932b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtNy0xLTEtMA_5dcc239c-0df9-4aa0-ad0d-e55f9aca31ae"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i86f5f0213b924cf4a2443b1755e0e558_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtOS0xLTEtMA_975d87f5-8649-45d9-be8e-b0009b9a0627">34.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i11784cd0180b4240bfe628b8a935091b_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctMS0xLTEtMA_6481c109-1f96-4b51-9540-0c638b2ca246">2.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id2b7165b4f9f4b159f2f118447ef21b2_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctMy0xLTEtMA_82dec22c-a8c9-48ba-b590-12020a9ee4a1"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctNS0xLTEtMA_250ca144-49b4-4358-9be8-060016628308">2.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i492cf935c87d44ea908c1584da4f932b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctNy0xLTEtMA_c3e0882a-374d-441d-b15c-58d2f8f332fe"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i86f5f0213b924cf4a2443b1755e0e558_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctOS0xLTEtMA_1d8d58ba-6e27-43a4-8af8-b36234c8f98f">2.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie913be1662fb496dadd88c102ecc6d7f_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktMS0xLTEtMA_6a691c2f-3202-4546-ac4b-9bd2e95eb6af">41.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktMy0xLTEtMA_87cf09b7-f212-4109-a345-5bf081725e9a"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb9d49fc86e54fa4aef040dc305765cc_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktNS0xLTEtMA_07d14ea2-d573-48c1-9f2d-72646e032788">41.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34c34c5498af462390f43272c1214aad_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktNy0xLTEtMA_b5fb6dfc-3cc8-405f-a471-ca33fa834e6b"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i80e1536360e0467e919e75a282b9c273_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktOS0xLTEtMA_1fb0670a-7226-4a2c-9df2-e9074c274f7a">41.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie913be1662fb496dadd88c102ecc6d7f_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtMS0xLTEtMA_ce6759fe-4323-4a88-8ecc-1af9cf7c75de">15.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtMy0xLTEtMA_28e08b7e-a601-431a-aaa9-209b90426601"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icb9d49fc86e54fa4aef040dc305765cc_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtNS0xLTEtMA_7409c232-216a-4746-833c-c0bcdf9b1aa1">15.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34c34c5498af462390f43272c1214aad_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtNy0xLTEtMA_e372d0a3-ff66-404c-944e-73466e950505"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i80e1536360e0467e919e75a282b9c273_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtOS0xLTEtMA_95c96cce-077d-4bb8-b73d-32de64188eda">15.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="iefeeeb2db2294664bccd8c84b545e9e8" continuedat="i0c81e19cfeff48f38c359c634f73f632"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available. As of March 31, 2021, we had approximately $<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTA5MzM_fb644623-add0-4654-8be0-42bdd5349919">736</ix:nonfraction> million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:duryear" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEwNTI_43edea2e-b25d-473c-9111-73de4e6f9de9">10</ix:nonnumeric> years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4Nzc_fe6c1cc3-3eca-4d12-b6f8-b31c0fffae99" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&nbsp;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&nbsp;Than<br>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&nbsp;Than<br>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi0xLTEtMS0w_a0c8f488-046b-493d-876b-a5c521fadae2">443.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi0zLTEtMS0w_2c57ac94-4f9f-471c-89e9-d2c9da62c2fa">30.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi01LTEtMS0w_3f5447fb-617a-4b03-bbf1-03ac0c5ecefc">147.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi03LTEtMS0w_c1db2b5b-dbb9-4339-bd85-e3b90188c587">125.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi05LTEtMS0w_fd035206-29a3-45ed-87fb-80d8f75d9c17">139.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains recognized in our consolidated condensed statements of operations for equity securities were $<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEyOTM_1603b77d-5a4a-4a3e-8cc3-1d7d6863f508">301.5</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEzMDA_87075633-ef07-464b-b626-2e752c780cc0">186.6</ix:nonfraction> million for the three months ended March&nbsp;31, 2021 and 2020, respectively. The net gains/losses recognized during the three months ended March&nbsp;31, 2021 and 2020 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded during the three months ended March&nbsp;31, 2021 and 2020 were not material.</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MzM_e76ecccd-0895-4923-939d-4c2beb6e2beb" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:66.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMS0xLTEtMS0w_eb255352-fa6a-4c64-a225-8e62a4dcd83c">12.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMS0zLTEtMS0w_f369aa22-544a-4427-8e14-70d740fd8b57">20.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMi0xLTEtMS0w_c0915cec-1b69-4c8a-a618-1a69bb19e2ea">6.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMi0zLTEtMS0w_b73a4321-d243-49ea-a565-f3e11d1da308">0.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMy0xLTEtMS0w_bb6ad23a-2187-4cbf-af30-90c366edb8c6">273.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMy0zLTEtMS0w_c077b1a3-8626-446e-b83d-8c2b073a1f10">348.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfNC0xLTEtMS0w_a59137b2-2304-4833-9ff7-ecf499863d91">170.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfNC0zLTEtMS0w_327a8289-f28a-4d10-8cd6-795132a6c38e">11.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material in the three months ended March&nbsp;31, 2021 and 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i0c81e19cfeff48f38c359c634f73f632"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonfraction unitref="number" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="2" format="ixt:numdotdecimal" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTMyNTY_6b9c8d39-fdea-48e5-afa2-2fa95285814f">94</ix:nonfraction> percent&nbsp;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of March&nbsp;31, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NzE_a9839108-e652-4358-9573-53d2df9f6f11" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMi0xLTEtMS0w_bd13b639-b34e-4f9d-8c65-fecbc648f30a">43.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMi0zLTEtMS0w_51bf6c4b-aa29-420c-8eec-0747e7429ade">38.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMy0xLTEtMS0w_040ad5a7-692f-4540-b5be-9523369e19e0">1.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMy0zLTEtMS0w_1e653ddc-ff54-4c93-96a1-4537196160e8">0.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfNC0xLTEtMS0w_ce19e297-533d-413d-941d-046530b9e687">0.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfNC0zLTEtMS0w_0e4a31a8-7d95-4afe-ad61-d332c6113e29">0.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ1NTM_822085b7-de69-4f12-9fcc-f4f09f0b1a9e">637.8</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ1NjA_a48ab26b-779b-4f99-a61f-9aa4caaccad6">754.9</ix:nonfraction> million&nbsp;of accounts receivable as of March&nbsp;31, 2021 and December 31, 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three months ended March&nbsp;31, 2021 and 2020&nbsp;were&nbsp;not material.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfNzUw_734b6905-09e7-46b9-b56e-c95a9f489cad" continuedat="idbfc2ddd18374407b894c36814e2001a" escape="true">Income Taxes </ix:nonnumeric></span></div><ix:continuation id="idbfc2ddd18374407b894c36814e2001a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was <ix:nonfraction unitref="number" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfNTQ_8b9ec730-8fe7-4646-93eb-2dd09797521a">8.2</ix:nonfraction> percent for the three months ended March&nbsp;31, 2021, compared with <ix:nonfraction unitref="number" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfMTAy_d13e69a1-1cfe-478e-bff8-2abee110c4fe">13.3</ix:nonfraction> percent for the three months ended March 31, 2020. The effective tax rates for both periods were reduced by net discrete tax benefits, with a larger net discrete tax benefit reflected for the three months ended March&nbsp;31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_67"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTM3MQ_caa192cb-ee93-4553-aef9-ddbce1695e61" continuedat="i9efcd6874112422f96d673b62266c60e" escape="true">Retirement Benefits</ix:nonnumeric></span></div><ix:continuation id="i9efcd6874112422f96d673b62266c60e"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTM3OQ_cf41afce-f762-4aa3-8f6f-81e7433c79b9" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNC0xLTEtMS0w_c749ef18-861e-4463-8169-6b7321b9482f">92.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNC0zLTEtMS0w_66c9e723-0d24-4c12-b562-f9b4fe13e8b4">78.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNS0xLTEtMS0w_4160c028-e794-43a7-b407-2ab58f1cfd97">84.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNS0zLTEtMS0w_6fab79d3-3582-4597-8fc6-c9c63d6aae5b">105.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNi0xLTEtMS0w_75b99afd-39d5-4de9-b5dd-a9422b47c1ca">238.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNi0zLTEtMS0w_a0507bf2-b131-42f0-9a2e-d4c6ccb73012">221.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNy0xLTEtMS0w_1f3eb112-d031-4e42-9398-91a0920ea90f">1.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNy0zLTEtMS0w_ff144d49-c207-48bb-a801-2cde463b6744">1.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfOC0xLTEtMS0w_f72501ab-f6b2-4260-8d28-e6536ac33f37">121.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfOC0zLTEtMS0w_f9a3aa4e-371f-498b-8324-5addef9c1b42">111.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfMTAtMS0xLTEtMA_1b1ca009-20c4-46d2-9fbf-310b18bd0525">61.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfMTAtMy0xLTEtMA_6d29c3a4-449b-4d8f-afa5-a32acc199740">74.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNC0xLTEtMS0w_4b78ce6c-5dcf-422e-93d6-5d7495f3e7dc">11.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNC0zLTEtMS0w_1ac7dda9-eaa5-4e32-a706-962f1d76fc41">9.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNS0xLTEtMS0w_88391b3c-4df5-48fb-bb30-56dff9c9101c">8.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNS0zLTEtMS0w_d99f1b0f-9a0c-4406-9d96-439b6f0e583e">11.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNi0xLTEtMS0w_90809314-5d2b-4b89-a8d2-40ca87064ecb">36.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNi0zLTEtMS0w_48cede54-448f-4596-91c2-cc8a1506d172">37.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNy0xLTEtMS0w_17f324ef-efcd-4ef1-8486-e02d323f3abc">14.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNy0zLTEtMS0w_2db2b24c-ce8a-40bf-89f3-8e807f16ee3b">14.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfOC0xLTEtMS0w_21906c70-f75e-4962-ba14-09758e501411">0.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfOC0zLTEtMS0w_6b2f4ab4-968e-4cf1-b85f-55497ae88986">0.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfMTAtMS0xLTEtMA_b3623aaa-13f1-42ae-82d2-678517f5ee5a">30.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfMTAtMy0xLTEtMA_19889fc8-568c-45d2-be18-99802445b28f">30.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contributed approximately $<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTU1_458f3c34-cdc8-4ba2-900f-20f868f7c017">15</ix:nonfraction> million to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans during the three months ended March&nbsp;31, 2021. We contributed approximately $<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="lly:PaymentforPensionBenefitsAdditionalDiscretionaryFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMjk1_90cd8118-d75c-44f5-91cc-b4c455bcc489">10</ix:nonfraction> million in discretionary funding during the three months ended March&nbsp;31, 2021. During the remainder of 2021, we expect to make contributions of approximately $<ix:nonfraction unitref="usd" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfNDE4_fd66c107-99d1-4312-bd66-ec6a72109add">20</ix:nonfraction> million to our defined benefit pension and retiree health plans to satisfy minimum funding requirements.</span></div></ix:continuation><div><span><br></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_70"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTY4NTU_3e47f319-aeb5-4506-bae7-0def76065ce3" continuedat="i816a27d1e3ac4996b61371136fd5aab6" escape="true">Contingencies</ix:nonnumeric></span></div><ix:continuation id="i816a27d1e3ac4996b61371136fd5aab6" continuedat="i8f120c0c060e4a3083609b7a24033659"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i8f120c0c060e4a3083609b7a24033659" continuedat="i30a413e2352c469b8c44f2c1777f026c"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of manufacturers are seeking approvals in the U.S. and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers.&nbsp;However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail.&nbsp;The loss of exclusivity in the U.S. could have a material adverse impact on our future consolidated results of operations and cash flows and would result in a rapid and severe decline in future revenue for the product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) is protected by a vitamin regimen patent until 2021, plus pediatric exclusivity through May 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Apotex Inc. (Apotex) alleging infringement of Alimta's vitamin regimen patent for its application to market a pemetrexed product. In December 2019, the U.S. District Court for the Southern District of Indiana granted our motion for summary judgment of infringement, and in December 2020, the U.S. Court of Appeals for the Federal Circuit affirmed that ruling. Apotex did not request reconsideration or a rehearing of that ruling. However, Apotex could petition the U.S. Supreme Court to review the case. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed) is prot</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ected by the vitamin regimen patent through June of 2021. Notwithstanding the existence of our vitamin regimen patent, several companies launched generic pemetrexed products at risk in France, Germany, and the Netherlands but those products were subsequently removed from those markets as a consequence of patent infringement actions brought by us. In many cases, those patent infringement actions are subject to appeals filed by the generic manufacturer. In March 2021, we entered into a settlement agreement with Fresenius Kabi Aktienngesellschaft that discontinued all pending European patent litigation involving the Fresenius Kabi group of companies including that between us and Fresenius Kabi France and Fresenius Kabi Groupe France.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings are ongoing regarding </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Alimta patents in various national courts throughout Europe. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to seek to remove any generic pemetrexed products launched at risk in other European markets, seek damages with respect to such launches, and defend our patents against validity challenges.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i30a413e2352c469b8c44f2c1777f026c" continuedat="i3dd6f65ddfed46a29e9c6baf9f5fa23d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in <ix:nonfraction unitref="patent" contextref="i9472948bb7f947afa49886afa824b300_I20210331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2MzQwMQ_d819cedb-081b-42e5-82ad-0618fa7ebdb1">nine</ix:nonfraction> differ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is expected in February 2022. Separately, the U.S. Patent and Trademark Office (USPTO) granted our request to initiate an&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;(IPR) to reexamine the validity of the <ix:nonfraction unitref="patent" contextref="i9472948bb7f947afa49886afa824b300_I20210331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2MzcyMg_d819cedb-081b-42e5-82ad-0618fa7ebdb1">nine</ix:nonfraction> Teva patents asserted against us in the litigation. In February 2020, the USPTO ruled in our favor and found that the claims asserted against us in <ix:nonfraction unitref="patent" contextref="i7408050434b1433f9057403b967bc044_D20200201-20200229" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsClaimsDismissed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzg3NA_d1b46b31-11b8-410b-97f0-7baa102975c3">six</ix:nonfraction> of Teva's <ix:nonfraction unitref="patent" contextref="i1dfd4b4b1d2a4b459b67e2e9c72eac8d_I20200229" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzg4OA_f9a97bbf-14fe-48fd-9c9e-d7a2414e5d7a">nine</ix:nonfraction> patents were invalid. In March 2020, the USPTO ruled against us on the remaining <ix:nonfraction unitref="patent" contextref="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsRuledUnpatentable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzk3Mw_b26ab727-7d6e-48ea-8ac3-d0257fc5b729">three</ix:nonfraction> Teva patents, finding that we failed to show that the remaining <ix:nonfraction unitref="patent" contextref="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsRuledUnpatentable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2NDA0MQ_f841c985-1711-4e5b-8ad4-45b8745cc52e">three</ix:nonfraction> patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the USPTOs March 2020 ruling, and Teva appealed the USPTOs February 2020 ruling to the U.S. Court of Appeals for the Federal Circuit. The district court litigation will proceed in parallel with the IPR appeals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from Alkem Laboratories Ltd.'s (Alkem) and Ascend Laboratories, LLC's (Ascend) submissions of Abbreviated New Drug Applications (ANDA) seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, Alkem's and Ascend's ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. Trial is scheduled for September 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotexs case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Actos  Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in <ix:nonfraction unitref="lawsuit" contextref="i19d9bfc8635f470e9a7adb121100256d_I20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDIyMg_fd9f7f9e-96ce-44ba-aeb1-732170eed896">four</ix:nonfraction> purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including <ix:nonfraction unitref="lawsuit" contextref="i4fbb93a5eb8140d2b2faeef2de2e7c59_I20111231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDM2NA_5dc345bd-832d-4e39-a834-aab4b34a17eb">one</ix:nonfraction> in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonfraction unitref="lawsuit" contextref="i9877de074e3b4cd68f3e14e738b53b96_I20120731" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDQ3MQ_8300ea75-acf6-4387-9ce4-b79101fdfa15">one</ix:nonfraction> in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonfraction unitref="lawsuit" contextref="idac89cba080843258ae570efc0620a18_I20171130" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDUzNw_8c08b91c-fe40-417a-857a-4fd8f7da97a7">one</ix:nonfraction> in Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and <ix:nonfraction unitref="lawsuit" contextref="iad757e1928624ece99a2023c2b06db4a_I20130131" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDYyMA_f2e89a15-0906-40b6-a1af-a626faf6b9c1">one</ix:nonfraction> in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i3dd6f65ddfed46a29e9c6baf9f5fa23d" continuedat="ia949258b688d4858a595f35696c7a35a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in March 2009, we are named as a defendant in approximately <ix:nonfraction unitref="lawsuit" contextref="ic92b96cca8ef435288a260a7692a4296_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDk2MA_bc860445-55e5-40b4-8741-58b5d2212caa">570</ix:nonfraction> Byetta product liability lawsuits in the U.S. involving approximately <ix:nonfraction unitref="plaintiff" contextref="i87320df79b3f461da082a107fa7a8e57_D20090301-20210331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTAzNA_86b8f62f-945f-4edb-a91b-1038d1e3f232">810</ix:nonfraction> plaintiffs. Approximately <ix:nonfraction unitref="lawsuit" contextref="i15f9ce4e2e9f47789b45d86896781f54_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTA2NA_15aedd19-9c24-4fe8-9599-8945a8a4bd62">55</ix:nonfraction> of these lawsuits, covering about <ix:nonfraction unitref="plaintiff" contextref="i6776f7310a5341a3b3f6bfdef846dfea_D20090301-20210331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTEwMg_89f54836-76a3-49aa-8e0d-532932ad120f">285</ix:nonfraction> plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately <ix:nonfraction unitref="lawsuit" contextref="ib44052b397dc4098a69265e6060b79a8_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTIxNw_45d66bec-80bd-4d70-b314-6702de437aa8">515</ix:nonfraction> of the lawsuits, covering about <ix:nonfraction unitref="plaintiff" contextref="i121dcf9b52ce46eead9ac16494dd1642_D20090301-20210331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTI1Mw_acb14dce-f1d9-4125-8b14-f74d953212ef">515</ix:nonfraction> plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. <ix:nonfraction unitref="lawsuit" contextref="ib73e27481f2e44bcb74fda4f3cecf682_I20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTQ0MA_2b62ad20-83f9-4943-94f7-10b6ae9e0435">Three</ix:nonfraction> lawsuits, representing approximately <ix:nonfraction unitref="plaintiff" contextref="i2fa2b0f3392543f2b160709e35c124d7_D20090301-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTQ4MQ_a7e9b17c-d70e-48bc-a6c0-1a80cecaaaeb">four</ix:nonfraction> plaintiffs, have also been filed in various state courts. Approximately <ix:nonfraction unitref="lawsuit" contextref="i9b029559694b48b08c94d12ad381445e_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTU1Nw_cd332168-7b7e-4def-969e-33524d253994">565</ix:nonfraction> of the lawsuits, involving approximately <ix:nonfraction unitref="plaintiff" contextref="if02307f1292e42dd8aa0a8c7f88d014f_D20090301-20210331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTYwMg_fa925bbc-0fe5-4176-8cf1-192d4bbac2a7">800</ix:nonfraction> plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while <ix:nonfraction unitref="plaintiff" contextref="i7ccdd965fb0d44ed8eaa51cd4f6af3a8_D20090301-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTc1Mw_0eaf45c3-96d4-42d7-9040-09a345f22958">six</ix:nonfraction> plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, <ix:nonfraction unitref="plaintiff" contextref="id5a9904ee8fe4ee9900bba9f1c855eb9_D20090301-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTgzNA_18fae89c-55a5-4de4-9f71-64269e4be7c3">one</ix:nonfraction> case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants and in April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of Californias grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of approximately <ix:nonfraction unitref="claimant" contextref="ic92b96cca8ef435288a260a7692a4296_I20210331" decimals="0" name="lly:LossContingencyNumberOfClaimants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MjUwOQ_b0c3cb9e-0d42-4405-8c75-73d4627b2cc5">20</ix:nonfraction> additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in August 2015, we are named as a defendant in approximately <ix:nonfraction unitref="lawsuit" contextref="i0ac86530d3c243cca63aa23529e06624_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MjgwMg_512f4d10-9cb5-4101-8426-0383a09ea45a">350</ix:nonfraction> Cialis product liability lawsuits in the U.S. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The plaintiffs appeal has been administratively closed until August 2021 pending completion of a procedure to resolve the claims in this litigation.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Product Liability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately <ix:nonfraction unitref="lawsuit" contextref="i9f7430fd06b947ef84b255b6fb8aee26_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3Mzk3Mw_f463ff8b-9fc9-4e1e-ac4e-f170e34292e2">95</ix:nonfraction> product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs Fourniers gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than <ix:nonfraction unitref="site" contextref="ida0a952118b340e6ba680f7df96d7075_I20210331" decimals="INF" name="lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5OTk4OQ_906b66e0-190e-4cf0-968b-6c4dd4326930">10</ix:nonfraction> sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="ia949258b688d4858a595f35696c7a35a" continuedat="i4b97466932e446e4a6aa6ac24c62d8f9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the governments enforcement of the administrative dispute resolution process against Lilly. The matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administration Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the governments enforcement of this administrative dispute resolution process against us.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, we received a civil investigative subpoena from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation  Cosmopolis Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&nbsp;<ix:nonfraction unitref="brl" contextref="ib5001859aff84e2dbe43c4543f7e5dbc_D20180701-20180731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDc3NA_6857a45c-3819-4d34-970a-cb762631fb45">300</ix:nonfraction>&nbsp;million&nbsp;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately <ix:nonfraction unitref="brl" contextref="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDc0Nw_e2d789bf-3bcd-4fca-8f7a-2d820feb62ea">950</ix:nonfraction>&nbsp;million Brazilian real (approximately $<ix:nonfraction unitref="usd" contextref="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDg1Mw_c4220554-edd4-46b2-b093-463ecdb9076e">165</ix:nonfraction>&nbsp;million as of March 31, 2021). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasils appeal to the superior labor court. The cost of any such health coverage has not been determined.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasils assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasils immovable property or, alternatively, a security deposit of <ix:nonfraction unitref="brl" contextref="i877919e055e34b8eb3844514babacc6f_D20190701-20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3OTIwOQ_90f3f437-1fd7-4da5-8caa-7ed08056a46b">500</ix:nonfraction> million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted. In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorneys application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named in approximately <ix:nonfraction unitref="lawsuit" contextref="iaa67ffc334f74fdd88aeff3e17eb06fd_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTE4NDY_e4ab0d19-3135-4405-b46c-585670ed37e7">30</ix:nonfraction>&nbsp;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i4b97466932e446e4a6aa6ac24c62d8f9" continuedat="i5909ff122cab477196ae7720a1a75ac7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China NDRC Antitrust Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, are named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for February 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justices motion to dismiss the relators second amended complaint. In January 2020, the relator appealed the District Courts dismissal to the U.S. Court of Appeals for the Fifth Circuit. We are also named as a defendant in <ix:nonfraction unitref="lawsuit" contextref="i69f451428d3e45a3a75cd744529fea05_I20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY4MzcyMw_41ae0345-139e-4f6a-becd-690569738367">two</ix:nonfraction> similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a decision by the U.S. Court of Appeals for the Fifth Circuit on the aforementioned District Court appeal. In April 2021, the New Jersey state court action was dismissed with prejudice.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation, Investigations, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi-Aventis U.S. LLC (Sanofi) and Novo Nordisk, Inc. (Novo Nordisk) were named as defendants in a consolidated purported class action lawsuit,&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. Also, filed in the same court in November 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and anti-trust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney Generals Office initiated litigation against us, Sanofi, and Novo Nordisk,&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney Generals federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney Generals Office filed a complaint against us, Sanofi, and Novo Nordisk,&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, federal and state antitrust law, and the state deceptive trade practices-consumer protection act. Harris County also alleges common law claims such as fraud, unjust enrichment, and civil conspiracy. This lawsuit relates to our insulin products as well as Trulicity. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i5909ff122cab477196ae7720a1a75ac7" continuedat="i430cf19227fa4b2ca85c054676d30ead"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a subpoena from the New York a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market. We received <ix:nonfraction unitref="request" contextref="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfRequestsForInformation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY5MTkyOQ_3fb9f236-ddf0-4450-a1cd-db4abbe7ce3b">two</ix:nonfraction>&nbsp;requests from the House of Representatives Committee on Energy and Commerce and a request from the Senates Committee on Health, Education, Labor, and Pensions seeking certain information related to the pricing of insulin products, among other issues. We also received requests from the House of Representatives Committee on Oversight and Reform and the Senates Committee on Finance, which seek detailed commercial information and business records. In January 2021, the Senates Committee on Finance released a report summarizing the findings of its investigation. We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i430cf19227fa4b2ca85c054676d30ead">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. A trial date has not been set.</ix:continuation> </span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_76"></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ3NQ_9cce71f0-5a2e-4a07-9024-04767baba9c5" continuedat="iabe2760b4b6f4a1e84f180e95df32b04" escape="true">Other Comprehensive Income (Loss)</ix:nonnumeric></span></div><ix:continuation id="iabe2760b4b6f4a1e84f180e95df32b04" continuedat="id03adcbd63e44e8f9d0fa1df59af90ab"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ5MA_f78d9883-ca92-4385-aa58-9aa0f82dde75" continuedat="ia5d403a94542481caa41a304ed41e058" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&nbsp;31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&nbsp;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&nbsp;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&nbsp;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&nbsp;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6b10da171de74c8882000a2f696152fd_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0xLTEtMS0w_78a39739-9b63-41a4-acd4-d7c83d35e235">1,427.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5614d38977b64c168c1b9fc251c757ca_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0zLTEtMS0w_1df9d921-1253-48a6-b48e-07878593c7f5">14.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iffd75cb32c5543a891d689e8933d4949_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi01LTEtMS0w_a3ac93ca-4247-4c91-9f58-db825ba70e44">4,751.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icaa91bb6c1a24ffcb202a27011d73dd0_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi03LTEtMS0w_0e08d2f4-cfbc-4fbc-8196-9a9e6d373397">332.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2845560a0ba2491a904c84ba82f35819_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0xMS0xLTEtMA_b95c5add-ec2e-4b00-8bc4-f85b5201cc4c">6,496.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i743947277250425485ee1e0a26d90120_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0xLTEtMS0w_c0ab2da5-9e0d-4189-aeee-e08fdd18f3c7">249.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0zLTEtMS0w_3d827e58-00b2-4ae4-b8b7-dfb7d50de94d">10.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC01LTEtMS0w_5c8b798f-9924-483e-b1ca-c4f4bc08608f">18.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC03LTEtMS0w_21befebb-4339-4a0a-bc26-9c2d3b91f906">252.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0xMS0xLTEtMA_95d4a7dd-f9c6-4ba6-9915-9437f2213d69">11.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i743947277250425485ee1e0a26d90120_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0xLTEtMS0w_6d6a1854-f0e0-42f9-a898-8c64ceb85f5d"></ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0zLTEtMS0w_320fb153-f84f-4e11-b2f9-96c16696c0fe">0.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS01LTEtMS0w_0ec7980a-a4bb-45d8-8dc8-2a226dcc585b">85.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS03LTEtMS0w_03c419d7-967c-4b5d-aa6a-e34325e5373d">3.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0xMS0xLTEtMA_e6d33f7c-83e3-4e2e-9756-f17f22ca71bb">89.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i743947277250425485ee1e0a26d90120_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0xLTEtMS0w_6e4c48a7-6803-4fc6-9fd5-dadab0c4f22b">249.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0zLTEtMS0w_2949c66b-7f13-435d-b171-a8739189b485">10.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi01LTEtMS0w_2ba96491-feb1-4e5b-9958-10acda5f8691">104.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi03LTEtMS0w_960576ee-c2bf-49ad-8a55-17240931e525">256.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0xMS0xLTEtMA_ab0fd064-1948-434c-8075-bd0ee7ba1e42">100.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9655bade5b00400dba7752533cb6743c_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0xLTEtMS0w_f72807ab-04e3-42f3-9b91-5ac517970c4d">1,677.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i577b7fef6c2c49bf87fe8cb8121248ce_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0zLTEtMS0w_d9518527-dcd6-45b9-8d95-a00451ca25f9">4.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie23fc76e1a5a432a8db78dd624ef5cc1_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC01LTEtMS0w_d5cae3be-3e8e-4950-b836-c1394a1d646f">4,646.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7caab5ff3a4d4ca8a64128cbbeb05cdd_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC03LTEtMS0w_923b98dd-798d-4af2-9f50-195d791242ea">76.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7b8b459cd1fc47f6baa6f11b48145ac4_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0xMS0xLTEtMA_2dc7c19e-1afa-4059-9cd7-5948bdeb4517">6,395.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&nbsp;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&nbsp;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&nbsp;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&nbsp;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic1eeb66393264479aecf1f1d2fcd51b1_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0xLTEtMS0w_a3e188dd-4ba7-4572-a5c9-8b781fb445ad">1,678.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1cc74d110d0145598aeabdd970d87f17_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0zLTEtMS0w_80d6720d-cdfb-4179-832f-a38f54409d00">4.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iaa58ad2146314403b3eff9eaf3e10324_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi01LTEtMS0w_a124b393-22dd-4e3f-a5ca-f5c3e8f20a93">4,638.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6ebe01e7039a44a4888856db6e4a7d39_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi03LTEtMS0w_838cd285-3c6f-4681-9151-2c31d5065336">211.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iffabc6d5c4614780a93ce1b21d701159_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0xMS0xLTEtMA_e7a45a8e-ea31-4d72-9553-4f33caf001e9">6,523.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i96ce660d25654b37a7243b236eca576b_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0xLTEtMS0w_5ee49e98-0d2b-45a4-8ee5-13478ae20a40">126.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i55b8fd6090834514913a2977fd43623e_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0zLTEtMS0w_8b90cd77-a86d-4854-b65e-dca8a0514fd3">1.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC01LTEtMS0w_3d06fc95-dea7-4d75-86d2-8bc01b238856">30.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC03LTEtMS0w_1fa5f343-0920-4563-90c5-f00ef034fcd7">348.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0xMS0xLTEtMA_fe43ed8f-5010-43a9-a55d-f8e75257b4ff">442.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96ce660d25654b37a7243b236eca576b_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0xLTEtMS0w_0c56285c-7dd2-4c09-b312-7ca3dd62a9cf"></ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i55b8fd6090834514913a2977fd43623e_D20200101-20200331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0zLTEtMS0w_6553ead3-dd79-41e2-9687-66065dd392e2">0.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS01LTEtMS0w_e1810fab-5447-4173-b344-778a15891af0">77.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS03LTEtMS0w_3f86e489-453d-4c01-b65e-4a57c7e0b7ae">3.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0xMS0xLTEtMA_e9dfd8fb-e550-4868-8161-5f36488a7c1c">80.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i96ce660d25654b37a7243b236eca576b_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0xLTEtMS0w_ffc7465a-49cb-43c3-bd78-576a1c44556c">126.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i55b8fd6090834514913a2977fd43623e_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0zLTEtMS0w_f03f954a-abd8-4f7a-9c83-be3e7b43e1eb">0.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi01LTEtMS0w_947d3455-091a-41bc-bea4-c4d115fa53aa">108.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi03LTEtMS0w_2ed5dc6e-1c4d-405e-b8b4-d1e51d7e649e">345.0</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0xMS0xLTEtMA_9440ac46-1488-4f69-b265-56aa4318bfdd">362.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icd5fe3b1199247e6a91eb8d01efc2392_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0xLTEtMS0w_4a0538de-b7d1-4273-b463-848b2baa3e91">1,804.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i41d912b5241343a9b988106cef8e0215_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0zLTEtMS0w_3bdd29a2-6af8-4a51-b9c7-c593b6190737">5.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i33afbb7d73484c0a83d56114c6756d5c_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC01LTEtMS0w_8cd48e6f-77a1-4bdf-9521-23fc0923036a">4,530.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i194e7735259d438eb363e7d9f3ae1523_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC03LTEtMS0w_8d439137-8e26-47ea-97b2-cae09bb23921">556.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i986fb3e559c0490ca09848e9ac9bf901_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0xMS0xLTEtMA_b5ca2f5c-ab0e-4270-bff9-174d4ab913b6">6,885.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="id03adcbd63e44e8f9d0fa1df59af90ab"><ix:continuation id="ia5d403a94542481caa41a304ed41e058"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i743947277250425485ee1e0a26d90120_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMi0xLTEtMS0w_4f5cb6fd-9422-448f-8f98-77ac4555bbd0">75.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i96ce660d25654b37a7243b236eca576b_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMi0zLTEtMS0w_f525edf9-0348-4d1b-82bb-51f0e93b9789">38.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMy0xLTEtMS0w_883bddba-fea5-4f3a-ad3f-6474fe6f4a7b">4.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i55b8fd6090834514913a2977fd43623e_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMy0zLTEtMS0w_c16ca3f2-ba44-4e24-8ac9-1945561dbe1f">0.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNC0xLTEtMS0w_bce29064-79f1-400a-a8e5-459edad3293d">31.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNC0zLTEtMS0w_0ebd877e-b1a4-4431-8f1b-6210cf69c41f">25.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibf742f7aff334b05a91842e894677604_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNS0xLTEtMS0w_c9ddf321-9843-49d2-aa1b-6fb091d5962a">68.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i02045ea33c7d43d4a34c42a37721b125_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNS0zLTEtMS0w_d2f63020-8259-4d96-81c1-8d60430234ee">91.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNi0xLTEtMS0w_258adb7c-aaf1-4b6a-b1e6-9ecb832080fd">170.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNi0zLTEtMS0w_801435d4-4ca8-4021-81d8-6449d5486f99">27.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ4NQ_f66e70a5-a9cd-4fa5-a881-07c935aacb9e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:33.552%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:6pt"><td colspan="30" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if48b9be7413d42df903afc9bf15c3c13_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNC0yLTEtMS0w_5a2a977e-38e5-4ebe-958c-f7d3077840f8">13.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i492583e2c9b044f29ac4a51092ddfbe8_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNC00LTEtMS0w_0d6a518d-7b11-4826-b884-532e1d038418">13.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Othernet, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibfdc30c8362d4397a4020c9b938662fa_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNS0yLTEtMS0w_d158155b-030d-4959-b25c-888722621ea5">122.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2917edad81e5463e9d61cceea8f62ea4_D20200101-20200331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNS00LTEtMS0w_c8129a61-84b9-4a70-9a92-383fb30d61df">111.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Othernet, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if82cce099c354dd78182619455a05af1_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNi0yLTEtMS0w_efccc077-c89d-4b27-9b85-b8fa673d1071">108.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNi00LTEtMS0w_1e6b4d10-6706-4d86-b337-2e9eab37f7bf">98.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if82cce099c354dd78182619455a05af1_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNy0yLTEtMS0w_c580848a-e94a-41cd-8dfa-878e0b170f9f">22.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNy00LTEtMS0w_8d83bd4a-1aa4-4939-aa2a-bbeb5c9d3091">20.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if82cce099c354dd78182619455a05af1_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfOC0yLTEtMS0w_3e0d06c5-6706-4bd4-bbb5-a1eba33a5fb8">85.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfOC00LTEtMS0w_4031e400-0895-4917-9390-56bd30269776">77.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i191727da20c34eae98d4dbc93f0337fe_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTAtMi0xLTEtMA_4e04b0d9-6b5b-4808-aaa3-80bea98b8414">3.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9638221883d14af2935d735e8cc9a360_D20200101-20200331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTAtNC0xLTEtMA_c04baaf6-8fd1-40e6-ab09-fb6107dcd0fa">3.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Othernet, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i37bfd76d6ecb46708142e81e2d19a33c_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTMtMi0xLTEtMA_85064f7a-6b84-4c31-8ac4-ac975595f81f">89.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c0ff30fbf7f474f9b43c59d3bc7e538_D20200101-20200331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTMtNC0xLTEtMA_f1a4b31d-bd84-436e-bb67-660bbc26f190">80.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div id="i3cd151b5d83246a98b0e0ef4a9feb269_82"></div><div><span><br></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: <ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RleHRyZWdpb246ZWVhYzYxMjIwNWFiNGNjOGEyZmZjZWRiYzNiOTU3MWJfMjMy_1a318be7-1d3c-48ef-806e-69be3396eac0" continuedat="ib39298d189b74de2a1cd015c8b67d895" escape="true">OtherNet, (Income) Expense</ix:nonnumeric></span></div><ix:continuation id="ib39298d189b74de2a1cd015c8b67d895"><ix:nonnumeric contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RleHRyZWdpb246ZWVhYzYxMjIwNWFiNGNjOGEyZmZjZWRiYzNiOTU3MWJfMjM1_d4756328-bc79-42ca-8998-9b628fa1d557" escape="true"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Othernet, (income) expense consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMi0xLTEtMS0w_0682fe7c-5a78-4669-a10b-d87c3985d48a">87.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMi0zLTEtMS0w_fab98565-94d1-4ace-87fa-9bae2aaa930d">92.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMy0xLTEtMS0w_3e1a5b04-1acf-471e-b99e-009bc4001da6">5.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMy0zLTEtMS0w_b492304a-08d1-4b0a-8050-87077da727db">14.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0xLTEtMS04Mzgx_db9b03ee-c25d-4f68-bfc5-7cd3e608f98c">301.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0zLTEtMS04NDA5_84491e38-880a-484c-a954-d38d6bfae84e">186.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0xLTEtMS0w_096ee406-ccac-4068-814f-d35a09b6962c">73.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0zLTEtMS0w_3b90c007-552a-4def-ae05-14cf9e733cb5">44.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNS0xLTEtMS0w_5752735c-e01b-4f10-b8ef-54d6f0e747f0">28.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNS0zLTEtMS0w_24c35329-0d10-4a2f-98ce-dd071e05f304">63.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Othernet, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNi0xLTEtMS0w_8c109cd8-0fc7-4fc2-8165-adb4a3c3602d">321.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNi0zLTEtMS0w_001f4e46-c11f-44a8-8d7f-1c46208bf7eb">89.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_85"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;2. Managements Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_88"></div><div><span><br></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tables present dollars in millions, except per-share data)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managements discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Part I, Item 1 of this Quarterly Report on Form 10-Q. Certain statements in this Part I, Item 2 of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" in this Quarterly Report on Form 10-Q and Risk Factors in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2020, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have been focused on maintaining a reliable supply of our medicines; reducing the strain on the medical system; developing treatments for COVID-19; protecting the health, safety, and well-being of our employees; supporting our communities; and ensuring affordability of and access to our medicines, particularly insulin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced negative impacts to our underlying business due to the COVID-19 pandemic, including decreases in new prescriptions as a result of fewer patient visits to physicians offices to begin or change treatment, changes in payer segment mix, and the use of patient affordability programs in the United States (U.S.) due to increased unemployment. Additionally, we have experienced, and may continue to experience, decreased demand as a result of lack of normal access and fewer in-person interactions by patients and our employees with the healthcare system. In certain locations in the U.S. and around the world with COVID-19 outbreaks, we temporarily halted in-person interactions by our employees with healthcare providers and increased virtual interactions. While in-person interactions have resumed in many locations, we may decide to halt such activity in the future and, in those cases, expect to resume such interactions as it is safe to do so and in compliance with applicable guidance and requirements. We may experience additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to discovering and developing new treatments for the patients we serve. At the beginning of the COVID-19 pandemic, we paused new clinical trial starts and enrollment in new trials in order to reduce the strain on the medical system, and we have resumed this activity in our clinical trials. However, significant delays or unexpected issues, such as higher discontinuation rates or delays accumulating data, affecting the timing, conduct, or regulatory review of our clinical trials, could adversely affect our ability to commercialize some assets in our product pipeline if the COVID-19 pandemic continues for a protracted period. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the start of the pandemic we have been working with a variety of organizations, including governmental agencies, to facilitate access to our COVID-19 therapies in various countries. The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorizations (EUA) for bamlanivimab and bamlanivimab and etesevimab administered together for higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19 and for baricitinib in combination with remdesivir in hospitalized COVID-19 patients. We have taken several steps in order to transition from bamlanivimab administered alone to bamlanivimab and etesevimab administered together in the U.S. for the treatment of COVID-19. In April 2021, we requested the FDA revoke the EUA for bamlanivimab alone. This request was not due to any new safety concern. The FDA subsequently revoked the EUA for bamlanivimab alone. We have agreed with the U.S. government to supply bamlanivimab and etesevimab together and to supply etesevimab to complement doses of bamlanivimab that the U.S. government previously purchased. As a result, we terminated the purchase agreement with the U.S. government to supply bamlanivimab alone and cancelled orders for any remaining doses scheduled to be delivered. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for bamlanivimab alone and for bamlanivimab and etesevimab administered together for patients that do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face unique risks and uncertainties in our development, manufacture, and uptake of potential treatments for COVID-19, including vulnerability to supply chain disruptions, higher manufacturing costs, difficulties in manufacturing sufficient quantities of our therapies, heightened regulatory scrutiny of our manufacturing practices,  restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us. Expedited authorization processes, including our EUA for bamlanivimab and etesevimab administered together, have allowed restricted distribution of products with less than typical safety and efficacy data, and additional data that become available may call into question the safety or effectiveness of our COVID-19 therapies. Additionally, the availability of superior or competitive therapies, or preventative measures, such as vaccines, coupled with the transient nature of pandemics, could negatively impact or eliminate demand for our COVID-19 therapies. Mutations or the spread of other variants of the coronavirus could also render our therapies ineffective. We may also be required to accept returns of certain bamlanivimab and etesevimab previously supplied together in the U.S. if the relevant EUA is revoked or terminated due to safety and efficacy concerns. In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations, including our compliance with Good Manufacturing Practices (cGMP), quality assurance, and similar regulations relating to our manufacture of COVID-19 therapies and other medicines. Any of these risks could prevent us from recouping our substantial investments in the research, development, and manufacture of our COVID-19 therapies. These risks could also affect other aspects of our business, including potentially resulting in delays or denials in the approval or launch of other products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to operate without significant negative impacts will in part depend on our ability to protect our employees and our supply chain. We have taken steps to protect our employees worldwide, with particular measures in place for those working in our manufacturing sites and distribution facilities. We have been able to largely maintain our normal operations. However, uncertainty resulting from the COVID-19 pandemic could have an adverse impact on our manufacturing operations, global supply chain, and distribution systems, which could impact our ability to produce and distribute our products and the ability of third parties on which we rely to fulfill their obligations to us, and could increase our expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the COVID-19 pandemic has affected our operations and demand for our products, it has not negatively impacted our liquidity position. We expect to continue to generate cash flows to meet our short-term liquidity needs and to have access to liquidity via the short-term and long-term debt markets. As part of our response to the COVID-19 pandemic, we worked quickly to ramp up the manufacturing of our COVID-19 antibodies in order to ensure ample supply. Due in part to the termination of the purchase agreement with the U.S. government to supply bamlanivimab alone and the cancellation of orders for the remaining doses of bamlanivimab alone that were scheduled to be delivered pursuant to the agreement, we have experienced impairment charges for excess inventory related to our COVID-19 antibodies during the three months ended March 31, 2021. We could experience additional impairments of our assets, including inventory related to our COVID-19 antibodies, or significant changes in the fair value of our assets due to the COVID-19 pandemic, including as a result of the factors discussed above. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Risk Factors in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2020 for additional information on risk factors that could impact our results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our key operating results:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.675%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,927.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644.7&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,260.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941.7&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.9&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,355.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456.5&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased for the three months ended March&nbsp;31, 2021 driven by increased volume and the favorable impact of foreign exchange rates, partially offset by lower realized prices. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses, defined as the sum of research and development and marketing, selling, and administrative expenses, increased for the three months ended March&nbsp;31, 2021, primarily due to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> research and development expenses for COVID-19 antibody therapies and baricitinib, as well as higher research and development expenses for late-stage assets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in net income and EPS for the three months ended March&nbsp;31, 2021 was primarily driven by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">higher research and development expenses, higher acquired IPR&amp;D, and higher asset impairment, restructuring, and other special charges,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partially offset by higher gross margin, higher other income, and lower income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlighted items also affect comparisons of our financial results for the three months ended March&nbsp;31, 2021 and 2020:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $299.3 million for the three months ended March 31, 2021 related to collaborations with Rigel Pharmaceuticals, Inc. (Rigel), Precision BioSciences, Inc. (Precision), Merus N.V. (Merus), and Asahi Kasei Pharma Corporation (Asahi). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $211.6 million for the three months ended March 31, 2021 primarily related to an intangible asset impairment resulting from the decision to sell the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. (Prevail). </span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 6 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized other income of $301.5&nbsp;million of net investment gains on equity securities. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $52.3 million for the three months ended March 31, 2020 related to a collaboration with Sitryx Therapeutics Limited (Sitryx). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $59.9 million for the three months ended March 31, 2020 primarily related to acquisition and integration costs associated with the acquisition of Dermira, Inc. (Dermira). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 6 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized other income of $186.6 million of net investment gains on equity securities. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new molecular entities (NMEs) are currently in Phase III clinical trials or have been submitted for regulatory review or have received first regulatory approval in the U.S., Europe, or Japan in 2021. In addition, the following table includes certain NMEs currently in Phase I or Phase II clinical trials. The following table reflects the status of these NMEs, including certain other developments since January&nbsp;1, 2021.  </span></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COVID-19 Therapies</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab administered alone</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase III trial met the primary and all key secondary endpoints. The EMA's CHMP issued a positive scientific opinion in the first quarter of 2021. In April 2021 the FDA revoked the EUA for bamlanivimab alone in the U.S.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab and etesevimab administered together</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that Phase III trials met the primary and key secondary endpoints. Additional Phase III trials are ongoing. The FDA granted EUA for higher-risk patients recently diagnosed with mild-to-moderate COVID-19 in the first quarter of 2021. We intend to submit to the FDA for approval in the second half of 2021. The EMA's CHMP issued a positive scientific opinion in the first quarter of 2021. Submitted in Europe in the first quarter of 2021. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIR-7831 and  bamlanivimab administered together</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the first quarter of 2021.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab, etesevimab and LY-CoV1404 administered together</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I trial initiated in April 2021.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Endocrinology</span></td></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that Phase III trials met the primary and key secondary endpoints. Additional Phase III trials are ongoing.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal Insulin-Fc</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing. </span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing.</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Psoriasis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not pursuing submission</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in April 2021 that we do not plan to pursue submission. </span></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase III trial met the primary and key secondary endpoints. Additional Phase III trials are ongoing. </span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CXCR1/2 Ligands Monoclonal Antibody</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL-2 Conjugate</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in April 2021. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PD-1 MAB Agonist</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the first quarter of 2021.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td></tr><tr style="height:59pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tanezumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osteoarthritis pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the first quarter of 2021 an Advisory Committee to the FDA concluded that the proposed risk evaluation and mitigation strategy will not ensure that the benefits outweigh the risks. In collaboration with Pfizer, we plan to continue to work with the FDA as it continues to review the submission. </span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer pain</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimers disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase II trial met the primary endpoint and that we expanded a Phase II trial to become a Phase III trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epiregulin/TGF MAB</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA1 Gene Therapy (PR001)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in the Prevail acquisition in January 2021. Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trials are ongoing. </span></div></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRN Gene Therapy (PR006)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontotemporal dementia</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACAP38 Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zagotenemab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimers disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted conditional marketing authorisation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe in the first quarter of 2021. Phase III trials are ongoing. </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer </span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pirtobrutinib (LOXO-305)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic lymphocytic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in the first quarter of 2021.</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mantle cell lymphoma</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td></tr></tbody></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EUAs remain active for certain countries outside of the U.S.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Vir Biotechnology, Inc. and GlaxoSmithKline plc. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaboration with Almirall, S.A. (Almirall) in Europe.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designated to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaboration with Pfizer, Inc (Pfizer). </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration with Innovent Biologics, Inc. (Innovent), Innovent, with collaboration from us, will pursue the initial registration of sintilimab injection (Tyvyt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in the U.S., and we will pursue initial registration of Tyvyt in other markets and all other subsequent registrations of Tyvyt.  </span></div><div style="margin-top:6pt"><span><br></span></div><div style="margin-top:6pt"><span><br></span></div><div style="margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products are currently in Phase II or Phase III clinical testing, have been submitted for regulatory review, or have received first regulatory approval in the U.S., Europe, or Japan for use in the indication described in 2021. The following table reflects the status of certain NILEX products, including certain other developments since January 1, 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tbody><tr><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Endocrinology</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with reduced ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing.</span></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr style="height:45pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baricitinib (Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In April 2021 the FDA extended the review period for the submission in the U.S. to the third quarter of 2021.</span></div></td></tr><tr style="height:53pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in April 2021 that a Phase III trial evaluating baricitinib 4 mg once daily plus standard of care did not meet the primary endpoint, but did result in a significant reduction in death.</span></td></tr><tr style="height:54pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alopecia areata</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Announced in the first quarter of 2021 and in April 2021 that Phase III trials met the primary endpoint. Phase III trials are ongoing. </span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:51pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjuvant breast cancer</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 patient-reported outcomes in combination with standard adjuvant endocrine therapy. Submitted in Japan in the first quarter of 2021.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trials are ongoing. </span></td></tr></tbody></table></div><div style="margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designated to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The FDA granted EUA in combination with remdesivir in hospitalized COVID-19 patients.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vitamin regimen patents to provide us with patent protection for Alimta through June 2021 in major European countries and Japan and through May 2022 in the U.S. These patents have been challenged in each of these jurisdictions and in many cases have been finally resolved in our favor. However, we and Eagle Pharmaceuticals, Inc. (Eagle) reached an agreement in December 2019 to settle all pending U.S. patent litigation, allowing Eagle a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition in the U.S., major European countries, and Japan following the loss of patent exclusivity will cause a rapid and severe decline in revenue, and we expect that the entry of generic competition in the U.S. will have a material adverse effect on our consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 to the consolidated condensed financial statements for a more detailed account of the legal proceedings currently pending regarding, among others, our Alimta patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compound patent for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A competitor launched a similar version of insulin lispro in certain European markets in 2017 and in the U.S. in the second quarter of 2018. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The formulation and use patents for Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have expired in major markets. We expect further decline in revenue as a result of the anticipated entry of generic and biosimilar competition due to the loss of patent exclusivity in major markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patent protection for Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in Japan in January 2020. We expect generics to enter the market in mid-2021. We expect that the entry of generic competition will cause a rapid and severe decline in revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Rates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro and Japanese yen. While we manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a substantial impact, either positive or negative, on our revenue, cost of sales, and operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could negatively impact our future consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trends Affecting Pharmaceutical Pricing, Reimbursement, Access, and Other Regulatory Matters </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., public concern over access to and affordability of pharmaceuticals continues to drive the regulatory and legislative debate.&nbsp;These policy and political issues increase the risk that taxes, fees, rebates, or other cost control measures may be enacted to manage federal and state budgets. Evolving regulatory priorities could further intensify these efforts and otherwise increase regulatory scrutiny over our operations. Key health policy initiatives affecting biopharmaceuticals include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Coronavirus Aid, Relief, and Economic Security (CARES) Act and subsequent stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis, </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign reference pricing in Medicare and private insurance,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modifications to Medicare Parts B and D,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provisions that would allow the Department of Health and Human Services (HHS) to negotiate prices for biologics and drugs in Medicare,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reduction in biologic data exclusivity,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proposals related to Medicaid prescription drug coverage and manufacturer drug rebates,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proposals that would require biopharmaceutical manufacturers to disclose proprietary drug pricing information, </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state-level proposals related to prescription drug prices and reducing the cost of pharmaceuticals purchased by government health care programs,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state proposals to permit importation of pharmaceuticals, including insulin, intended for sale in foreign markets, and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Biden administration's regulatory rule freeze affecting all federal agency rules that had not gone into effect as of January 20, 2021, impacting the implementation or effectiveness, as applicable, of final rules related to the 340B prescription drug program, rebate reform in Medicare Part D, drug importation including insulin, and foreign reference pricing in Medicare Parts B and D. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we announced we would distribute all 340B ceiling priced products directly to covered entities and their child sites only. We provide 340B discounts to a contract pharmacy only if it is a wholly owned subsidiary of a covered entity, if a covered entity does not have an in-house retail pharmacy or, in the case of insulin, if the subject covered entity and its contract pharmacies agree to pass along the discount to patients without any markup for dispensing fees and without billing insurance or collecting duplicate discounts. We have been transparent with regulators on our distribution activity and continue to comply with all 340B program requirements. Certain covered entities and their trade associations have initiated litigation questioning whether our program, and similar actions by other manufacturers, violate 340B program requirements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2020, three covered entities sued HHS and the Health Resources and Services Administration (HRSA) in the U.S. District Court for the District of Columbia seeking to compel the agencies to take enforcement action against us and three other companies, among other requested relief. On October 21, 2020, a trade association representing certain covered entities sued HHS in the same court seeking to compel the agency to promulgate administrative dispute resolution regulations. On December 11, 2020, a number of associations and entities filed suit against HHS in the U.S. District Court for the Northern District of California requesting immediate enforcement of the contract pharmacy guidance. On December 31, 2020, the General Counsel of HHS issued an advisory opinion alleging that honoring contract pharmacy agreements is mandatory. In January 2021, we filed suit against HHS, the Secretary of HHS, the HRSA, and the Administrator of the HRSA in the U.S. District Court for the Southern District of Indiana seeking a declaratory judgment that HHS's attempt to require manufacturers to permit contract pharmacy distribution is unlawful and a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. On March 16, 2021, the U.S. District Court for the Southern District of Indiana issued an order granting our request for a preliminary injunction.  See Note 9 to the consolidated condensed financial statements for additional information.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California and several other states have enacted legislation related to prescription drug pricing transparency and it is unclear the effect this legislation or future legislation will have on our business. Several states have also passed importation legislation, including Colorado, Florida, Maine, New Hampshire, New Mexico, and Vermont. As of late 2020 several of these states were actively working with the former presidential administration to implement an importation program from Canada. On November 22, 2020, Florida announced it submitted a proposed importation plan to the U.S. In 2020, HHS and the FDA also took several actions to advance state importation initiatives, including issuing requests for proposals for personal importation and reimportation of insulin and a final rule on the Importation of Prescription Drugs. We continue to review these state proposals and legislation, as well as federal rules, commentary to the rulemaking, and guidance published by HHS and the FDA, the impact of which is uncertain at this time. Currently, it is unclear if the Biden administration will adopt any of the importation initiatives put forth by the former presidential administration. We will continue to monitor and assess these developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the private sector, consolidation and integration among healthcare providers significantly affects the competitive marketplace for pharmaceuticals.&nbsp;Health plans, pharmacy benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance.&nbsp;Private third-party insurers, as well as governments, typically maintain formularies that specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to control costs by negotiating discounted prices in exchange for formulary inclusion. Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels, and higher deductibles. Consequently, pharmaceutical companies compete for formulary placement not only on the basis of product attributes such as efficacy, safety profile, or patient ease of use, but also by providing rebates. Value-based agreements, where pricing is based on achievement (or not) of specified outcomes, are another tool that may be utilized between payers and pharmaceutical companies as formulary placement and pricing are negotiated. Price is an increasingly important factor in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. We anticipate these downward pricing pressures will continue to negatively affect our consolidated results of operations. In addition to formulary placement, changes in insurance designs continue to drive greater consumer cost-sharing through high deductible plans and higher co-insurance or co-pays. We continue to invest in patient affordability solutions (resulting in lower revenue) in an effort to assist patients in affording their medicines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main coverage expansion provisions of the Affordable Care Act (ACA) are currently in effect through both state-based exchanges and the expansion of Medicaid.&nbsp;A trend has been the prevalence of benefit designs containing high out-of-pocket costs for patients, particularly for pharmaceuticals. In addition to the coverage expansions, many employers in the commercial market continue to evaluate strategies such as private exchanges and wider use of consumer-driven health plans to reduce their healthcare liabilities over time.&nbsp;Federal legislation, litigation, or administrative actions to repeal or modify some or all of the provisions of the ACA could have a material adverse effect on our consolidated results of operations and cash flows. At the same time, the broader paradigm shift towards performance-based reimbursement and the launch of several value-based purchasing initiatives have placed demands on the pharmaceutical industry to offer products with proven real-world outcomes data and a favorable economic profile.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Centers for Medicare and Medicaid Services published in the Federal Register a final regulation impacting the rules for calculating Medicaid rebate amounts, though the provision most likely to have a material impact on us relates to the inclusion of copayment assistance programs in best price and will take effect January 1, 2023. We are evaluating the impact of this regulation. We do not anticipate the changes related to "line extensions," which are scheduled to take effect January 1, 2022, to be material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2021, President Biden signed into law the American Rescue Plan Act of 2021 (ARP). Section 9816 of the ARP removed Medicaid's maximum rebate percentage effective January 1, 2024. We are evaluating the impact of this legislation. We expect to see continued focus on regulating pricing, potentially resulting in additional legislation and regulation under the newly elected Congress and the Biden administration. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations, including our compliance with cGMP, quality assurance, and similar regulations. Any regulatory issues concerning these matters could lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products pending resolution of the issues, and reputational harm, any of which would adversely affect our business. See Risk Factors in Part I, Item 1A of our Annual Report on  </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International operations also are generally subject to extensive price and market regulations.&nbsp;Cost-containment measures exist in a number of countries, including additional price controls and mechanisms to limit reimbursement for our products.&nbsp;Such policies are anticipated to increase in impact and reach, given the pressures on national and regional health care budgets that come from a growing, aging population and ongoing economic challenges. As additional reforms are finalized, we will assess their impact on future revenues. In addition, governments in many emerging markets are becoming increasingly active in expanding health care system offerings.&nbsp;Given the budget challenges of increasing health care coverage for citizens, policies may be proposed that promote generics and biosimilars only and reduce current and future access to branded pharmaceutical products. The COVID-19 pandemic is also creating additional pressure on health systems worldwide. As a result, cost containment and other measures may intensify as governments manage and emerge from the pandemic.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations could affect our effective tax rate, results of operations, and cash flows. Countries around the world, including the U.S., are actively considering and enacting tax law changes. The Biden administration's tax proposal contains significant changes, including increases to the tax rates at which both domestic and foreign income of U.S. companies would be taxed. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax policy in countries in which we operate. In addition, global tax authorities routinely examine our tax returns and are expected to become more aggressive in their examinations of profit allocations among jurisdictions, which could affect our anticipated tax liabilities.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strategically invest in external research and technologies that we believe to complement and strengthen our own efforts. These investments can take many forms, including acquisitions, strategic alliances, collaborations, investments, and licensing arrangements. We view our business development activity as an important way to achieve our strategies, as we seek to bolster our pipeline and enhance shareholder value. We continuously evaluate business development transactions that have the potential to strengthen our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza cloth, a medicated cloth for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the three months ended March&nbsp;31, 2021, we decided to sell the rights to Qbrexza. See Note 5 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. Under the terms of the agreement, we acquired a gene therapy program for patients with neurodegenerative diseases.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated condensed financial statements for further discussion regarding our recent acquisitions.</span></div><div style="margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_91"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,941.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328.8&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,864.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that revenue for the three months ended March 31, 2020 for many of our products was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased revenue by approximately $250 million worldwide, including approximately $200 million in the U.S. and approximately $50 million outside the U.S. We believe that this increase in U.S. revenue primarily impacted our diabetes portfolio, with estimated increases of approximately $70 million to $80 million for insulin products and approximately $30 million to $40 million for Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also estimate that U.S. revenue for Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was favorably impacted by approximately $20 million to $25 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. for the three months ended March&nbsp;31, 2021, the increase in volume was primarily driven by COVID-19 antibodies, Trulicity, and Taltz, partially offset by lower volume for Alimta. In the U.S. for the three months ended March&nbsp;31, 2021, the decrease in realized prices was primarily driven by increased rebates to gain broad commercial access for Taltz, partially offset by modest list price increases. Segment mix was not a major driver of U.S. price performance during the three months ended March 31, 2021, as increased utilization in more highly-rebated government segments was offset by lower utilization in the 340B segment, primarily for the diabetes portfolio. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. for the three months ended March&nbsp;31, 2021, the increase in volume was primarily driven by COVID-19 antibodies, Alimta, Olumiant, Tyvyt, and Verzenio, partially offset by decreased volume for Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Forteo, and Cymbalta.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by product for the three months ended March&nbsp;31, 2021 and 2020: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,116.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,452.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229.4&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">810.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695.8&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.1&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">153.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.5&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.7&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.5&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.7&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">240.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.4&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.7&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.4&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">257.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.2&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,941.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,864.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity, a treatment for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, increased  20 percent in the U.S. during the three months ended March&nbsp;31, 2021, driven by increased demand, partially offset by lower realized prices. Trulicity's lower realized prices in the U.S. were primarily due to higher contracted rebates, partially offset by a favorable segment mix that reflected lower utilization in the 340B segment, and modest list price increases. Revenue outside the U.S. increased 12 percent during the three months ended March&nbsp;31, 2021, driven by increased volume and, to a lesser extent, favorable foreign exchange rates, partially offset by lower realized prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of COVID-19 antibodies, treatments that were authorized pursuant to EUAs for mild to moderate COVID-19 for higher-risk patients, was $650.6&nbsp;million in the U.S. during the three months ended March&nbsp;31, 2021. Revenue outside the U.S. was $159.5&nbsp;million during the three months ended March&nbsp;31, 2021. The availability of vaccines and other preventative measures, coupled with the transient nature of pandemics, could negatively impact or eliminate demand for these COVID-19 antibodies. In addition, mutations or the spread of other variants of the coronavirus could also render our COVID-19 antibodies ineffective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humalog, an injectable human insulin analog for the treatment of diabetes, decreased 17 percent in the U.S. during the three months ended March&nbsp;31, 2021, driven by lower realized prices as higher contracted rebates and discounts were partially offset by lower utilization in the 340B segment. Revenue outside the U.S. decreased 4 percent during the three months ended March&nbsp;31, 2021, driven by decreased volume, partially offset by the favorable impact of foreign exchange rates. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue. However, due to the impact of competition and due to pricing pressure in the U.S. and some international markets, we expect some price decline and loss of market share to continue over time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Alimta, a treatment for various cancers, decreased 19 percent in the U.S. during the three months ended March&nbsp;31, 2021, primarily driven by lower volume as a result of customer buying patterns and, to a lesser extent, lower realized prices. Revenue outside the U.S. increased 26 percent during the three months ended March&nbsp;31, 2021, primarily driven by increased volume in Germany and, to a lesser extent, the favorable impact of foreign exchange rates. We will lose our patent protection for Alimta in Japan and major European countries in June 2021. We expect the limited entry of generic competition in the U.S. starting February 2022 and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition following the loss of exclusivity will cause a rapid and severe decline in revenue. See "Executive Overview - Other Matters- Patent Matters" for more information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis, decreased 24 percent in the U.S. during the three months ended March&nbsp;31, 2021, primarily driven by lower realized prices due to increased rebates to gain broad commercial access, partially offset by increased demand. Revenue outside the U.S. increased 32 percent during the three months ended March&nbsp;31, 2021, primarily driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humulin, an injectable human insulin for the treatment of diabetes, increased 2 percent in the U.S. during the three months ended March&nbsp;31, 2021, driven by higher realized prices, partially offset by decreased demand. Revenue outside the U.S. increased 1 percent during the three months ended March&nbsp;31, 2021, driven by the favorable impact of foreign exchange rates and higher realized prices, largely offset by decreased volume. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance, a treatment for type 2 diabetes and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, increased 5 percent in the U.S. during the three months ended March&nbsp;31, 2021, driven by increased demand. Revenue outside the U.S. increased 31 percent during the three months ended March&nbsp;31, 2021, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio, a treatment for HR+, HER2- metastatic breast cancer, increased 34 percent in the U.S. during the three months ended March&nbsp;31, 2021, primarily driven by increased demand, and, to a lesser extent, higher realized prices. Revenue outside the U.S. increased 64 percent during the three months ended March&nbsp;31, 2021, primarily driven by increased volume.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Basaglar, a long-acting human insulin analog for the treatment of diabetes, decreased 24 percent in the U.S. during the three months ended March&nbsp;31, 2021, driven by decreased demand caused by competitive pressures and, to a lesser extent, lower realized prices. Revenue outside the U.S. decreased 3 percent during the three months ended March&nbsp;31, 2021, driven by lower realized prices and decreased volume, partially offset by the favorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Basaglar. A competitor launched a similar version of glargine in the U.S. in 2020. Due to the impact of competitive pressures, we expect some price decline and loss of market share over time. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Cyramza, a treatment for various cancers, decreased 10 percent in the U.S. during the three months ended March&nbsp;31, 2021, primarily driven by decreased demand and lower realized prices. Revenue outside the U.S. increased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 percent for the three months ended March&nbsp;31, 2021, driven by the favorable impact of foreign exchange rates and increased volume. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_97"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue was 72.4 percent for the three months ended March&nbsp;31, 2021, a decrease of 6.9 percentage points compared with the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&nbsp;31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in gross margin percent was primarily due to unfavorable product mix driven by sales of COVID-19 antibodies, the unfavorable effect of foreign exchange rates on international inventories sold, higher amortization of intangibles expense related to Retevmo, charges resulting from excess inventory of COVID-19 antibodies due in part to the termination of the purchase agreement with the U.S. government for bamlanivimab following discontinuation of the product's distribution on its own in the U.S., and, to a lesser extent, the impact of lower realized prices on revenue.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 percent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.68 billion for the three months ended March&nbsp;31, 2021. The increase </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in research and development expenses for the three months ended March&nbsp;31, 2021 was driven primarily by approximately $220 million of research and development expenses for COVID-19 antibody therapies and baricitinib, as well as higher research and development expenses for late-stage assets. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses increased 2 percent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to $1.58 billion for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&nbsp;31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $299.3 million of acquired IPR&amp;D charges for the three months ended March&nbsp;31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to collaborations with Rigel, Precision, Merus, and Asahi. We recognized $52.3 million of acquired IPR&amp;D charges for the three months ended March&nbsp;31, 2020 related to a col</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laboration with Sitryx.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $211.6 million for the three months ended March&nbsp;31, 2021. The charges for the three months ended March&nbsp;31, 2021 were </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily related to an intangible asset impairment resulting from the decision to sell the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $59.9 million for the three months ended March&nbsp;31, 2020, primarily related to acquisition and integration costs associated with the acquisition of Dermira. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Othernet, (income) expense was income of $321.1 million for the three months ended March&nbsp;31, 2021 compared with income of $89.1 million for the three months ended March&nbsp;31, 2020.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in other income was driven primarily by higher net gains on investment securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 8.2 percent for the three months ended March&nbsp;31, 2021, compared with 13.3 percent for the three months ended March 31, 2020. The effective tax rates for both periods were reduced by net discrete tax benefits, with a larger net discrete tax benefit reflected for the three months ended March&nbsp;31, 2021. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_103"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition and Liquidity&nbsp;&nbsp;&nbsp;&nbsp;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements. For a discussion of our capital requirements, see Management's Discussion and Analysis of Results of Operations and Financial Condition in Part II, Item 7 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents decreased to $3.00 billion as of March&nbsp;31, 2021, compared with $3.66 billion as of December&nbsp;31, 2020. Refer to the consolidated condensed statements of cash flows for additional information on the significant sources and uses of cash for the three months ended March&nbsp;31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $3.28 billion and $2.99 billion as of March&nbsp;31, 2021 and December&nbsp;31, 2020, respectively. See Note 6 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions. The acquisition was funded primarily through cash on hand. See Note 3 to the consolidated condensed financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, total debt was $16.20 billion, a decrease of $390.8&nbsp;million compared with $16.60&nbsp;billion as of December&nbsp;31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, we had a total of $5.24 billion of unused committed bank credit facilities, $5.00 billion of which is available to support our commercial paper program. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2021, we did not repurchase any shares under our $8.00 billion share repurchase program authorized in June 2018. As of March&nbsp;31, 2021, we had $1.00 billion remaining under this program. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2021, we paid dividends of approximately $774.8 million, or $0.85 per share, to our shareholders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; various international government funding levels; and fluctuations in interest rates, foreign currency exchange rates (see "Executive Overview - Other Matters - Foreign Currency Exchange Rates"), and fair values of equity securities.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_106"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Expectations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have updated certain elements of our 2021 financial guidance. The update to our 2021 financial guidance includes acquired IPR&amp;D charges, asset impairment, restructuring and other special charges, and excess inventory charges related to COVID-19 antibodies, as well as net gains on investments in equity securities recognized during the three months ended March 31, 2021. The update to 2021 financial guidance also reflects lower expected revenue from COVID-19 antibody sales due to lower expected demand and higher expected research and development expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share for 2021 are now expected to be in the range of $7.03 to $7.23. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We now anticipate 2021 revenue to be between $26.6 billion and $27.6 billion, including an estimated $1.0 billion to $1.5 billion of revenue from COVID-19 therapies. Revenue growth is additionally expected to be driven by volume from Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Cyramza, Emgality, Tyvyt, and Retevmo, as well as by COVID-19 therapies. Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity. We expect mid-single digit net price declines globally in 2021. In the U.S., we expect low-to-mid-single digit net price declines, driven primarily by increased rebates to maintain broad commercial access and segment mix, partially offset by lower utilization in the 340B segment. Outside the U.S., we expect net price declines in China, Japan and Europe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue for 2021 is still expected to be approximately 77 percent. Research and development expenses for 2021 are now expected to be in the range of $6.9 billion to $7.1 billion, reflecting additional investments in potential therapies for Alzheimer's disease and approximately $400 million to $500 million of continued investment in COVID-19 therapies. Marketing, selling, and administrative expenses for 2021 are still expected to be in the range of $6.2 billion to $6.4 billion. Othernet, (income) expense for 2021 is now expected to be income in the range of $150 million to $250 million. The 2021 effective tax rate is now expected to be approximately 13 percent. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_109"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available Information on our Website</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The website link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained in, or that can be accessed through, our website is not a part of, or incorporated by reference in, this Quarterly Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_112"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;4. Controls and Procedures</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the companys disclosure controls and procedures, which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Quarterly Report on Form&nbsp;10-Q) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David A. Ricks, president and chief executive officer, and Anat Ashkenazi, senior vice president and chief financial officer, evaluated our disclosure controls and procedures (as such terms are defined in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020) as of March&nbsp;31, 2021, and concluded that they were effective.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Changes in Internal Controls</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first quarter of 2021, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_115"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART II. Other Information</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_118"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;1. Legal Proceedings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. See Note 9 to the consolidated condensed financial statements for information on various legal proceedings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Item should be read in conjunction with "Legal Proceedings" in Part I, Item 3 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10xk.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2020.</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_121"></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;1A. Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material risk factors are disclosed in "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2020. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2020. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_124"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_127"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock and related shareholder matters is described in "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and in "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" in Part III, Item 12 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the three months ended March&nbsp;31, 2021:</span></div><div style="margin-bottom:11pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br>Shares Purchased<br>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&nbsp;Price Paid&nbsp;<br>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&nbsp;Number of Shares<br>Purchased&nbsp;as Part of<br>Publicly Announced<br>Plans or Programs<br>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar&nbsp;Value&nbsp;<br>of Shares that May Yet Be <br>Purchased Under&nbsp;the&nbsp;<br>Plans or Programs<br>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we did not repurchase any shares under our $8.00 billion share repurchase program authorized in June 2018.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_130"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;6. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as a part of this Quarterly Report:</span></div><div style="margin-bottom:17pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">Amended Articles of Incorporation are incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000119312521033302/d111779dex31.htm">Bylaws, as amended, are incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on February 9, 2021</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit101.htm">Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan (with non-compete)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit102.htm">Release Agreement, effective as of February 9, 2021, by and between Eli Lilly and Company and Joshua L. Smiley</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT&nbsp;31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit311.htm">Rule&nbsp;13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit312.htm">Rule&nbsp;13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 32.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit32.htm">Section 1350 Certification</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 101.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files (embedded within the Inline XBRL document)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 104.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of our consolidated assets are not filed as exhibits to this Quarterly Report. We will furnish a copy of these agreements to the SEC upon request.</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_136"></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance, and Chief Accounting Officer</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div>
</div>


	</div>

	<div id="form-information-modal" data-test="form-information-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="form-information-modal-title" data-test="form-information-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">
				<i id="form-information-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="14"></i>

				<i id="dialog-box-copy-content" title="Click to Copy all Dialog Box Content." class="reboot fas fa-copy m-1 click" tabindex="14"></i>

				<i id="dialog-box-close" data-name="Form Information Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="14"></i>

			</div>
		</div>
		<div class="reboot dialog-content">
			<div id="form-information-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="dialog-content-copy-content" class="reboot float-right click color-inherit" tabindex="14">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="14"></textarea>
			</div>
			<div id="form-information-modal-carousel" class="reboot carousel pointer-event" data-interval="false" data-ride="carousel">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-1" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-2" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-3" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-4" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button id="form-information-prev" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="prev" tabindex="14">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="form-information-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button id="form-information-next" data-test="form-information-next" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="next" tabindex="14">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="settings-modal" data-test="settings-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="settings-modal-title" data-test="settings-modal-title" class="reboot lead mb-0">Settings</p>
			<div class="reboot dialog-header-actions">
				<i id="settings-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="15"></i>

				<i id="settings-modal-close" data-name="Settings Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="15"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<form class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Hover
						over Fact for quick information.</label>
					<select id="hover-option-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="true">On</option>
						<option class="reboot" value="false">Off</option>
					</select>
				</div>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Auto
						Scrolling Position</label>
					<select id="scroll-position-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="start">Top</option>
						<option class="reboot" value="center">Center</option>
					</select>
					<small class="reboot form-text text-muted col-sm-12" tabindex="15">Selecting
						a fact from the Sections Menu or the Fact Menu will automatically
						scroll that element to the (Top, or Middle) of the viewer window.
						This setting will have no use on IE 10, or Safari.</small>
				</div>
				<hr class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tagged-data-example-1">Tagged Data</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tagged-data-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 6.66667%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 102, 0); color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 102, 0), rgba(255, 102, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 102, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot search-results-example-1">Search
							Results</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="search-results-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 14.0523%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 215, 0); color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 215, 0), rgba(255, 215, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 215, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot selected-fact-example-1">Selected Fact</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="selected-fact-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tag-shading-exmple-1">Tag Shading
							(hover)</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tag-shading-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 0%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 0, 0); color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 0, 0), rgba(255, 0, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 70%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgba(255, 0, 0, 0.3);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot text-block-exmple-1">Text Block Indicators</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="text-block-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
			</form>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around"></div>
	</div>

	<div id="taxonomy-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="taxonomy-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">

				<i id="taxonomy-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="16"></i>

				<i id="taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="16"></i>
				<i id="taxonomy-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="16"></i>

				<i id="taxonomy-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-close" class="reboot fas fa-times m-1 click" tabindex="16"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<p id="taxonomy-modal-subtitle" class="reboot text-center font-weight-bold"></p>
			<div id="taxonomy-copy-paste" class="reboot form-group d-none">
				<label>Copy and Paste Below Content.</label>
				<a id="taxonomy-copy-content" class="reboot float-right click color-inherit" tabindex="16">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="16"></textarea>
			</div>
			<div id="taxonomy-modal-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-1" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-2" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-3" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-4" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="prev" tabindex="16">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="next" tabindex="16">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="taxonomy-nested-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p class="reboot lead mb-0">
				Nested Facts
				<span class="reboot" id="nested-page"></span>
				<span class="reboot">/</span>
				<span class="reboot" id="nested-count"></span>
			</p>
			<div class="reboot dialog-header-actions">
				<i id="taxonomy-nested-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="17"></i>

				<i id="nested-taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-close" class="reboot fas fa-times m-1 click" tabindex="17"></i>
			</div>
		</div>
		<div class="reboot dialog-content pt-0">
			<div id="modal-nested-fact-labels" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot d-flex">
					<button data-test="modal-taxonomy-nested-prev" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="prev" tabindex="17">
						<i class="reboot fas fa-chevron-left" title="Previous"></i>
						<span class="reboot sr-only">Previous</span>
					</button>
					<div id="modal-taxonomy-nested-label-carousel" class="reboot carousel-inner">
						<!-- Below is populated dynamically VIA JS -->
					</div>
					<button data-test="modal-taxonomy-nested-next" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="next" tabindex="17">
						<i class="reboot fas fa-chevron-right" title="Next"></i>
						<span class="reboot sr-only">Next</span>
					</button>
				</div>
			</div>
			<div id="taxonomy-nested-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="taxonomy-nested-copy-content" class="reboot float-right click color-inherit" tabindex="17">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="17"></textarea>
			</div>
			<div id="modal-taxonomy-nested-content-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-1" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-2" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-3" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-4" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div id="taxonomy-nested-nav-controls" class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="prev" tabindex="17">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-nested-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
				<!-- Below is populated dynamically VIA JS -->
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="next" tabindex="17">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>



</body></html>